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Neutrophils are essential for effective innate immunity. Conversely, 
inappropriate or excessive neutrophil activation can result in damaging 
inflammation. This damage is implicated in the pathogenesis of a number of 
respiratory diseases including acute respiratory distress syndrome (ARDS) 
and chronic obstructive pulmonary disease (COPD) which are also both 
frequently complicated by hypoxia. Cells sense and respond to hypoxia 
through the activity of the transcription factor HIF (hypoxia inducible factor) and 
its regulatory hydroxylases, the prolyl hydroxylase domain enzymes (PHDs) 1-
3. In the presence of oxygen, PHDs hydroxylate HIF, preventing the HIF 
mediated transcriptional response. Close links exist between the pathways 
which regulate hypoxic and inflammatory responses. Our group has previously 
found that in mouse models of infection, acute hypoxia leads to increased 
sickness and that this is driven by neutrophilic inflammation. 
I have used a murine model of Lipopolysaccharide (LPS) -induced acute lung 
injury, characterised by neutrophil influx, to investigate how exposure to 
hypoxia alters lung inflammation. Using high-resolution mass spectrometry, I 
have defined the proteome of the inflammatory lung neutrophil. I have shown 
that hypoxia results in a distinct proteomic signature in inflammatory 
neutrophils. Hypoxia drives lung neutrophilic inflammation through increased 
neutrophil degranulation and upregulation of inflammatory receptors. 
I have also identified key metabolic alterations in hypoxic neutrophils. The 
hypoxic lung represents a low glucose, high protein environment and 
neutrophils adapt to exploit this. I have shown that neutrophils can scavenge 
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proteins from their extracellular environment, catabolise these proteins in the 
lysosome and utilise the breakdown products for metabolism. These 
processes are upregulated in hypoxic lung neutrophils which show increased 
lysosomal protein expression, increased protein uptake and increased 
glutaminolysis. Utilising heavy labelled protein extracts, I have traced 
breakdown products from scavenged proteins into central carbon metabolism, 
demonstrating that extracellular protein can fuel neutrophilic inflammation. 
Finally, I have investigated the role of the prolyl hydroxylase PHD1 in 
regulating neutrophilic inflammation. Using a neutrophil specific PHD1 
knockout mouse line, I have identified a specific role for PHD1 in regulating 
neutrophil metabolism and survival. I have found that the microenvironment, 
particularly oxygen availability, determines the impact of PHD1 loss with 
consequences for inflammation resolution in vivo. 
In summary, hypoxia is a key regulator of neutrophil function and is associated 
with increased neutrophilic inflammation. Utilising a proteomic approach, I 
have identified the mechanisms which drive the hyperinflammatory phenotype 
including the ability of neutrophils to scavenge proteins from the environment 
to fuel inflammation. I have also shown that PHD1, a key component of the 
hypoxic signalling pathway, may regulate these functions. A more complete 
understanding of these mechanisms will help to identify therapeutic targets for 
treatment of neutrophilic inflammation in the lung. 
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II. Lay Summary 
Neutrophils are a subset of white blood cells which act as the first responders to 
infection or injury. However, they can also damage our own tissues and inappropriate 
neutrophil recruitment or persistence of neutrophils after the risk of infection has 
passed can cause disease. This is true in the lung where neutrophils are associated 
with both acute illnesses (such as acute lung injury) and chronic diseases (such as 
smoking related lung disease). Areas of infection or injury often have low oxygen 
levels and low nutrient levels and neutrophils are well adapted to function in this 
environment. Additionally, low oxygen levels alter the way neutrophils behave and 
may increase their capacity to cause tissue damage. The aim of this project was to 
understand how low oxygen levels change the behaviour of neutrophils and how this 
may lead to more severe illness. 
In order to address this, I used a mouse model of acute lung injury (ALI) which is 
known to cause neutrophils to move into the airways and cause lung damage. I 
compared mice which had ALI alone with mice which had ALI and were also exposed 
to low oxygen levels. I used proteomics to find differences between the lung 
neutrophils from these two groups. Proteomics describes a technique where all of the 
proteins in a sample of cells are extracted and analysed to show how much of each 
protein there is (the proteome of a cell). Computer software is then used to find 
patterns in the data which shed light on the important pathways and processes which 
explain the differences we see. 
I have shown that in low oxygen levels, mice with an acute lung injury become sicker 
and develop more severe lung damage than the mice in normal oxygen levels. I have 
found that there are many differences between the proteomes of neutrophils from the 
two different groups. An important difference is that neutrophils from the low oxygen 
mice showed higher levels of receptors which transmit inflammatory signals, 
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suggesting they are more damaging to the lung than neutrophils in normal oxygen 
levels. I have also shown for the first time that, when there are low levels of sugar to 
use as fuel, as is the case in the lung, neutrophils can adapt their behaviour 
accordingly. They switch on pathways which allow them to take up protein from the 
environment and they can break down this protein and use it as fuel for energy. 
Finally, I have shown that by targeting a specific protein (PHD1) which is part of the 
machinery which allows cells to respond to low oxygen levels, we can alter neutrophil 
behaviour and response to low oxygen levels, resulting in more rapid recovery of the 
lung following acute lung injury in low oxygen conditions. 
These findings have important implications for human lung diseases. Treatments 
which stop neutrophil mediated tissue damage have been difficult to develop 
because, without neutrophils, we are vulnerable to very serious infections. By better 
understanding how neutrophils behave in the context of an acute inflammatory 
response, as seen in the acute lung injury model, we aim to develop more specific 
therapies which could restore normal neutrophil function, without switching it off 
altogether. The data in this thesis has identified a novel neutrophil behaviour, namely 
using proteins to fuel inflammation, and further research will aim to find ways to target 
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Chapter 1: Introduction 
The neutrophil in health and disease 
Neutrophils are essential mediators of the innate immune response, without 
which we are subject to overwhelming infection. This is evidenced by a number 
of primary immunodeficiencies, such as chronic granulomatous disease 
(CGD) and leucocyte adhesion deficiency (LAD), characterised by defective 
neutrophil function which result in susceptibility to life-threatening bacterial and 
fungal infections[1].  
Neutrophils are the most abundant circulating leucocyte. They are derived 
from granulocyte/macrophage precursors (GMPs) in the bone marrow and are 
released into the circulation as mature, terminally differentiated cells. They 
have a relatively short half-life in the circulation, usually in the order of hours. 
However, in vivo labelling experiments have shown that neutrophils may 
persist for up to 5 days in the circulation[2]. There is also a large pool of 
neutrophils ‘in reserve’ in the bone marrow which can be rapidly mobilised to 
the circulation in response to inflammatory or infective stimuli[3]. Likewise, 
circulating blood neutrophils can rapidly migrate to injured tissue.  Neutrophils 
are the first cells of the innate immune system to arrive at a site of infection 
and have an arsenal of antimicrobial functions which serve to recognise, 
control and eradicate infectious agents. 
Neutrophil homeostasis 
Neutrophil numbers are regulated by a variety of mechanisms. These include 
the rate of production, release from the bone marrow and removal by cell death 
in the periphery or following return to the bone marrow. Chemokines play an 
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important role in this homeostasis. They are small molecules with 
characteristic conserved cysteine residues, subdivided based on the position 
of these residues (CXC and CC chemokines). Their receptors are seven 
transmembrane G-protein coupled receptors whose downstream signalling 
includes activation of PI3-kinase, required for chemotaxis. Chemokine signals 
are essential in regulating neutrophil release from the bone marrow. CXCL12 
signalling through the receptor CXCR4 is a strong retention signal for 
neutrophils in the bone marrow[4]. Conversely, CXCR2 expression on bone 
marrow neutrophils mediates mobilisation of neutrophils from the marrow in 
response to ligands including granulocyte colony-stimulating factor (G-
CSF)[5]. Furthermore, upregulation of CXCR4 can aid homing to the bone 
marrow for clearance. This phenomenon has been recognised in both 
senescent circulating neutrophils[6] and in inflammatory neutrophils during 
resolution of inflammation in the liver[7]. Chemokines also play an important 
part in recruitment of neutrophils from the circulation to the site of injury. They 
are released by cytokine activated endothelial and epithelial cells, tissue 
resident cells and other leukocytes in injury or infection, leading to neutrophil 
chemotaxis. This response is then amplified as neutrophils themselves secrete 
further chemokines to recruit further effectors of the immune response. 
Pathogen and damage recognition pathways 
Unlike the lymphocytes of the adaptive immune system, neutrophils do not 
recognise specific pathogens but possess a number of pattern recognition 
receptors (PRRs) which can sense both microbial motifs (pathogen associated 
molecular patterns, PAMPs) and ‘self’ danger signals known as danger 
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associated molecular patterns (DAMPs). Infective and sterile tissue injury will 
result in the generation of DAMPs, predominantly from necrotic cells. DAMPs 
include ATP, heat shock proteins (HSP), mitochondrial DNA and formylated 
peptides and nucleic acids. The presence of DAMPs in the microenvironment 
has a significant impact on the innate immune response, creating 
microenvironmental danger signals. 
Extracellular ATP enhances neutrophil recruitment, although the mechanism 
is complex and not a simple chemotactic signal. Chemotaxis is amplified by 
neutrophil release of ATP in response to activating stimuli, and ATP acts in an 
autocrine fashion to ligate the G-protein coupled P2Y2 receptor to control 
orientation[8]. Mitochondrial derived peptides also act as DAMPs. They are 
formylated peptides which resemble bacterial peptides and signal via the same 
formylated peptide receptors (FPRs, discussed below) to mediate neutrophil 
chemotaxis and activation. A hierarchy of processes is proposed to control 
neutrophil chemotaxis in response to DAMPs and mitochondrial formylated 
peptides are found to be crucial for the last stages of migration[9].   
Neutrophils express multiple PRR subtypes which recognise PAMPs including 
Toll-like receptors (TLRs), C-type lectin receptors (CLRs) and NOD-like 
receptors (NLRs). TLRs 1,2 and 4 recognise components of the bacterial cell 
wall while TLR7 (in mice) and TLR8 (in humans) recognise viral single 
stranded RNA. Lipopolysaccharide (LPS) is a major component of the outer 
membrane of gram-negative bacteria, it is a well described TLR-4 agonist and 
is used throughout this thesis as an inflammatory stimulus, both in vivo and in 
vitro. Neutrophils also express multiple CLRs which recognise carbohydrate 
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moieties. The CLRs Dectin-1 and 2 as well as Mincle recognise fungal cell wall 
components while MDL-1 recognises flaviviruses such as the Dengue virus. 
CLRs are cell surface receptors while TLRs can be expressed either on the 
cell surface or on the endolysosome membrane. NOD like receptors are 
cytoplasmic PRRs and can be broadly divided into two subgroups: NOD1 and 
NOD2 recognise components of peptidoglycan in the bacterial cell wall and 
downstream signalling results in neutrophil activation while the NLRP 
receptors form an inflammasome complex[10,11]. Finally, formylated peptide 
receptors (FPRs) are a family of G-protein coupled receptors which recognise 
both bacterial and mitochondrial formylated peptides. Neutrophils express 
both FPR1 and FPR2 and activation of these receptors stimulates multiple 
neutrophil functions including chemotaxis, degranulation, and the respiratory 
burst[12]. Through this repertoire of receptors neutrophils recognise and 
respond to a wide range of pathogens. More recently, a zebrafish model has 
shown that neutrophils are only recruited in response to PAMPs when there 
are concurrent DAMP signals, suggesting a potential mechanism for innate 
immune tolerance of non-pathogenic infectious agents[13]. 
DAMPs and PAMPs, combined with chemoattractant signals and adhesion 
molecules on the inflamed endothelium combine to recruit neutrophils to the 
area of injury. Neutrophil migration in response to these signals depends upon 
expression of receptors and ligands on the surface of both the endothelium 
and on the neutrophil itself and is discussed in further detail in chapter 3.  
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Phagocytosis 
Upon recruitment and pathogen recognition, neutrophils begin to target the 
infection. Along with macrophages, neutrophils are termed the professional 
phagocytes. Phagocytosis may occur in response to PRR ligation or binding 
of opsonised pathogens to Fcg receptors. Irrespective of the upstream signals, 
activation of these receptors results in intracellular signalling cascades 
involving PI3K and Phospholipase C(PLC) [14] which ultimately lead to actin 
cytoskeletal rearrangement and formation of a phagosome. Phagosomal 
maturation ensues, resulting in fusion of the phagosome with intracellular 
granules present in neutrophils. These organelles possess multiple 
antimicrobial proteases and also recruit antimicrobial enzymes such as the 
NADPH oxidase which produces reactive oxygen species (ROS) [15]. These 
combined mechanisms result in effective intracellular pathogen killing. In 
addition to these intracellular killing mechanisms, neutrophils may also kill 
extracellular pathogens through the release of antimicrobial components via 
the process of degranulation which will be discussed in detail in chapter 3.  
Respiratory burst 
The neutrophil respiratory burst describes the increased oxygen consumption 
which accompanies phagocytosis of pathogens. The respiratory burst occurs 
due to the increased generation of reactive oxygen species (ROS) by the 
NADPH oxidase, a multicomponent enzyme which generates ROS through 
electron transfer from cytosolic NADPH to O2 within the membrane bound 
organelle[16]. Upon activation, the cytosolic components of the oxidase 
translocate to join the membrane bound b-type cytochrome component found 
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in neutrophil granules, thus forming a functional electron transfer system. ROS 
are highly toxic to invading pathogens and the ROS containing granules may 
fuse with the phagosome, facilitating intracellular killing or may be released 
upon degranulation. The critical importance of the NADPH oxidase is 
highlighted by the overwhelming infections that characterise the clinical course 
of patients with CGD, in which there is a mutation in one of the components of 
the NADPH oxidase. Neutrophils also generate mitochondrial ROS (mROS), 
independent of NADPH oxidase activity[17] and, although less well 
characterized, mROS are thought to be important in neutrophil apoptosis[17] 
and NETosis[18]. Although predominantly active within the phagolysosome 
ROS may also diffuse into the cytosol and may cross the cell membrane into 
the extracellular environment where they may act as signalling molecules. 
Additionally, ROS have the capacity to alter the redox state of the cell which in 
turn has implications for signalling. Tyrosine phosphorylation is pivotal in cell 
proliferation, differentiation and in cell to cell communication. It is involved in 
transducing signals from diverse mediators including f-Met-Leu-Phe (fMLF), 
tumour necrosis factor-a (TNF-a) and granulocyte-macrophage colony-
stimulating factor (GM-CSF). Oxidants may alter the phosphorylation state of 
a protein either through inhibition of phosphatase activity or through induction 
of kinase activity[19] and therefore alter the activity of a wide range of 
signalling pathways. 
Mechanisms of neutrophil cell death and implications for inflammation 
An unusual facet of neutrophil biology is their propensity to undergo 
constitutive apoptosis, or programmed cell death.  In both homeostasis and 
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the inflammatory response, the mechanism of neutrophil death is important. 
Apoptosis is a highly regulated and controlled process which results in 
cessation of both transcription and secretion of cytotoxins, effectively 
‘dismantling’ the cytotoxic neutrophil machinery while maintaining the 
cytoplasmic membrane integrity and therefore avoiding release of toxins into 
the surrounding tissues. Apoptotic neutrophils are recognised by other 
immune cells, particularly macrophages which can take up (efferocytose) the 
dying cells and dispose of them in a safe fashion. Importantly, efferocytosis is 
a polarising stimulus for macrophages, stimulating a pro-resolution 
macrophage phenotype. Apoptosis can be triggered by two distinct pathways, 
the intrinsic and extrinsic pathways. The extrinsic pathway is activated by 
binding of cell surface death receptors such as the TNF-related apoptosis-
inducing ligand receptors (TRAIL-R1 and TRAIL-R2) and the FAS receptor. 
Activation by their ligands, TRAIL and Fas Ligand respectively, leads to 
activation of the initiator caspases 8 and 10, facilitated by adaptor proteins 
found on the cytoplasmic domain of the death receptor. A cascade of caspase 
cleavage and activation ensues culminating in activation of the effector 
caspases 3 and 7 which trigger apoptosis[20]. The intrinsic pathway is, as the 
name suggests, activated by intracellular stress signals such as DNA damage 
or metabolic stress. In many cell types hypoxia is also an apoptotic signal, 
however, in neutrophils, hypoxia is a profound survival stimulus[21]. Defining 
hypoxia, both experimentally and in physiological conditions is discussed in 
more detail below. Stress signals result in activation of BCL-2 homology 
domain 3 (BH3)-only protein which in turn activates Bax and Bak activity, 
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resulting in mitochondrial outer membrane permeabilisation. This membrane 
permeabilisation leads to release of mitochondrial intermembrane space 
proteins such as SMAC (second mitochondria derived activator of caspases) 
and cytochrome c into the cytoplasm which ultimately activate caspase 9, 
triggering apoptosis through activation of the effector caspases 3 and 7. Anti-
apoptotic proteins such as BCL-2 and MCL1 prevent mitochondrial membrane 
permeabilisation through interactions with BH3-only proteins and the pro-
apoptosis Bax and Bak. MCL1 is the primary anti-apoptotic protein in 
neutrophils and, in comparison to the pro-apoptotic Bax, MCL1 has a relatively 
short half-life. This imbalance is thought to contribute to constitutive neutrophil 
apoptosis in the absence of survival stimuli[22]. Survival stimuli for neutrophils 
are diverse and include bacterial products such as LPS but also a number of 
cytokines, including GM-CSF, G-CSF, IL-1b, IFN-g and TNF-a. Their 
downstream signalling converges on overlapping pathways including PI3K, 
ERK and NFkB to tip the balance of pro- versus anti-apoptotic factors and 
delay apoptosis. 
Failure of neutrophil apoptosis can lead to persistence of neutrophilic 
inflammation and delayed neutrophil apoptosis has been suggested to 
contribute to both ARDS and sepsis. Ex vivo culture of blood neutrophils from 
patients with sepsis revealed an inverse correlation between rates of 
neutrophil apoptosis and sepsis severity and neutrophil apoptosis was lower 
still in those patients who developed sepsis related ARDS[23]. Soluble factors 
in the BAL fluid of patients with ARDS can prolong neutrophil survival in 
vitro[24] and neutrophils isolated from the blood of patients with ARDS show 
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reduced apoptosis compared to healthy controls following ex vivo culture[25]. 
Furthermore, there are lower rates of apoptosis in the peripheral blood 
neutrophils of patients with cystic fibrosis[26] and sputum neutrophils of 
patients with COPD[27].  
Failure of neutrophil apoptosis leads not only to persistent neutrophilic 
inflammation but may also result in necrosis of neutrophils, another 
mechanism of cell death which, unlike apoptosis, results in loss of cytoplasmic 
membrane integrity and therefore release of cytotoxins into the surrounding 
tissues. This may also occur in secondary necrosis if the apoptotic neutrophils 
are not cleared by efferocytosis in a timely manner. Apoptosis is an active, 
ATP requiring process and so, energetic failure may contribute to neutrophil 
necrosis. 
More recently a novel mechanism of neutrophil cell death, termed NETosis 
has been described. Neutrophil extracellular traps (NETs) are formed of 
chromatin, DNA, histones and granular proteins such as elastase or MPO and 
have bactericidal activity[28]. NETs were subsequently found to form during 
an active cell death process, dependent on ROS production and distinct from 
apoptosis and necrosis: NETosis[29]. Although first described in vitro, intravital 
microscopy has subsequently shown that NET formation and NETosis also 
occur in vivo[30]. The requirement for ROS is confirmed by the absence of 
NETs in patients with CGD[29] and the restoration of anti-fungal NET formation 
by restoration of NADPH oxidase function in these patients[31]. There is an 
alternative, NADPH oxidase independent NETosis pathway although this is 
less well defined. NETosis can be stimulated by microbes, antibodies and 
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chemical stimuli such as phorbol 12-myristate 13-acetate (PMA) and plays an 
important role in immunity through their capacity to kill large extracellular 
pathogens (such as Aspergillus species) and trapping pathogens to prevent 
disseminated infection[32]. Like many neutrophil antimicrobial functions, 
NETosis, if dysregulated, also has the capacity to cause inflammatory injury. 




Inflammation and Infection in the Lung 
Gas exchange in the lung 
The primary function of the lung is to allow gas exchange, and this is achieved 
through the pulmonary circulation. Deoxygenated blood moves from the right 
ventricle to the pulmonary arteries which branch to form pulmonary arterioles 
and then capillaries. The capillaries are in direct contact with the alveolus, the 
terminal point of the airways and it is at this point that gas exchange occurs by 
diffusion. This diffusion relies upon a number of important anatomical factors 
including the close apposition of the capillary basement membrane with the 
alveolar epithelial basement membrane, the vast surface area of the alveoli 
(approximately 70 m2) and the narrow aperture of the pulmonary capillaries 
which ensures that red blood cells are close to the endothelial surface. The 
lungs also have a second circulatory supply from the left heart consisting of 
the bronchial arteries which supply oxygenated blood to the more proximal 
airways. There are some anastomoses between the two circulations but most 
blood returns to the left heart via the pulmonary veins and then into the 
systemic circulation. An important and unique aspect of the pulmonary 
circulation is ventilation-perfusion coupling: unlike most other tissues, in 
response to hypoxia the pulmonary circulation vasoconstricts, thus avoiding 
funnelling blood through poorly ventilated areas of lung where gas exchange 
cannot take place. This may occur in multiple respiratory pathologies where 
inflammation, infection or fibrosis may lead to thickening of the extracellular 
matrix and impaired diffusion and/or damage to the alveolar epithelial cells and 
impaired mucus clearance. Therefore, despite its role in oxygenating the 
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blood, areas of the lung may be subject to marked hypoxia in the diseased 
state. When extensive lung injury occurs, this failure of gas exchange may lead 
to systemic hypoxia, as well as localised hypoxia and this is often associated 
with significant morbidity and mortality. 
Defining normoxia and hypoxia 
In human physiology, when breathing room air (21% O2) the normal arterial 
partial pressure of oxygen (pO2) is approximately 10-12kPa. In the 
deoxygenated venous blood, the normal pO2 is 4-5kPa. Measuring oxygen 
tension in living tissues is technically challenging, methods include imaging 
modalities such as positron emission tomography (PET) and magnetic 
resonance spectroscopy (MRS). PET uses injected tracer compounds and 
indirectly measures oxygenation based on the redox status of cells. Its utility 
is limited by anatomical resolution[35].  MRS provides a higher level of 
resolution and, using perfluorocarbon probes, can measure absolute O2 
levels[36]. Other techniques which have been described include oxygen 
electrodes which rely on reduction of O2 by a negatively charged noble metal 
electrode and, more recently, fibre-optic techniques. Fibre-optic measurement 
is advantageous as, unlike the electrodes, the probe does not consume the 
oxygen within the microenvironment. Much of the work in this area has 
focussed on hypoxia in the tumour microenvironment but some studies have 
attempted to define the ‘normal’ pO2 of specific tissues and organs. The 
kidney, intestine and liver have been reported to have heterogenous oxygen 
levels. Measurement of renocortical oxygen levels in patients undergoing 
kidney transplant found a relatively high mean pO2 of 9.5kPa[37] while intra-
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operative measurement of intestinal oxygen levels found the pO2 to be 7-
8kPa[38]. However, both the kidney and liver have also been found to have 
areas of much more marked hypoxia, particularly in the renal medulla. Parts 
of the skin are found to be profoundly hypoxia, with a pO2 of <2kPa. A study 
of patients with lung tumours measured the pO2 in normal lung tissue at the 
time of tumour resection and this showed a highly variable degree of 
oxygenation (which the authors suggest may reflect incomplete lung deflation) 
but the median pO2 in normal lung was 5.6kPa[39]. These studies show that, 
even in the absence of inflammation, cells, particularly circulating leucocytes, 
may be exposed to a wide range of oxygen concentrations. True “normoxia” is 
therefore difficult to define and will vary from tissue to tissue and this poses an 
experimental challenge. In the literature and throughout this thesis, for in vitro 
experiments, normoxic culture is defined as 21% O2, i.e. normal room air while 
in vitro hypoxia is defined as 1% O2.  Cells in culture may therefore be exposed 
to higher oxygen concentrations than would be expected in the tissue or 
circulation and so, while cell culture in these extremes of oxygen levels is an 
important tool in the investigation of hypoxic responses it is important to 
consider more physiological models in parallel. One such example which will 
be used in this thesis is the exposure of mice to hypoxia which, it is hoped, will 
provide a more physiological hypoxic challenge. 
Neutrophils in the lung 
In both infective and inflammatory disorders, the recruitment of immune cells 
to the airways occurs rapidly. In the context of infection, such as pneumonia, 
this is a critical step in containing and eradicating the infectious agent. 
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However, dysfunctional neutrophilic inflammation may be harmful and, if 
inappropriately activated, neutrophils have the capacity to cause severe 
damage to host tissues. In the lung, neutrophilic inflammation is implicated not 
only in acute diseases such as ARDS [40] but also in chronic disorders 
including COPD [41], cystic fibrosis [42] and bronchiectasis. The degree of 
neutrophilic infiltration in these diseases often correlates with disease severity 
and with lung damage. Furthermore, these chronic diseases are also 
characterised by recurrent and chronic infection, suggesting that the recruited 
neutrophils are simultaneously damaging and immunologically incompetent. 
There is therefore considerable interest in developing therapeutics which 
specifically target neutrophilic inflammation. This poses a significant challenge 
as damping down the harmful inflammation whilst preserving essential innate 
immunity represents a delicate balancing act. 
Understanding the factors which influence the nature of the neutrophil 
response in the lung will be essential in targeting neutrophilic inflammation with 
the ultimate goal of resolving inflammation and restoring immune function. 
Pathogenesis of acute respiratory distress syndrome (ARDS) 
ARDS may occur in both pulmonary and extra-pulmonary diseases (such as 
burns, sepsis or pancreatitis). It is associated with a high mortality rate and, 
despite being first described in the 1970s,  current therapeutic strategies 
revolve around supportive therapy with no specific licenced therapy available. 
This is reflected in the minimal improvement in outcomes over recent decades. 
Irrespective of the underlying cause, ARDS is characterised by protein-rich 
oedema in the alveoli and lung interstitium, attributable to increased pulmonary 
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vascular permeability[43]. The primary cause of the vascular injury is 
neutrophil mediated damage[44]. There is evidence that additional alveolar 
epithelial injury is required, in parallel with the vascular injury, for the 
development of ARDS. Epithelial injury may occur in response to a chemical 
stimulus, (for example acid from aspirated gastric contents or inhalation of 
toxins) or a pressure injury, particularly in mechanically ventilated 
patients[45,46]. However, like the vascular injury, epithelial damage is most 
commonly caused by the release of factors from infiltrating immune cells, 
particularly neutrophils. The neutrophil is therefore an attractive therapeutic 
target in this disease because it is essential in the pathogenesis and 
perpetuation of the inflammatory response. However, in order to develop such 
a therapy, a more comprehensive understanding of how and why the 
dysfunctional neutrophilic inflammation develops is required. 
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Microenvironmental regulation of inflammation 
The vital role of the microenvironment in regulating inflammatory responses is 
increasingly recognised. In addition to the DAMP and PAMP signals described 
above, multiple other environmental stimuli including the cytokine 
environment, nutrient availability and oxygen tension play a part in shaping the 
inflammatory response. 
Cytokines and neutrophil priming 
Neutrophils are exquisitely sensitive to the cytokine environment and possess 
a wide range of cytokine receptors. Cytokines acting upon neutrophils can be 
divided into different classes with different structures, receptors and signalling 
pathways. 
Type I cytokines consist of 4 a-helices and include IL-4, IL-6, granulocyte 
colony-stimulating factor (G-CSF) and GM-CSF. Type II cytokines contain 6 a-
helices and include Interferon (IFN)-a, -b and -g and IL-10. Both Type I and 
type II cytokine signalling is mediated by JAK-STAT pathways. The IL-1 super 
family includes the three known forms of IL-1 (IL-1a, IL-1b and IL-1Ra) and IL-
18. IL-1b is a critical regulator of the inflammatory response and is 
predominantly produced by macrophages but may also be produced by 
epithelial cells and fibroblasts. In neutrophils its main effect is to prolong 
survival. TNF-a is a key inflammatory cytokine. It is produced in large 
quantities by activated macrophages and can act upon both macrophages and 
neutrophils. It is important in priming and activating neutrophils.  
Neutrophil priming describes the phenomenon whereby exposure to a 
‘priming’ stimulus results in an amplified response from the neutrophil following 
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subsequent activation. Neither the priming stimulus nor the activating stimulus 
in isolation is able to unleash the full antimicrobial potential of the neutrophil 
but together they induce a potent effector cell function. Priming agents include 
pathogen derived factors such as LPS and the influenza A virus and ‘self’ 
inflammatory mediators such as TNF-a[47], IL-8 and GM-CSF[48].  These 
priming stimuli may be generated by other immune cells or by endothelial cells. 
The consequences of priming are manifold: classically priming is measured by 
enhanced ROS production and increased phagocytic activity, however, primed 
neutrophils may also alter the make-up of their surface receptors, thus 
changing their capacity to respond to subsequent cytokine signals. Primed 
neutrophils also show enhanced degranulation and survival. The physiological 
importance of priming is clear: a fully activated neutrophil is potentially highly 
toxic to host tissue, but neutrophils must be activated quickly to be effective 
when required to fight infection. The intermediate primed stage avoids having 
high numbers of active neutrophils in the circulation but means that in 
response to a danger stimulus, there is a rapidly available population of potent 
effector cells. 
Interestingly, priming may be reversible in response to certain stimuli, including 
platelet activating factor (PAF). This ‘depriming’ is also a safety mechanism – 
if after a period of priming, the neutrophil is not fully activated it can ‘stand 
down’ again, retaining the capacity to be reprimed and fully activated at a later 
stage[49]. Recent studies in acute lung injury suggest that a failure of this 
depriming may contribute to the neutrophil mediated cell damage seen in this 
condition[50]. 
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Hypoxic regulation of inflammation and immunity 
Multiple links exist between hypoxia signalling pathways and inflammatory 
processes. Inflammation may lead to local or systemic hypoxia, for example in 
an abscess where lack of blood supply results in profound local hypoxia or in 
lung inflammation (such as ARDS) where impaired gas exchange can lead to 
systemic hypoxia. Additionally, an influx of inflammatory cells may lead to 
hypoxia as the demand for oxygen outstrips supply, known as inflammatory 
hypoxia[51]. The links between hypoxic signalling and inflammation are 
bidirectional: hypoxia may also exacerbate inflammation through activation of 
inflammatory pathways and through effects on immune cell fate and function. 
Cellular responses to hypoxia are essential for life and are now recognised to 
be dysregulated in a wide range of disease processes. The key players in 
these pathways are a family of transcription factors, the Hypoxia Inducible 
Factors (HIFs) and their regulatory proteins, the prolyl hydroxylase domain 
enzymes (PHDs) and Factor Inhibiting HIF (FIH). The active HIF transcriptional 
complex is a heterodimer of the oxygen sensitive HIFa subunit and the 
constitutively expressed HIFb subunit (also known as the aryl hydrocarbon 
receptor nuclear translocator, ARNT)[52]. This complex activates transcription 
through binding to Hypoxia Response Elements (HREs) present on a broad 







Figure 1.1 The hypoxic response is regulated by HIFs and their inhibitory hydroxylases 
The Hypoxia Response Is Regulated by Hypoxia-Inducible Factors (HIFs) and Their Inhibitory 
Hydroxylases. The active form of HIF comprises an a and a b subunit. The prolyl hydroxylase 
domain enzymes (PHDs), and an asparaginyl hydroxylase, factor inhibiting HIF (FIH), act as 
the cellular oxygen sensors: these require oxygen for hydroxylation of the HIFa subunit. Prolyl 
hydroxylation targets HIFa for proteasomal degradation by the von Hippel–Lindau (VHL) 
protein and asparaginyl hydroxylation prevents binding of the transcriptional co-factor 
p300/CBP, preventing HIF-mediated transcription under oxygen-replete conditions.  
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The hypoxia-sensing pathways are highly conserved, and the prolyl 
hydroxylase domain enzymes may also be termed EGLNs due to their early 
identification as homologues of the C. Elegans oxygen sensor EGL-nine[54]. 
In this nomenclature PHD1, 2 and 3 are known as EGLN 2,1 and 3 
respectively. The PHDs are part of a family of 2-oxoglutarate (2OG) and Fe(II)-
dependent hydroxylases. Protein hydroxylation is increasingly recognised as 
an important post-translation modification which may directly alter protein 
structure, provide a stepping stone for further modifications or regulate protein-
protein interactions[55]. The first described 2-OG dependent hydroxylases 
were those which catalysed proline hydroxylation in procollagen, regulating the 
stability of the collagen triple helix[56]. The PHDs hydroxylate prolyl residues 
within the Oxygen Dependent Degradation Domain (ODDD) of the HIFa 
subunit[57]. This hydroxylated form of HIFa binds the Von Hippel Lindau 
protein which has E3 ubiquitin ligase activity and targets the HIFa subunit for 
proteasomal degradation[58]. Prolyl hydroxylation by PHDs requires molecular 
oxygen and 2-OG as substrates and therefore provides the oxygen-sensing 
element of the pathway – in the absence of oxygen, HIFa cannot be 
hydroxylated and, instead of being degraded, accumulates and translocates 
to the nucleus where it binds the HIFb subunit and activates transcription. The 
requirement for 2-OG also links hypoxic signalling to metabolic processes and 
this will be discussed in more detail below. Factor Inhibiting HIF (FIH) is 
another 2-OG-dependent hydroxylase which also acts as a cellular oxygen 
sensor through a distinct mechanism[59]. FIH hydroxylates asparagine 
residue 803 in the HIFa subunit which, instead of targeting it for degradation 
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prevents HIFa C-terminal transactivation domain (CAD) interactions with the 
coactivator P300, thus preventing HIF mediated transcriptional responses[60]. 
Over the last half century, hydroxylation by 2-OG dependent enzymes has 
been found to regulate gene expression at multiple levels. Hydroxylation by 
the 2-OG dependent Jumonji C domain (JMJD) containing proteins regulates 
histone methylation status, an important factor in transcriptional activity. The 
JMJD containing protein JMJD6 has also been implicated in the regulation of 
RNA splicing[55]. Additionally, the ten-eleven translocation (TET) group of 2-
OG oxygenases alter DNA methylation status by converting 5-methyl cytosine 
residues to 5-hydroxymethyl cytosine which is, through base excision repair, 
replaced with an unmethylated cytosine[61]. The suppression of TET activity 
during hypoxia in the tumour microenvironment was associated with 
hypermethylation of predominantly enhancer and promotor regions[62]. 
Hypermethylation of tumour suppressor gene promotors results in reduced 
expression of these proteins and has been hypothesised to drive 
tumorigenesis. Thus, through the action of this family of 2-OG dependent 
hydroxylases, oxygen availability regulates gene expression at multiple levels, 
shaping cellular identity and behaviour. 
Isoform specific roles for HIFs and PHDs 
An important consideration in understanding cellular responses to hypoxia is 
the added capacity to ‘fine tune’ the hypoxic response which is afforded by the 
existence of multiple isoforms of both HIFa and PHD. 
To date three isoforms of HIFa have been described with HIF-1a and HIF-2a 
being the best characterised and most ubiquitously expressed. HIF-3a is the 
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most structurally distinct isoform and is present in multiple splice variants 
which have complex and variable roles[63]. While HIF-3a may regulate 
transcription of some hypoxia inducible genes, it also has a role in regulating 
HIF-1a and HIF-2a activity. Despite similarities in structure and function of the 
HIF-1a and HIF-2a isoforms, there are key differences in their transcriptional 
repertoire which provide an additional level of complexity in the hypoxic 
transcriptional response. This differentiation is multifactorial, relating to 
variations in tissue expression, temporal regulation and differences in gene 
specificity. Interestingly, this specificity is driven not by the DNA binding 
domain but by the N-terminal transactivation domain[64]. The balance of HIF-
1a versus HIF-2a has important implications for inflammation outcome. 
The three PHD isoforms found in mammals are thought to have arisen through 
gene duplication early in vertebrate evolution[65] and are represented by a 
single isoform in Caenorhabditis elegans, Egl9. While the Egl9 gene is 
essential for regulation of HIF in C elegans, all three mammalian isoforms have 
HIF hydroxylation activity[54]. However, an increasing body of evidence 
suggests that the PHD isoforms are non-redundant in mammalian cells and 
the specific function of each PHD isoform is the subject of extensive and 
ongoing research. Pharmacological inhibition of specific PHDs is not yet 
possible, although current compounds may have a degree of selectivity. 
However, generation of cell-specific, isoform specific, knockout animals and 
the use of other techniques such as SiRNA have enabled researchers to begin 
to elucidate the function of specific PHDs. All three PHDs are widely expressed 
in cells of the innate and adaptive immune system. PHD2 is generally 
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considered to be the dominant isoform in the regulation of HIFa under 
physiological oxygen tensions[66] while PHD3 is often upregulated in hypoxic 
conditions. It is also important to consider that the PHDs have been postulated 
to have HIF independent activity in the context of inflammation and 
malignancy. NF-kB is a transcription factor which, like HIF, regulates a diverse 
group of genes including cytokines, immune receptors and stress response 
genes[67]. In some contexts NF-kB activity is linked to hypoxic signalling in a 
HIF dependent fashion[68,69]. However, there is also evidence that PHD 
activity may directly regulate NF-kB, impacting inflammatory and malignant 
outcomes[70-72]. FIH has also been found to regulate NF-kB activity and 
knockdown of FIH and PHD1 had an additive effect in reducing NF-kB 
activity[73]. This cross talk between inflammation and hypoxia has important 
implications in infection, sterile inflammation, ischaemic injury and within the 
tumour microenvironment. 
HIFs/PHDs in neutrophil Biology 
As the first responders of the innate immune response, neutrophils are 
required to function in a hostile microenvironment, and this often incudes 
exposure to marked hypoxia. Neutrophils express all of the oxygen sensing 
machinery described above (although there is little data in the current literature 
regarding the role of FIH in neutrophils). In the context of an acute 
inflammatory response, neutrophils demonstrate distinct temporal expression 
profiles of the HIFa isoforms [74], with early upregulation of HIF-1a in an acute 
lung injury model (6 hours post-stimulus) and delayed HIF-2a upregulation, 
peaking as the HIF-1a levels fall at 24 hours. Importantly, loss of HIF-2a in 
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myeloid cells results in enhanced resolution of neutrophilic inflammation 
(associated with a pro-apoptotic neutrophil phenotype), consistent with HIF-2a 
being the dominant isoform in the latter stages of the neutrophilic inflammatory 
response. Additionally, expression of HIF isoforms varies with neutrophil type 
with differential expression noted in bone marrow, blood and inflammatory 
tissue neutrophils. HIF-1a has been shown to be essential for a range of 
myeloid cell functions[75], including delayed neutrophil apoptosis in 
hypoxia[69]. In contrast to this, loss of HIF-2a in neutrophils does not result in 
loss of hypoxic survival[74]. These data highlight the importance of 
environmental context and timing in determining the role of individual HIF 
isoforms in the inflammatory response. 
Given the critical role of HIF in neutrophil survival and function, it is of little 
surprise that manipulation of PHD activity has profound consequences for the 
neutrophil and PHD2 and PHD3 have both been shown to regulate neutrophilic 
inflammation. Genetic ablation of PHD2 in myeloid cells or pharmacological 
inhibition of PHD2 activity resulted in exaggerated inflammation in response to 
the pathogen Streptococcus Pneumoniae. This was not due to a failure of 
pathogen clearance but rather an over-exuberant neutrophil response, also 
noted in response to sterile, LPS induced inflammation. This resulted in 
increased migration, enhanced neutrophil survival and upregulation of 
glycolysis with consequent increased energy charge[76]. Importantly, this 
response was associated with increased stability of HIF-1a. In contrast to 
these findings, investigation of the role of PHD3 in neutrophilic inflammation 
identified an unexpected phenotype[77]. Both hypoxia and inflammatory 
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stimuli were found to increase levels of PHD3 in neutrophils (consistent with 
findings in other cell types[66]). Interestingly, despite preserved HIF 
transcriptional activity (as measured by synthesis of the HIF target genes 
GAPDH and Glut1), loss of PHD3 led to a failure of neutrophil hypoxic survival. 
This had important consequences in vivo with improved resolution of LPS 
induced acute lung injury and reduced inflammation in a mouse model of 
colitis. Taken together, these data highlight the isoform specific actions of 
PHDs. Studies of macrophage function in the context of PHD3 loss highlight 
the cell specific functions of these enzymes. In a model of LPS-induced 
peritoneal inflammation which is predominantly macrophage mediated, loss of 
PHD3 results in an overwhelming innate immune response which was 
lethal[78], in contrast to the neutrophil phenotype described above. These data 
demonstrate that hypoxia, and hypoxic signalling pathways, may be either pro- 
or anti-inflammatory and the context of the inflammatory insult is of vital 
importance in determining the outcome. The impact of hypoxia on the 
infiltrating immune cell population must also be balanced with the effect of 
hypoxia on the tissue in question. As discussed above, inflammation in the 
lung, and adaptive ventilation-perfusion matching may lead to areas of hypoxia 
within the lung and HIF activity has also been shown to have both beneficial 
and detrimental effects in the lung tissue. 
HIFs/PHDs in the Lung 
The lung is exposed to an enormous range of foreign but innocuous material 
and so must have robust immune tolerance mechanisms. However, it is also 
susceptible to both sterile inflammation and infection with pathogens including 
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viruses, bacteria and fungi. HIF-1a is stabilised in alveolar epithelial cells in 
response to inflammatory stimuli[79]. Resolution and repair in the alveolus is 
dependent upon proliferation and trans-differentiation of alveolar cells and 
HIF-1a dependent VEGF expression was found to be critical for this 
response[79]. HIF-1a was also stabilised in response to stretch injury, 
consistent with mechanical ventilation. Interestingly, this normoxic induction of 
HIF was also found to be protective in acute lung injury (ALI) models[80]. HIFa 
stabilisation was dependent on induction of succinate dehydrogenase and 
consequent inhibition of PHD activity (discussed in detail below). Alveolar 
epithelial cell specific HIF-1a deletion is associated with increased morbidity 
and mortality in stretch induced ALI. In contrast to these findings, Xi et al[81] 
found that, in the context of influenza induced alveolar epithelial cell loss, HIF-
1a activation may be associated with dysfunctional alveolar remodelling. The 
authors found that hypoxia, dependent on HIF-1a activity, was key in 
determining epithelial cell fate and that mice lacking epithelial cell HIF-1a 
recovered more quickly with improved expansion of the type II alveolar cell 
population and restoration of normal epithelium. In addition to these findings 
focussing on acute lung injury, both HIF-1a and HIF-2a in the lung epithelium 
have been shown to play a role in chronic, cobalt induced, lung 
inflammation[82,83]1. Loss of HIF-1a was associated with a switch from type 
1 inflammation (characterised by cytokines such as TNF-a and IL-2) to type 2 
(allergic-type) inflammation with fewer neutrophils but increased eosinophilic 
inflammation and increased Th2 cytokines such as IL-4[82]. HIF-2a deletion 
was similarly associated with enhanced and prolonged eosinophilic 
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infiltration[83]. Interestingly, the time frame of this eosinophilic inflammation 
varied depending on which HIFa isoform was targeted, consistent with other 
studies showing that the predominant isoform varies over the time course of 
an inflammatory response[74], with HIF-2a appearing to predominate in the 
latter, reparative stages of inflammation in the lung. 
The impact of hypoxia on an inflammatory response in the lung is therefore 
difficult to predict and likely to be highly context specific. 
Metabolism and metabolites in inflammation regulation 
Neutrophils are unusual in that, even in the quiescent state, they generate the 
vast majority of their ATP through glycolysis, irrespective of oxygen availability. 
One major advantage of this is their capacity to generate energy rapidly in 
hypoxic environments. However, metabolic intermediaries also have functions 
out-with ATP generation, including in modulation of immune responses. 
Metabolic Intermediaries in Immunity 
The field of immunometabolism is rapidly expanding as novel roles for 
metabolic intermediaries are discovered. There are also close links between 
metabolic signalling pathways and the HIF/PHD hypoxic signalling pathways 
described above (Figure 1.2). The TCA cycle intermediary 2-oxoglutarate is 
an essential substrate for PHD and FIH activity. However, other TCA cycle 
intermediaries including fumarate[84], succinate[85] and citrate[86] can inhibit 
PHD activity. Succinate is also produced during the hydroxylation of HIF by 





Figure 1.2 Multiple links exist between metabolic and hypoxic signalling pathways 
HIF activation leads to enhanced glycolysis through HIF mediated transcription of glycolytic 
enzymes and glucose transporters. HIF activity is, in turn, regulated by a number of TCA cycle 
intermediaries through their effects on PHDs. Metabolic factors may also regulate 
inflammation, for example through ROS production, polarisation of monocytes and regulation 
of CD8+ T cell functions.  
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Metabolic adaptations are also essential in the  polarisation of immune cells, 
particularly macrophages and T cells and HIF mediated transcription is closely 
linked to these metabolic responses. Macrophage activation is associated with 
a metabolic switch from oxidative phosphorylation (OxPhos) to glycolysis[87]. 
This phenotype is favoured by HIF-1a mediated transcription of glycolytic 
genes and glucose transporters and occurs in both hypoxia and in response 
to inflammatory stimuli such as LPS. HIF-2a may be dispensable for regulation 
of some key glycolytic genes[88]. Tannahill et al[89] identified succinate as a 
HIF-1a dependent inflammatory signal in macrophages: succinate production 
by macrophages is required for HIF-1a stabilisation which is, in turn, required 
for production of the cytokine IL-1b.  In a study which has fascinating parallels 
with this work in macrophages, Tyrakis et al[90] describe the critical role played 
by HIFa dependent accumulation of the metabolite S-2-Hydroxyglutarate (S-
2HG) in memory CD8+ T cell development. The authors demonstrate that S-
2HG can enhance proliferation and persistence of memory CD8+ T cells 
through altered epigenetics with consequences for T cell anti-tumour activity. 
In both of these papers, glutamine is an important source of the succinate or 
S2HG through anaplerosis.  
It is not only metabolic intermediaries and enzymes which can influence 
immunity but also the metabolic sensing machinery of the cell and this sensing 
machinery is also closely associated with the hypoxic signalling pathway. 
mTOR and AMPK sense the metabolic microenvironment  
The serine/threonine kinase mammalian (or mechanistic) target of rapamycin 
(mTOR) is a critical regulator of cellular metabolism. mTOR forms two different 
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kinase complexes with discrete upstream regulators and downstream targets. 
This selectivity is determined by the complex specific components. Both 
mTORC1 and mTORC2 contain mTOR (the catalytic component) and mLST8 
while RAPTOR and RICTOR are specific to mTORC1 and 2 respectively. 
RAPTOR (regulatory protein associated with mTOR) binds TOR signalling 
motifs on mTOR substrates, thus recruiting them to the mTORC1 complex and 
also plays a role in subcellular localisation of the complex. RICTOR performs 
a similar role within the mTORC2 complex[91]. The role of mLST8 (also known 
as GbL) in this context is complex and varies with the stage of embryonic 
development and between mTORC1 and 2. In cell culture systems, acute 
knock down of mLST8 by SiRNA, demonstrated that its expression is 
necessary for mTOR mediated phosphorylation of the downstream kinase S6K 
and also influences the nutrient sensitive interaction between mTOR and 
RAPTOR[92] and thus was essential for mTORC1 signaling. However, 
embryonic ablation of mLST8 showed that, in development, mTORC1 
signalling does not require mLST8 but the mLST8 deficient embryo was a 
phenocopy of the RICTOR deficient embryos. mLST8 was required for 
mTOR/RICTOR interactions and therefore mTORC2 signalling[93]. Both 









Figure 1.3 mTOR complexes regulate metabolism, survival and growth 
mTORC1 and mTORC2 contain some common and some specific proteins, as  
illustrated. These include both activating and inhibiting cofactors and also molecules which 
target the complex to specific intracellular locations (RAPTOR and RICTOR). mTORC1&2 are 
activated by distinct upstream signals and, through phosphorylation of multiple downstream 
targets, facilitate metabolic and biosynthetic adaptations to environmental stimuli.  
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Active mTORC1 drives anabolic processes, particularly protein synthesis in 
conditions which are suitable for growth, i.e. in response to endocrine growth 
signals, favourable cellular energetics and adequate macromolecular building 
blocks such as amino acids (Figure 1.3). Two key downstream targets of 
mTORC1 are p70S6 Kinase 1(S6K1) and eIF4E binding protein (4EBP) which 
act to regulate translation through regulation of eukaryotic initiation factors 
(eIFs). S6K acts directly through phosphorylation and activation of eIF4B and 
indirectly via phosphorylation, and therefore enhanced degradation of the 
protein programmed cell death 4 (PDCD4) which would otherwise inhibit 
eIF4B. mTORC1 mediated phosphorylation of 4EBP results in its dissociation 
from eIF4E, allowing formation of the eIF4F complex and therefore promoting 
translation. In addition to regulation of protein synthesis, mTORC1 also 
regulates lipid synthesis via activation of the sterol responsive element binding 
protein (SREBP) and both purine and pyrimidine synthesis via activation of the 
mitochondrial tetrahydrofolate cycle[94] and carbamoyl-phosphate synthetase 
(CAD) [95,96] respectively.  mTORC1 also plays an important part in 
regulating protein catabolism and the related process of autophagy. mTORC1  
phosphorylates the essential component of the autophagosome ULK1 which 
precludes its activation by the AMP activated protein kinase (AMPK). 
Additionally, mTORC1 phosphorylates the transcription factor TFEB which 
results in its retention within the cytoplasm, preventing TFEB mediated 
lysosomal biogenesis[97]. The lysosome is the primary site of intracellular 
protein catabolism, and is essential in autophagy and so, through this 
mechanism, mTORC1 acts to further suppress protein breakdown. Finally, 
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mTORC1 has been found to regulate glucose metabolism, inducing a switch 
from oxidative phosphorylation to glycolysis, at least in part through 
upregulation of HIF-1a and therefore the HIF target genes involved in 
glycolysis[98]. 
In contrast, mTORC2 activity requires release from its negative regulatory 
subunit mSIN1. This is achieved through PtdIns(3,4,5)P3 (PIP3) binding the 
pleckstrin homology (PH) domain of mSIN1p[99], halting its inhibition of mTOR 
kinase activity and occurs downstream of insulin/PI3kinase signalling 
pathways. The major downstream target of mTORC2 is AKT which in turn 
promotes cell survival and growth. AKT may also phosphorylate mSIN1, 
promoting mTORC2 activity in a positive feedback loop. mTORC2 also 
phosphorylates and activates protein kinase C (PKC) family members which 
are involved in cytoskeletal rearrangement. 
mTOR is thus a master regulator of cellular metabolic processes, able to 
respond to diverse stimuli and orchestrate a comprehensive response to the 
metabolic environment. An important parallel signalling pathway in this role is 
via AMP activated protein kinase (AMPK). In contrast to mTOR, AMPK is 
activated in response to metabolic stress, specifically by rising AMP:ATP 
ratios. The downstream action of AMPK is often the converse of mTOR 
activity. For example, AMPK switches on catabolic processes such as glucose 
uptake, fatty acid oxidation and autophagy and inhibits synthesis of proteins, 
fatty acids and glycogen[100]. The balance of mTOR and AMPK activity 
therefore has profound consequences for cell growth and survival and will be 
defined by the metabolic environment. Given the equally important role of 
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hypoxia in regulating these processes, it is perhaps unsurprising that there is 
considerable crosstalk between mTOR, AMPK and hypoxic signalling 
pathways. mTOR activity is supressed by hypoxia due to upregulation of the 
HIF target gene REDD1 and its subsequent activation of the mTOR inhibiting 
tumour suppressor complex (TSC) [101]. Hypoxia has been found to activate 
AMPK independently of HIF-1a[102] but chemical stabilisation of HIF has also 
been reported to increase phosphorylated (active) AMPK[103]. This hypoxia 
induced AMPK activity serves to further suppress mTOR activity in hypoxia 
due to both AMPK mediated TSC2 activation and through direct AMPK 
phosphorylation of RAPTOR[104]. 
mTOR and inflammation 
There are contradictory reports on the regulation of inflammation by mTOR. 
While mTOR inhibitors, typified by Rapamycin, have been used as 
immunosuppressive therapies, particularly in organ transplant, mTOR 
inhibition has also been reported to have pro-inflammatory effects[105,106]. 
As with manipulation of HIF signalling, the cell type, microenvironmental 
context and timing of mTOR targeting are all likely to determine the 
inflammatory outcome. Relatively little is known about the role of mTOR in 
regulating neutrophilic inflammation. Consistent with its activation of AKT and 
PKC, mTORC2 regulates neutrophil migration through alterations in the actin 
cytoskeleton[107]. One study found that mTORC1 mediated HIF-1a was 
required for NET formation in neutrophils[108] however, another study found 
that mTOR inhibition with rapamycin led to accelerated NET formation[109]. 
Importantly, the stimulus for NET formation varied between these studies, and 
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this may have contributed to the contradictory results. mTOR has also been 
implicated in neutrophil cytokine generation with rapamycin treatment in vitro 
leading to reduced TNF-a and IL-6 production[110]. Lorne and colleagues also 
found that pre-treatment with intra-peritoneal rapamycin reduced the severity 
of LPS-induced lung injury although, whether this was due to a specific effect 
on neutrophils is not clear. 
The potential role of mTOR in neutrophils is particularly interesting for three 
reasons. Firstly, as terminally differentiated cells, neutrophils do not proliferate 
and so their requirement for the building blocks of cell growth will be lower than 
those of proliferating cells such as T lymphocytes or tumour cells, thus the 
anabolic effects of mTORC1 activation may have different consequences in 
neutrophils. Secondly, neutrophils undergo constitutive apoptosis but, 
unusually, this is delayed in hypoxia and so it is possible that hypoxic inhibition 
of mTOR in neutrophils may alter cell survival. Finally, neutrophils are primarily 
glycolytic at baseline and so there is no “glycolytic switch” in response to 
metabolic or hypoxic stress (although, glycolysis can be further upregulated in 
activated neutrophils) so the effect of glucose deprivation on both mTOR and 





The literature discussed above demonstrates the vital role played by 
neutrophils in innate immunity but also their capacity to contribute to pathology, 
particularly in the lung. This double-edged sword represents a significant 
challenge in the design of therapies which target neutrophil mediated disease. 
In order to address this unmet clinical need, a more comprehensive 
understanding of the pathways and processes which regulate neutrophil 
function during the inflammatory response is required. There is an increasing 
body of evidence which points to the microenvironment as a critical regulator 
of inflammatory responses. In the lung this will include variations in oxygen 
and nutrient availability as well as diverse cytokine signals. Inflammation, 
hypoxia and metabolism are inextricably linked with multiple points of crosstalk 
identified in their respective signalling pathways. How these factors regulate 
neutrophil function is of interest, in part due to specific aspects of neutrophil 
biology: mature neutrophils are non-proliferative and terminally differentiated; 
they exhibit high basal rates of glycolysis with very limited aerobic respiration 




The broad aim of this thesis is to determine the mechanisms which govern 
hypoxic regulation of neutrophil function. More specifically, it will address the 
following questions: 
• How does hypoxia regulate neutrophilic inflammation in vivo and what 
are the consequences of this regulation? 
• What defines the proteome of inflammatory lung neutrophils and how is 
this regulated by hypoxia? 
• How does the microenvironment of the hypoxic lung contribute to 
neutrophilic inflammation in this context? 
• How do metabolic signalling pathways and hypoxic signalling pathways 




Chapter 2: Methods 
Isolation and culture of human peripheral blood neutrophils 
Human peripheral blood neutrophils were isolated by dextran sedimentation 
and discontinuous percoll gradient. Peripheral venous blood was taken from 
healthy volunteers with written informed consent as approved by the Centre 
for Inflammation Research Blood Resource Management Committee (AMREC 
15-HV-013). Blood was drawn using a 21-gauge (21G) butterfly needle. 36ml 
of whole blood was transferred into a 50ml polystyrene falcon tube containing 
4ml of 3.8% Sodium Citrate and mixed by gentle inversion of the tube. The 
anticoagulated blood was centrifuged at 350G for 20 minutes (acceleration 5, 
deceleration 5). The platelet rich plasma layer was carefully removed. 6ml of 
6% dextran was added to the remaining cell-rich component and topped up to 
50ml with pre-warmed 0.9% sodium chloride (NaCl). This was incubated at 
37°C for 30 minutes to allow dextran sedimentation of the erythrocytes. The 
leucocyte rich top layer was then carefully removed and topped up to 50ml 
with 0.9% NaCl prior to centrifugation at 350G for 6 minutes to pellet the 
leucocytes. A discontinuous percoll gradient was then used to separate 
granulocytes from the whole leucocyte population. A stock solution of 90% 
percoll (GE Healthcare) was made using 10% vol/vol of 10X PBS. 73%, 61% 
and 49% percoll were made by dilution of the 90% stock with 1X PBS as 
detailed in Appendix 1. Gradients were made in 15ml polystyrene falcon tubes. 
3ml of 73% percoll was pipetted into the bottom of the tube and 3ml of 61% 
percoll was gently layered on top. The leucocyte pellet was then resuspended 
in 3ml of the 49% percoll and carefully layered onto the 61% layer. The percoll 
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gradient was centrifuged at 720G for 20 minutes (acceleration 1, deceleration 
0). The peripheral blood mononuclear cell layer was removed from the 
interface between the 49% and 61% layers. The granulocyte layer (at the 
73%/61% interface) was removed carefully using a sterile pastette. The cells 
were then washed twice with sterile 1X PBS prior to haemocytometer counts 
and downstream use. Purity was assessed by morphology on cytocentrifuge 
slides. 
 
Cytocentrifuge slide preparation 
Cytocentrifuge slides (Cytospins) allow analysis of cellular morphology and 
were used throughout this thesis. The cytospin equipment consists of a glass 
slide, a filter paper and a cytospin chamber with a funnel for cells, held together 
with a slide holder. 100µl-200µl of cell suspension (1x105-5x105 cells) was 
pipetted into the funnel and the cytospin was centrifuged at 300 revolutions 
per minute (rpm) for 3 minutes in a CytoSpin3 cytocentrifuge (Thermo 
Scientific). Slides were fixed with 100% methanol and stained using the 
Shandon Kwik-Diff staining system (Thermo Scientific): Slides were first 
stained with Eosin and then with Methylene Blue to delineate nuclear 
structures. Slides were mounted using DPX moutant (Sigma-Aldrich) and a 






C57BL/6JOlA mice were purchased from Envigo, UK. Male mice aged 8-10 
weeks were used in all experiments.  
PHD1 whole animal knockout animals and PHD1fl/fl mice were a gift from Peter 
Carmeliet (VIB Vesalius Research Centre, KU Leuven, Belgium). PHD1fl/fl 
animals were crossed with MRP8-Cre-ires/GFP animals purchased from the 
Jackson Laboratory (stock number 021614) to generate neutrophil specific 
PHD1 deficient mice[111] (Figure 2.1) which will be referred to as follows: 
PHD1fl/flMRP8Cre+/- (knockout, KO) or PHD1fl/flMRP8Cre-/- (wild-type, WT). KO 
mice were healthy and born at normal mendelian frequency. Animals were age 
and sex matched for experiments and used at 2-3 months of age. 
All mouse experiments were conducted in accordance with the Home Office 













Figure 2.1: Generation of the PHD1fl/fl MRP8Cre+/- mouse line 
Mice which were heterozygous for the MRP8 driven Cre recombinase were crossed with 
homozygous PHD1 floxed mice to generate neutrophil specific PHD1 deficient mice (Cre+) 
and wild-type litter mate controls (Cre-).  
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In Vivo mouse models 
Exposure to Hypoxia 
Mice were exposed to hypoxia (10% inspired O2) in an InVivo Hypoxic Cabinet 
System (Coy Labs, USA). This sealed system allows animals to be housed in 
10% oxygen at room temperature with excess CO2 scavenged using 
Sofnolime soda lime chips (Molecular Products, UK) with colour indicator. In 
models of acute hypoxia, LPS stimulated or naïve mice were put into hypoxia 
for 2-48 hours prior to tissue harvest. 
LPS Induced acute lung injury 
Mice were treated with lipopolysaccharide (LPS) from Pseudomonas 
aeruginosa 10 (1mg/ml, Sigma Aldrich) for 10 minutes using oxygen driven 
nebulisation to generate an acute lung injury. Following LPS treatment, 
animals were housed in either normal room air or in hypoxia. Animals were 
culled using an overdose of intraperitoneal (IP) anaesthetic at the appropriate 
time point (2-48 hours post-nebulisation) and tissues harvested. 
Intraperitoneal chloroquine administration 
Following administration of nebulised LPS, as described above, mice were 
treated with intraperitoneal (IP) chloroquine diphosphate (Sigma Aldrich) at a 
dose of 50mg/kg diluted in PBS. Control mice were given IP PBS alone. 
Administration of chloroquine was either immediately following LPS treatment 
or four hours following LPS treatment and/or exposure to hypoxia, as detailed 
in the results section. Following chloroquine or PBS injection, animals were 
housed as before in either normoxia or hypoxia until being culled by overdose 
of intraperitoneal anaesthetic 24 hours post-LPS. 
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Isolation of murine neutrophils 
Blood neutrophils: 
Following overdose of anaesthetic, the peritoneal cavity was dissected, and 
blood withdrawn from the inferior vena cava (IVC) using a 21G needle and 1ml 
syringe. For neutrophil functional assays the syringe was heparinised prior to 
blood collection and for flow cytometry 30µl of 5mM EDTA was added to the 
collection vessel for anticoagulation. For all experiments red blood cell lysis 
was carried out as follows: 1ml of red blood cell lysis buffer (Biolegend) was 
added per 100µl of whole blood in a 15ml falcon tube and incubated at room 
temperature for 5 minutes then topped up to 15ml with PBS. Samples were 
centrifuged for 5 minutes at 350G, the supernatant discarded, and the lysis 
step repeated followed by washing in PBS. Blood neutrophils were purified for 
functional assays using the EasySep negative magnetic selection kit (Stemcell 
technologies). A detailed protocol is in Appendix 2. In brief, the samples were 
blocked with rat serum to reduce non-specific binding, an antibody cocktail 
which binds the unwanted leucocytes with biotinylated antibodies was added 
and, following incubation, cells were washed and resuspended with a biotin 
selection cocktail and then magnetic beads which bind the antibody complexed 
cells. The unwanted cells were then removed by incubation on a plate magnet. 
Following neutrophil isolation cell counts were assessed by haemocytometer 
and purity by morphology on cytospin. Using this technique, purities of 85-95% 
were achieved.  
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Bronchoalveolar lavage (BAL) neutrophils: 
BAL cells were isolated after collection of venous blood. Following dissection 
of the peritoneal cavity the diaphragm was exposed and punctured to induce 
a pneumothorax. The diaphragm and thoracic cavity were then dissected to 
expose the lungs. The trachea was cannulated using a 24G cannula which 
was tied in place. The lungs were washed with ice cold 0.9% NaCl (5 aliquots 
of 0.8ml to give a total of 4ml) and BAL fluid kept on ice until further processing. 
Cell counts were carried out using a haemocytometer and purity assessed by 
morphology on cytospin.  
Highly pure BAL neutrophils 
A discontinuous percoll gradient was used to purify BAL neutrophils for RNA, 
protein and metabolite assays. The protocol is similar to that described for 
human blood neutrophil isolation but was optimised for murine BAL cells: 
Percoll densities were adjusted (as detailed in Appendix 1) and the gradient 
was centrifuged for longer and at a higher speed. BAL cells were first pelleted 
by centrifugation at 350G for 10 minutes. BAL samples from 1-3 mice 
(depending on the final cell number required) were pooled onto a single percoll 
gradient. 3ml of 78% percoll was pipetted into the bottom of a 15ml falcon tube, 
followed by 3ml of 69% percoll. The cell pellet(s) were resuspended in 3ml of 
52% percoll which was then layered onto the 69% layer. The gradient(s) were 
centrifuged at 1200G for 30mins with an acceleration of 1 and deceleration of 
0. Following centrifugation, the macrophages accumulated on the top of the 
52% layer and were removed using a sterile pastette. The neutrophils (within 
the 69% layer) was then removed using a fresh sterile pastette and placed into 
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a 50ml polystyrene falcon tube. This was topped up to 50ml with sterile PBS 
to wash off the percoll and the purified neutrophils pelleted at 350G for 8 mins. 
Residual red cells were lysed by hypotonic saline lysis: The pellet was 
resuspended in 7ml of 0.2% NaCl and incubated at room temp for 5 mins prior 
to adding 7ml of 1.6% NaCl and pelleting the cells by spinning at 350G for 8 
minutes. The pure neutrophils were then counted by haemocytometer prior to 
storage or lysis as appropriate. A cytospin was made prior to the final 
centrifugation step to assess purity by morphology. During optimisation of this 
protocol, purity was also confirmed by flow cytometry and the neutrophils were 
found to be >98% pure. 
Bone Marrow Neutrophils: 
A discontinuous percoll gradient was also used to isolate bone marrow 
neutrophils. Details of the reagents described and percoll preparations are in 
Appendix 1. Both hind limbs were dissected out and stored in a clean bijou on 
ice until processed. The limb was dislocated at the knee and ankle and muscle 
and connective tissue removed from the femur and tibia. Each bone was 
flushed using 10ml of 1xHBSS with 0.2% BSA. The cell suspension was 
resuspended using a pastette and passed through a 70µm filter into a fresh 
50ml polystyrene falcon tube and then centrifuged at 450G for 10 minutes. 
90% vol/vol percoll stock was made using 10X HBSS with NaHCO3 and this 
stock was used to make 81%, 62% and 55% percoll with 1x HBSS (as detailed 
in Appendix 1). All three percoll preparations were layered in a 15ml falcon 
tube and the cells were resuspended in 3ml of 1xHBSS with 0.2% BSA which 
was layered on top of the 52% percoll layer. The gradient was centrifuged at 
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2000G for 30 minutes (acceleration 1, deceleration 0). Bone marrow monocyte 
precursors were removed from the top layer with a pastette and cultured as 
required. Neutrophils were removed from the middle layer and washed in 30ml 
of 1xHBSS with 0.2%BSA. Hypotonic saline red blood cell lysis was carried 
out as described above in the highly pure BAL neutrophil protocol.  
Highly pure bone marrow neutrophils 
Following the percoll purification above, neutrophil purity was found to be 
approximately 90%. In order to generate highly pure bone marrow neutrophils 
samples, cells from the neutrophil layer were resuspended in 1xHBSS with 
0.2% BSA and purified by fluorescence-activated cell sorting (FACS) based 
on the forward/side scatter profile and auto-fluorescence as previously 
described[112]. Cells were collected into 1xHBSS with 0.2% BSA and washed 
with PBS prior to downstream applications. Using this technique, purities of 
>98% were consistently achieved (as analysed by flow cytometry of sorted cell 
populations. 
Murine Lung Digest 
Following the BAL protocol described above, the right ventricle was 
cannulated, and the circulation flushed with 10ml of ice-cold PBS to minimise 
circulating leucocytes within the lung vasculature prior to harvest. Both lungs 
were dissected out and any associated tissues removed before the digest 
protocol. The lung tissue was mechanically dissociated using scissors prior to 





Enzyme Working concentration Source Product code 
Collagenase V 0.8mg/ml Sigma-Aldrich C9263-1G 
Collagenase D 0.625mg/ml Roche 11088882001 
Dispase 1mg/ml Gibco 17105-041 
DNAse 30µg/ml Roche 101 104 159 001 
 
Whole lung tissue was incubated in 2ml of the enzyme cocktail at 37°C for 45 
minutes with continuous shaking and underwent vigorous manual shaking 
every 10 minutes during the digest step. The digest was then passed through 
a 100µm filter into a 50ml polystyrene falcon tube and the plunger of a 5ml 
syringe was used to disrupt any remaining clumps of tissue. The filter was 
rinsed through with PBS and the sample topped up to 50ml. The cell 
suspension was pelleted by centrifugation at 300G for 5 minutes at 4°C. The 
pellet was resuspended in 1ml of red cell lysis buffer (Sigma Aldrich) for 2 
minutes at room temperature before topping up to 50ml with PBS and 
centrifuging again at 300G for 5 minutes at 4°C. The pellet was then 
resuspended in 5ml of FACS buffer (PBS with 5%BSA and 2mM EDTA) and 
passed through a 40µm filter. The cell suspension was counted using a 
NucleoCounter automatic cell counter (Eppendorf)  and after centrifugation at 
300G for 5 minutes, resuspended at a density of 1x106cells/ml. An aliquot of 





For all experiments, murine neutrophils were cultured at a density of 1x106/ml 
and human neutrophils at a density of 5x106/ml. Media was supplemented with 
1% Penicillin Streptomycin (Gibco) and 10% dialysed FCS (Gibco) unless 
otherwise stated.  Neutrophils were cultured in RPMI 1640 media with 2mM 
glutamine (Gibco). The glucose replete media had 11mM D-glucose. 
Standard cell culture was carried out in a Thermo Scientific Heraeus BB15 
CO2 incubator. For hypoxic cell culture, conditions were as above but cells 
were cultured in a Ruskin hypoxic work station (Ruskin, UK) with an O2 of 1% 
and CO2 of 5%. Humidity in the hypoxic work station was maintained at 70%. 
Human embryonic kidney (HEK) 293 Cells 
HEK cell lysates were used as a substrate to analyse the downstream use of 
scavenged proteins. This human cell line was generated by transfection of 
human embryonic kidney cells with adenovirus fragments[113]. HEK 293 cells 
were a gift from Alex Von Kriegsheim (IGMM, University of Edinburgh). Control 
cells were cultured in glucose replete DMEM (Gibco) with 10% dialysed FCS, 
1% Penicillin Streptomycin and 2mM L-glutamine. For glutamine labelling 
experiments, standard L-Glutamine was substituted with 13C5 labelled 
Glutamine (Cambridge Isotopes, USA) for 72 hours prior to being harvested 
and lysed.  
Acetone precipitation of HEK cell proteins 
Cells were harvested by washing with ice-cold PBS. The cells were then 
washed three times with fresh PBS to remove any residual media. The cell 
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pellet was then lysed by hypotonic lysis in 4ml of sterile water prior to 
sonication at 4°C for 10 minutes. The lysate was then divided into aliquots for 
acetone precipitation of protein as follows: The acetone was pre-cooled to -
20°C and then added to the sample at a ratio of 4:1 by volume. The tube was 
vortexed and then incubated at -20°C for 60 minutes. The sample was then 
centrifuged at 13,000G for 10 minutes and the supernatant (containing small 
molecules such as metabolites and amino acids) was discarded. Residual 
acetone was allowed to evaporate by holding the uncapped tube at room 
temperature for 30 minutes. The pellet was resuspended in PBS. Some 
residual insoluble protein material remained and so the sample was 
centrifuged at 13,000rpm for 10 minutes to pellet this material and the 
supernatant utilised for downstream culture. Protein content was measured 
using a BCA assay (Thermo Scientific) and normalised between labelled and 
unlabelled samples. 
Ex vivo culture of BAL neutrophils with labelled proteins 
BAL neutrophils were isolated and purified by percoll gradient as detailed 
above. Following purification neutrophils were resuspended in glucose and 
glutamine free DMEM (Gibco) supplemented with 10% FCS and 400µg/ml of 
HEK cell protein isolated by acetone precipitation as above. Neutrophils were 
cultured at a density of 1x106/ml for 18 hours in hypoxia. Following this period 
of culture, cells were washed three times with sterile 0.9% NaCl prior to 
methanol lysis as detailed below. 
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Bone marrow derived monocytes 
Bone marrow derived monocytes (BMDMs) were generated by taking the top 
layer of cells from the percoll gradient (described above). Cells were counted 
by haemocytometer and resuspended at 3x105/ml in DMEM/F-12 Glutamax 
media (Gibco) with 10% FCS and 1% Penicillin Streptomycin. Media was 
supplemented with 20% L929 conditioned media (as a source of M-CSF) for 
the first 7 days of culture. On day 7 cells were washed and then harvested 
using acutase and after washing in PBS were resuspended in RNA lysis buffer. 
An aliquot was retained to analyse differentiation by flow cytometry based on 





Sample preparation for proteomic analysis 
The workflow for proteomic sample generation is illustrated in Figure 2.2 and 
details of the lysis buffers used are in Appendix 3.  1 x106  highly purified BAL 
neutrophils were lysed in SDS lysis buffer with TCEP at a10mM working 
concentration and boiled for 5 minutes. Samples underwent 15 minutes of 
sonication then incubation with benzonase for 15 mins at 37°C. Protein 
concentration was estimated using the EZQ protein quantitation kit (Invitrogen) 
as per manufacturer instructions. Following quantification, iodoacetamide 
(IAA) was added at a working concentration of 20mM and lysates incubated 
for 1 hour at room temperature. In-solution digestion was carried out using SP3 
beads and LysC (overnight incubation at 37°C) at a concentration of 1µg LysC 
(Promega) per 100µg protein followed by trypsin (Promega) digestion, also at 
1µg enzyme per 100µg protein overnight at 37°C. Peptides were eluted using 
acetonitrile (ACN) and quantified using the CBQCA assay. Samples were 
diluted to a concentration of 1µg/15µl with 5% formic acid and 1µg of peptide 
was submitted for single shot analysis or fractionation. During optimisation 
experiments, single shot analysis of BAL neutrophils recovered approximately 
2000 proteins, while fractionation prior to analysis yielded over 5000 proteins, 
the fractionation strategy was therefore used for all samples. Samples were 
fractionated using strong anion exchange chromatography, analysed in an 
LTQ-Orbitrap Velos MS, and raw data processed using MaxQuant 
software[114]. Subsequent statistical analysis and figure generation was 









Figure 2.2: Proteomic sample processing 
Following purification, BAL neutrophils underwent cell lysis. Proteins were then reduced, 
alkylated and digested using LysC and trypsin. HPLC fractionation improved the yield of 
identifiable proteins. Samples were analysed by mass spectrometry.  
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Neutrophil protein lysates 
Neutrophils possess high levels of proteases necessitating careful lysis with 
strong protease inhibition to avoid breakdown of proteins of interest. In order 
to allow measurement of phosphorylated proteins in neutrophil protein lysates 
the lysis protocol was further optimised to ensure preservation of 
phosphorylated proteins. Protocols for making the buffers described are 
included in Appendix 3. For human peripheral blood neutrophils, 5-10 million 
neutrophils were used per sample and for murine protein lysates, 1 million 
neutrophils were used per sample. 
Isolated neutrophils were washed twice with cold PBS following culture or 
purification. Cells were pelleted by centrifugation at 300G for 5 minutes and 
the supernatant removed.  The pellet was resuspended in Laemmli buffer with 
PMSF, phosphatase inhibitors and protease inhibitors (100µl Laemmli buffer 
per 1 million murine or 10 million human neutrophils). An equal volume of 2x 
SDS lysis buffer was then added and mixed by pipetting. The sample was then 
boiled for 5 minutes prior to storage at -80°C until use. 
Immunoblot for protein expression 
Neutrophil protein lysates were analysed for protein expression by western 
blot. Details of the gels and buffers used are in Appendix 4. Proteins were 
separated by SDS-PAGE using the BioRad mini-protean system prior to wet 
transfer onto PVDF membrane (Merck Millipore). Membranes were blocked 
using 5% skimmed milk powder for a minimum of 2 hours. Primary antibodies 
were made up in 5% skimmed milk in 1X TBS-Tween (TBST, 0.05% Tween) 
and membranes incubated at 4°C overnight on a rolling platform. Details of 
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primary antibodies and their working concentrations are in Appendix 4.  
Membranes underwent three 10-minute washes  in 1X TBST prior to 
incubation with the appropriate horseradish peroxidase (HRP) conjugated 
secondary antibody for 1 hour at room temperature. The membrane was 
washed as above prior to developing in enhanced chemiluminescent (ECL) 
detection reagent (GE Healthcare). Chemiluminescence was assessed using 
a Licor Odyssey Fc machine and quantified using ImageStudioLite software. 
Protein quantification was normalised to a loading control as follows: The 
membrane was stripped using Restore Western Blot stripping buffer (Thermo 
Scientific), washed with dH2O and then re-probed for the loading control 
protein (or, for the non-phosphorylated form of the protein of interest where 
appropriate) with primary and secondary antibodies as above. The membrane 




Neutrophil RNA extraction and TaqMan analysis of gene expression 
The relative paucity of mRNA in neutrophils compared to other immune cells 
means that even a small percentage of contaminating cells can significantly 
influence the results of gene expression analysis and so in all experiments 
highly pure neutrophils were used to generate mRNA samples.  
A minimum of 1x106 neutrophils was required to generate sufficient quantity 
and quality of mRNA. The mirVana miRNA isolation kit (Invitrogen) was used 
to isolate mRNA from samples. A detailed protocol is in Appendix 5. In brief, 
the cell pellet is resuspended in a denaturing lysis solution to stabilise RNA 
and inactivate RNAses. The RNA was extracted using an acid-
phenol:chloroform step and then further purified by immobilisation on a glass-
fibre filter prior to elution with water. The samples then underwent a DNase 
step to ensure removal of any contaminating genomic DNA using the 
Invitrogen TURBO DNA free kit (protocol in Appendix 5). The quantity and 
purity of the RNA was assessed using a Nanodrop 100 spectrophotometer. 
The quantity of RNA used to generate cDNA was dependent on the nature of 
the samples and ranged from 250ng to 1µg. Samples for direct comparison 
were always normalised to generate the same quantity of cDNA and were 
made up to 12.4µl in RNase-free water. cDNA was made using AMV reverse 
transcriptase and random primers(Promega), details of the master mix used 
are in Appendix 6. Samples were run on a Techne Thermal cycler as follows: 
• 23°C for 5 minutes  
• 42°C for 2 hours 
• 99°C for 2 minutes (to heat inactivate AMV RT) 
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Samples were stored at -20°C until use.  
Gene expression was analysed using predesigned qPCR primer/probe assays 
(detailed in Appendix 6) and Prime Time Gene Expression Mastermix (IDT, 
Leuven). For all assays, samples were run in triplicate and the gene of interest 
expressed relative to expression of a housekeeping gene (beta-actin). Assays 
were run on a 7900HT Fast real-time PCR system (Applied Biosystems) with 
the following negative controls: no RNA, no RT and no cDNA. Data was 




Analysis of metabolites 
HPLC-MS analysis of metabolites 
Highly pure BAL neutrophils were analysed for metabolite abundance. 
Following percoll purification as described, cells were washed in ice cold 0.9% 
NaCl prior to being pelleted (300G for 5 minutes). The pellet was lysed by 
resuspension in 80% Methanol which had been stored overnight at -80°C and 
kept on dry ice during resuspension. Prior to analysis, the lysed sample was 
centrifuged at 20,000G for 10 minutes at 4°C and the supernatant removed 
into a fresh Eppendorf tube. The pellet was retained, and protein content 
measured by Pierce BCA assay (Thermo Scientific). Samples were analysed 
at the VIB Center for Cancer Biology in Leuven using a Dionex UltiMate 3000 
LC System (Thermo Scientific) coupled to a Q Exactive Orbitrap mass 
spectrometer (Thermo Scientific) operated in negative mode. Data collection 
was performed using Xcalibur software (Thermo Scientific). All data values 
were subsequently corrected for protein content based on the BCA assay. 
Measurement of intracellular glycogen stores 
BAL neutrophils were isolated 24 hours following LPS induced lung injury. 
1.5x106 highly pure BAL neutrophils cells were lysed in ice cold water and then 
boiled for 5 minutes. The lysate was centrifuged at 13,000G for 5 minutes and 
the supernatant used for measurement of intracellular glycogen using a 
colorimetric plate assay (Sigma Aldrich). The supernatant was used at a 1:2 
dilution and the assay run as per the  manufacturer’s protocol. 
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Murine BAL supernatant analysis 
The first 0.8ml aliquot of BAL fluid was used to analyse the activity or quantity 
of a number of proteins and metabolites within the BAL fluid. The freshly 
isolated aliquot was kept on ice and centrifuged at 2000rpm for 10 minutes at 
4°C to pellet the BAL leucocytes and erythrocytes present in the aliquot. The 
supernatant was removed into a fresh tube, flash frozen on dry ice and stored 
at -80°C until use. In all assays commercial kits were used as per the 
manufacturer protocol and the optimal dilution of samples was ascertained for 
each different analyte. The optimised dilutions were as follows and product 
details are in the Appendix 11 
 Dilution of BAL Fluid 
Activity assays  
Elastase Neat 
Myeloperoxidase Neat 
Quantification assays  
Albumin 1:100000 







*following deproteinization using 25kDa spin column 
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Analysis of murine neutrophils by flow cytometry 
Murine whole blood 
300-500µl blood was collected into 30µl EDTA and underwent red cell lysis as 
described above. Cells were counted using a haemocytometer and 2x105 cells 
were stained for flow cytometric analysis 
Murine BAL 
Whole BAL was counted by haemocytometer and resuspended at a density of 
1x106. An aliquot of 2x105 cells were then stained for analysis. 
Murine lung digest 
Following digest as described above, 2x105 cells were stained and analysed 
by flow cytometry. 
Murine flow cytometry staining protocol: 
Viability assay: For lung digest samples only, samples were first resuspended 
in Live/Dead fixable Aqua stain (Invitrogen) as per manufacturer’s protocol.  
For all tissue types, samples were blocked in 25µl of PBS with 10% mouse 
serum and 1% Fc Block (Biolegend) for 15 minutes on ice. The antibody 
master mix was made up in PBS (with the exception of intracellular staining, 
see below) and 50µl of master mix was added to each sample. Antibody 
concentrations and fluorophore details are in Appendix 7. Cells were stained 
for 30 minutes on ice in the dark prior to being washed three times in FACS 
buffer and either being fixed in 4% PFA for 15 minutes at room temperature or 
analysed immediately on a BD LSR Fortessa cell analyser. For all flow 
cytometry experiments, data was acquired using FACS Diva software and 
analysed using FlowJo software (version 10.1). 
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Intracellular staining of BAL neutrophils for flow cytometry 
Whole BAL was first prepared as above and incubated with an anti-Ly6G 
antibody to allow identification of the neutrophils on subsequent flow 
cytometry. Samples were washed twice with PBS prior to staining for 
intracellular markers.  A commercial “cytofix/cytoperm” kit was used for this 
assay (BD Biosciences) to improve intracellular staining. Cells were 
resuspended in 200µl of fixation/permeabilisation solution for 20 minutes at 
4°C. All wash and subsequent antibody incubation steps were carried out in 
1x Perm/Wash buffer to maintain permeabilisation (this wash solution contains 
FBS and saponin). Following fixation, samples were washed and resuspended 
in 50µl of Perm/Wash buffer containing the fluorophore conjugated primary 
antibody. Samples were incubated for 30 minutes at 4°C and then washed 
twice. Samples were then resuspended in FACS buffer and analysed as 
detailed above.  
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Neutrophil Functional Assays 
Phagocytosis 
Phagocytosis was assessed by uptake of fluorescently labelled, heat killed E 
Coli. BAL neutrophils were isolated as above, resuspended at 1x106 cells/ml 
and incubated at 37°C for 1 hour in RPMI with 10% FCS with the bacteria at a 
multiplicity of infection (MOI) of 1. For each sample an ice control was run to 
account for extracellular adhesion of bacteria. In this case cells were incubated 
as above but in an iced water bath for 1 hour. All samples were washed 3 times 
with ice cold PBS prior to being resuspended in FACS buffer and analysed by 
flow cytometry. 
Chemotaxis 
Chemotaxis assays were performed on murine BAL neutrophils isolated 
following LPS induced lung injury. Whole BAL was counted and resuspended 
at 2x106cells/ml. The assay measured movement of cells across a filter 
towards a chemoattractant (KC, also called CXCL1, for murine neutrophils) 
using the ChemoTx plate system (Neuro Probe). A positive control, 
chemokinesis control and negative control were run with each assay and a 
dose response was measured by using different concentrations of the 
chemoattractant. An example plate plan is in Appendix 8. The chemoattractant 
or control was pipetted into the bottom well of the plate, the filter was then 
placed on top and the cell suspension pipetted onto the filter. The plate was 
incubated at 37°C for 1 hour with a lid on. Residual cell suspension was 
removed from the top of the filter using a cotton bud and the plate centrifuged 
(without the lid) for 10 minutes at 300G. The filter was removed and the cellular 
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concentration (i.e. the number of cells which have migrated across the filter) 
was measured in each well using a haemocytometer count of the resuspended 
well contents. This number was adjusted for the volume in each well to give 
an absolute cell count. 
Respiratory burst assay 
Neutrophil respiratory burst was measured by a chloromethyl derivative of 
2’,7’-Dichlorodihydrofluorescein diacetate (CM-H2DCFDA, Invitrogen). Upon 
oxidation H2DCFDA becomes the green fluorescent 2’,7’-Dichlorofluorescein. 
The dye is cell permeable and passively enters the cell. Upon oxidation it emits 
a green fluorescent signal which can be measured by flow cytometry. The 
baseline oxidative stress and respiratory burst capacity of BAL neutrophils was 
measured as follows: 
CM-H2DCFDA was resuspended in at 50µg/5µl of DMSO. This was then 
diluted 1:100 with PBS to make up the stock solution. 3µl of this stock solution 
was added to 100µl of BAL neutrophils at 1x106/ml and cells were incubated 
at 37°C for 45 minutes. To measure respiratory burst capacity, the formylated 
peptide F-met-leu-phe (fMLF, Sigma Aldrich), a potent stimulator of 
neutrophils, was added after 45 minutes for a further 45 minutes at a final 
concentration of 10µM. Following this second incubation the samples were 





Measurement of neutrophil apoptosis  
Neutrophils display characteristic nuclear morphology both when viable and 
when undergoing apoptosis allowing the extent of apoptosis to be analysed by 
nuclear morphology on a cytospin with light microscopy. Alternatively, 
apoptosis may be quantified using flow cytometry techniques. These exploit 
one of two key events which occur during apoptosis and if used in combination 
can distinguish early and late apoptosis. Annexin V binds phosphatidylserine 
(PS) residues which are externalised (and thus available to bind to Annexin V) 
early in the process of apoptosis. Annexin V is conjugated to a fluorophore to 
allow identification of PS positive cells by flow cytometry.  Cells dying by both 
apoptosis and necrosis will undergo a loss of membrane integrity. TO-PRO-3 
stain is a cell impermeable dye which binds double stranded DNA. Once the 
plasma membrane is compromised during cell death, TO-PRO-3 can bind the, 
now accessible, DNA and emits far-red fluorescence. Thus, by dual staining 
with both Annexin V and TO-PRO-3 cells can be identified as viable (double 
negative), early apoptotic (Annexin V positive), late apoptotic (double positive) 
or necrotic (TO-PRO-3 positive). 
Apoptosis by morphology 
Following culture and/or treatment, a cytospin was generated. Apoptosis was 
assessed by morphology and 300 neutrophils in total are counted to ascertain 
the percentage of apoptosis for each cytospin. 
Apoptosis by flow cytometry  
Following culture and/or treatment, cells were washed in PBS prior to staining. 
1X Annexin binding buffer (BD Biosciences UK) was made and cells were 
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resuspended in 100µl of 1x binding buffer with Phycoerythrin (PE) conjugated 
Annexin V at a dilution of 1:25. Samples were incubated on ice for 20 minutes. 
TO-PRO-3 stain was made up at a 1:5000 dilution with 1x Annexin binding 
buffer. Immediately before running the sample on the flow cytometer, 100µl of 
diluted TO-PRO-3 was added to the sample. 
Cell counts with flow cytometry 
In order to measure cell loss in conjunction with flow analysis of apoptosis, 
CountBright beads (Invitrogen) were used to provide an accurate total cell 
count. 10µl of bead suspension was added to each sample prior to the addition 
of TO-PRO-3 stain. These 7µm beads are provided in a suspension at a known 
concentration and are fluorescent across multiple channels. They can 
therefore be gated on and counted by the flow cytometer and the ratio of cells 
to beads used to calculate the cellular concentration of the sample.  
Flow cytometry was carried out on a BD LSR Fortessa cell analyser. Data 





Dextran and albumin uptake assays 
In order to investigate the capacity of neutrophils to take up proteins and other 
substances from the extracellular environment, uptake assays were carried 
out using three different compounds: 
70kDa dextran has been shown to be taken up exclusively via fluid phase 
uptake, i.e. macropinocytosis. Neutrophil macropinocytosis was measured by 
culturing neutrophils in media supplemented with Texas-Red labelled 70kDa 
dextran (Invitrogen) at a final concentration of 1mg/ml. Samples were then 
washed once in ice-cold citric acid (pH5.5) then twice with cold PBS. Uptake 
was quantified by flow cytometry and localisation assessed by confocal 
microscopy (see below). 
Fluorescently labelled BSA (Invitrogen) was used to measure neutrophil 
albumin uptake. Neutrophils were cultured in complete media with FITC or 
Texas-Red labelled BSA (Invitrogen) at a final concentration of  200µg/ml. 
Double-quenched (DQ) Green BSA (Invitrogen) was used to measure 
proteolytic cleavage of BSA taken up by neutrophils. This compound is a 
derivative of BSA which is labelled with sufficient BODIPY dye that the dye is 
self-quenching. Upon proteolytic cleavage, a single, BODIPY-labelled albumin 
peptide is released and is de-quenched, resulting in a fluorescent signal. 
Importantly, this signal in independent of pH. For both the fluorescent and DQ 
labelled BSA, samples were washed as detailed above for the dextran assay 
and fluorescence measured by flow cytometry and localisation analysed by 
confocal microscopy. 
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In order to assess the effect of hypoxia and glucose deprivation on albumin 
uptake and breakdown, neutrophils were pre-incubated in either normoxia or 
hypoxia, in glucose deplete or replete media for 2 hours prior to the addition of 
the fluorescently labelled compound (± LPS at a final concentration of 
100ng/ml).  
Lysosomal inhibitors were used to treat unstimulated neutrophils as follows: 
Following two hours of culture (to equilibrate to culture conditions), the 
protease inhibitor E64 or chloroquine (Sigma-Aldrich) were added at a final 
concentration of 2µM and 10µM respectively, both for 1 hour prior to 
fluorescent albumin being added. 
The mTOR inhibitor rapamycin (Sigma-Aldrich) or the activator of mTOR 
MHY1485 (Merck chemicals) was added to neutrophils at final concentrations 
of 50nM and 2µM respectively. As before, cells were equilibrated to culture 
conditions for 2 hours first and the inhibitor was added for 1 hour prior to the 
addition of LPS and fluorescent albumin. For both the lysosomal inhibitor 
experiments and the mTOR modulating experiments, fluorescent albumin 
products were added for 90 minutes and the cells were subsequently washed 
and run on flow cytometry as before. 
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Confocal microscopy of neutrophils 
Confocal microscopy was used to delineate the intra-cellular location of the 
fluorescently labelled compounds described above. Following culture with 
fluorescent compounds, neutrophils were washed with ice-cold PBS three 
times. Neutrophils then underwent fixation and permeabilisation prior to 
additional staining. Two different strategies were used for this process: 
1. Co-localisation of dextran and BSA: Cells were cultured with Texas Red 
dextran and FITC-BSA simultaneously (as detailed above). The cells 
were then washed and fixed in 4% PFA for 15 minutes at room 
temperature followed by permeabilisation with 0.1% Triton X100 for 15 
minutes at room temperature. The cells were washed again in PBS 
before staining with a deep-red cell mask (Invitrogen) by resuspending 
the washed cells in 200µl of cell mask at a final concentration of 1µg/ml 
for 30 minutes at room temperature. 
2. LAMP1 staining for colocalization of DQ-Green signal with the 
lysosome: A commercial “cytofix/cytoperm” kit was used for this assay 
(BD Biosciences) to improve intracellular staining. Cells were 
resuspended in 200µl of fixation/permeabilisation solution for 20 
minutes at 4°C. All wash and subsequent antibody incubation steps 
were carried out in 1x Perm/Wash buffer to maintain permeabilisation 
(this wash solution contains FBS and saponin). The primary antibody 
was a mouse monoclonal antibody to human LAMP1 (Abcam) and cells 
were stained for 1 hour at a final antibody concentration of 10µg/ml 
before being washed twice and stained with an Alexa Fluor 647 
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conjugated goat anti-mouse secondary antibody (Abcam) used at 1:200 
(50µl per sample) for 1 hour at room temperature.  
For both strategies, cells were washed twice following the final staining step 
and the pellet resuspended in ProLong Gold liquid mountant with DAPI for 
nuclear staining (Invitrogen). This suspension was pipetted (with care to avoid 
bubbles) onto a glass slide and covered with a glass coverslip. Slides were left 
to dry for at least 24 hours in the dark. Confocal images were acquired using 
a Leica SP5 confocal laser scanning microscope with Leica Application Suite 
software. 




Chapter 3: Systemic Hypoxia Results in a 
Hyperinflammatory Neutrophil Phenotype 
Introduction 
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are 
clinical syndromes characterised by lung inflammation, increased vascular 
permeability, and hypoxaemia[116]. ALI and ARDS represent a continuum 
with more severe hypoxia defining ARDS. ALI and ARDS are associated with 
significant morbidity and mortality (a meta-analysis of published data found the 
average mortality rate for ARDS was 43%)[117].  In addition to being a defining 
feature of ALI and ARDS[118], the degree of hypoxia is also associated with 
negative outcomes, including increased alveolar damage[119] and increased 
mortality[120]. Neutrophil infiltrates are characteristic of ARDS and the extent 
and persistence of lung neutrophilia are correlated with increased 
mortality[121].  Hence, the impact of hypoxia on neutrophilic inflammation is 
an important consideration in this disease. 
The inflammatory response is a dynamic process, in functional immunity this 
is characterised by onset of inflammation (due to infection or injury), 
recruitment and activation of immune cells, removal of the pathogen or healing 
of the injury and resolution of the inflammatory response. Neutrophils play an 
important part in initiation of immunity due to their capacity to move rapidly to 
sites of injury and control the invading pathogen through multiple antimicrobial 
tools. Neutrophils also facilitate induction of adaptive immunity. In viral 
infections such as Influenza, infected neutrophils are able to act as antigen 
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presenting cells (APCs) to CD8+ T lymphocytes[122]. Neutrophils are also an 
important source of inflammatory cytokines and chemokines which have been 
shown to recruit dendritic cells (professional APCs) to the site of infection[123]. 
Timely resolution of the inflammatory response is essential to restore 
homeostasis. Neutrophils which have been recruited to the site of infection or 
inflammation must be cleared to avoid release of further inflammatory 
mediators and perpetuation of the inflammatory response. Apoptosis or 
programmed cell death is an important step in resolution of neutrophilic 
inflammation[22]. Neutrophils undergoing apoptosis become unresponsive to 
inflammatory stimuli, stop releasing inflammatory mediators and are subject to 
uptake by macrophages (efferocytosis) [124] which in turn, polarises a pro-
resolution macrophage phenotype. Failure of neutrophils to undergo apoptosis 
may therefore result in persistent inflammation and significant tissue damage. 
In order to understand regulation of the neutrophil inflammatory response, we 
must therefore consider each stage of the response because the sum of all 
these events will determine the overall outcome. 
Neutrophils are the most abundant leucocyte in the circulation. They are 
therefore poised ready to move in response to danger signals in the tissues. 
Neutrophil recruitment typically occurs by transendothelial migration in the 
post-capillary venule. At sites of inflammation this is mediated by regulation 
and activation of a series of receptors present on the neutrophil surface.  
Additionally, activation of the endothelium in response to infection or injury 
results in upregulation of receptors and ligands which facilitate recruitment and 
migration of neutrophils. Both neutrophils and endothelial cells express 
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Selectins and their carbohydrate ligands. Selectin-ligand interactions allow 
tethering and rolling of neutrophils. This is initially a reversible interaction but 
additional activation of neutrophils (for example by chemoattactants or 
inflammatory stimuli) results in L-selectin shedding and upregulation of 
molecules involved in firm adhesion such as the integrin MAC-1 (a heterodimer 
of CD11b and CD18) which binds intracellular adhesion molecule 
(ICAM)1[125].  Subsequent crawling of neutrophils in response to chemokine 
signalling is followed by extravasation via transendothelial migration. Both the 
architecture and vascular supply to the lung have resulted in specific 
adaptations to neutrophil recruitment in this organ. The more proximal airways 
are supplied by the bronchial arterial circulation and neutrophils migrate from 
these vessels as described above. Meanwhile, the pulmonary circulation, 
whose primary role is in gas-exchange, predominates in the distal airways and 
alveolus. The alveolar capillaries are small in diameter, often smaller than the 
circulating neutrophils[126]. This has two important consequences, firstly 
neutrophils are required to deform from their usual spherical shape in order to 
pass through narrow capillaries. Secondly, neutrophil progress through the 
pulmonary vasculature is slowed down resulting in a pool of so-called 
marginated neutrophils within the pulmonary circulation[127]. This slowing is 
also thought to obviate the need for a rolling step in recruitment from these 
vessels. Neutrophil migration into the alveolus from the pulmonary circulation 
does not occur in the post-capillary venules but rather from the capillary bed 
and does not rely on the traditional rolling, firm attachment, crawling paradigm 
described above. The factors which regulate neutrophil transendothelial 
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migration in this context vary with the inflammatory stimulus but are likely still 
to be at least partially dependent on integrins and selectins[128].  
Chemotaxis within the tissue is then mediated by further chemokine-receptor 
interactions. CXCR2 is an important chemokine receptor present on 
neutrophils. In the mouse, CXCR2 binds to the chemokines KC and MIP2 (also 
known as CXCL1 and CXCL2) and CXCR2 and its ligands have been found 
to be essential for neutrophil recruitment to the lung[129-131].   
Upregulation of CD11b and shedding of CD62L (L-selectin) have been widely 
used as a measure of neutrophil activation status both in the circulation and in 
the lung[25,132]. Although, as the process of extravasation above describes, 
transmigration alone is likely to be associated with upregulation of CD11b and 
shedding of CD62L, indeed, in studies of patients with sarcoidosis[133] and 
asthma[134], both patients and controls showed higher CD11b and lower 
CD62L in lung compared with blood neutrophils. So, while surface expression 
of these molecules may provide some clues as to the activation status of 
neutrophils, more detailed analysis of neutrophil functions is required to fully 
understand their activity and capacity for host tissue damage. 
In sterile inflammatory disorders, such as ARDS, the neutrophil antimicrobial 
arsenal has the capacity to cause severe host tissue damage. An important 
facet of the neutrophil antimicrobial response is the release of proteases, 
oxidant-producing enzymes and other molecules from granules upon 
appropriate stimulation. In order to facilitate rapid release of these proteins in 
response to infection, granules and their contents are preformed and 
packaged during neutrophil maturation in the bone marrow. This packaging 
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also serves to protect the neutrophil from the toxic granule contents[135]. Four 
different granule types are recognised, azurophil or primary granules, specific 
(secondary) granules, gelatinase or tertiary granules and secretory vesicles. 
Each has a specific repertoire of proteins, targeted to the appropriate granule 
subtype during granulopoiesis through a temporally regulated programme of 
transcription and translation[136]. Granules contain proteins which are 
released upon degranulation but also cell surface receptors in their inner 
membrane which, upon fusion of the granule membrane with the neutrophil 
plasma membrane, are presented on the cell surface. Degranulation is 
necessarily a highly regulated process as inappropriate release of these toxic 
proteins risks host cell and tissue damage. Neutrophil elastase is a serine 
protease present in azurophilic granules. Elastase release in the lung 
correlates with disease severity in cystic fibrosis[137] and serum elastase 
levels are increased in patients with COPD[138]. The serine protease inhibitor 
alpha 1-antitrypsin (encoded by the serpinA1 gene) inhibits neutrophil elastase 
and alpha 1-antitrypsin deficiency is associated with development of 
emphysematous lung disease due to unopposed elastase mediated lung 
damage[139].  Regulation of neutrophil degranulation is therefore key in 
neutrophilic inflammation in the lung. Degranulation requires a coordinated 
intracellular response involving recruitment of granules to the plasma 
membrane, tethering of the granule membrane to the target membrane, fusion 
of the two membranes and release of granule contents. These processes 
require intracellular calcium signaling, cytoskeletal reorganization and 
activation of multiple intracellular signaling cascades. All of this occurs in 
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response to activation of various extracellular receptors including the 
formylated peptide receptors, GM-CSF receptors and toll-like receptors. 
Hypoxia (which often accompanies respiratory disease) and inflammatory 
processes frequently co-exist. Neutrophils are required to function in markedly 
hostile environments where oxygen and nutrient availability are often low. As 
such, neutrophils are well adapted to survive and function in hypoxia. 
Neutrophils are unusual in that hypoxia is a profound survival stimulus for 
these, usually short lived, cells[21]. Key neutrophils functions including 
chemotaxis[140], and phagocytosis[141] are also preserved in hypoxic 
conditions. There is increasing evidence that hypoxia and hypoxic signaling 
pathways may result in enhanced neutrophilic inflammation. Hypoxia is known 
to increase neutrophil degranulation[142] and our group has shown that 
systemic hypoxia in the context of bacterial infection results in significant, 
neutrophil mediated, morbidity and mortality[143]. Furthermore, PHD2 
inhibition or loss and subsequent HIF activation in myeloid cells resulted in 
exaggerated neutrophilic inflammation in response to Streptococcus 
Pneumoniae and in an LPS-induced acute lung injury model. 
These data suggest that neutrophils display a degree of plasticity not 
previously recognised. The concept of polarisation in immune cells is well 
established in T cell and macrophage biology. It is increasingly apparent that 
neutrophils are a less homogeneous population than was previously thought. 
There is evidence that, in the context of the tumour environment, neutrophils 
can be polarised to an anti- or pro-tumour phenotype (so called N1 or N2 
respectively) with TGF-b signalling favouring pro-tumour neutrophil 
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development[144]. More recently, treatment with a peroxisome proliferator-
activated receptor g (PPARg) agonist was shown to favour an N2 neutrophil 
phenotype in neuronal inflammation following ischaemic injury and was 
associated with enhanced resolution of inflammation[145]. The nature of the 
neutrophil response is therefore heterogenous and is likely to be influenced by 
microenvironmental factors within the inflammatory milieu. I hypothesise that 
hypoxia, a common feature of inflammatory environments, will play an 
important role in shaping neutrophil responses. Given the evidence that 
hypoxia may enhance neutrophilic inflammation, I sought to define the 
mechanisms by which this occurs in the context of acute lung inflammation. I 
hypothesised that hypoxia results in a hyperinflammatory neutrophil 




Hypoxia exacerbates acute lung injury, independent of neutrophil number 
To investigate the role of hypoxia in regulating neutrophilic lung inflammation, 
I utilised a murine model of LPS-induced acute lung injury. This model of sterile 
inflammation produces a homogeneous and reproducible neutrophil mediated 
lung injury and allows study of the effect of hypoxia on host immune cells 
without the complication of hypoxic regulation of bacterial function associated 
with infection models. In the context of LPS induced ALI, concurrent exposure 
to hypoxia results in profound hypothermia over the first 24 hours (Fig 3.1A). 
Exposure to hypoxia in the absence of LPS nebulisation resulted in mild 
hypothermia but this resolved fully by 24 hours. This is a well-established 
model of neutrophilic inflammation and so it was interesting to note that the 
increasing sickness in hypoxia is not associated with increasing numbers of 
neutrophils in the BAL fluid for the first 24 hours (Fig 3.1B). However, by 48 
hours post-injury, there is a trend towards higher neutrophil numbers in 
hypoxia, suggestive of impaired inflammation resolution (Fig 3.1B). At 24 hours 
post-LPS, there was also no difference in interstitial lung neutrophils (Fig 3.1C) 
and significantly fewer circulating neutrophils (Fig 3.1D). 
In addition to the hypothermia observed in hypoxia, analysis of the BAL fluid 
supernatant also revealed increased lung injury with significantly increased 
albumin (Fig 3.2A) and IgM (Fig 3.2B) leak in hypoxia. Furthermore, there was 
evidence of increased neutrophilic inflammation with higher neutrophil 
elastase activity in hypoxic BAL supernatant, despite the similar numbers of 




Figure 3.1: Hypoxia results in increased sickness without higher neutrophil numbers 
(A) Body temperature of mice following nebulised LPS (black circles), hypoxia (10% O2) alone 
(black triangles ) and hypoxia following nebulised LPS (white circles), n=4. (B) BAL neutrophil 
counts of mice housed in either normal room air (normoxia) or hypoxia (10 %O2) following 
nebulised LPS, n≥4. (C) Lung neutrophil counts and (D) blood neutrophil counts of mice 
housed in normoxia or hypoxia for 24 hours following LPS nebulisation, n≥6, data merged 2 
(C) or 3 (D) experiments. (A) analysed by 2-way ANOVA with Tukey’s multiple comparisons 
test, (B) significance analysed by multiple t-tests (corrected for multiple comparisons using 
Bonferroni method), * p<0.05, ** p<0.01, **** p<0.0001. (C)&(D) Mann-Whitney test of 
significance. (A)&(B) Data represents mean ± SEM, (C)&(D) Data represents individual values 
and mean ± SEM. 
 















































































Figure 3.2: Hypoxia results in increased lung damage and increased neutrophilic 
inflammation 
BAL supernatant from normoxic and hypoxic mice, 24 hours post-LPS was analysed for (A) 
albumin (n=9 over 3 experiments) and (B) IgM (n=6 over 2 experiments)  by ELISA and for (C) 
elastase activity by the EnzCheck activity assay (n=5). Mann-Whitney test of significance. 



















































Hypoxia influences activation status and chemokine receptor expression in 
BAL neutrophils 
In order to investigate the phenotypic differences between hypoxic and 
normoxic neutrophils, I analysed the surface receptor expression profiles of 
blood and BAL neutrophils from hypoxic and normoxic animals subjected to 
LPS induced ALI. Analysis of ex vivo BAL neutrophils by flow cytometry 
revealed evidence of increased activation with hypoxic neutrophils showing 
significantly increased CD11b expression (Fig 3.3A) and significantly 
enhanced CD62L shedding (Fig 3.3B). The chemokine receptor CXCR2 which 
recognises the chemokines KC (CXCL1) and MIP2 (CXCL2) mediates 
neutrophil recruitment to the lung[129,146,147]. Expression of this receptor on 
peripheral blood neutrophils is regulated by in vivo hypoxia with significantly 
lower levels of expression found on blood neutrophils from hypoxic mice (Fig 
3.3C). These data suggest that other factors must play a role in neutrophil 
recruitment in hypoxia because the lower numbers of circulating neutrophils 
coupled with the preserved numbers of lung neutrophils seen in hypoxia (Fig 
3.1B-D) would suggest an enhanced capacity for neutrophil recruitment in the 










Figure 3.3: Hypoxia results in increased neutrophil activation and augmented 
chemokine and chemokine receptor expression  
BAL neutrophils isolated 24 hours post- nebulised LPS from normoxic or hypoxic mice were 
analysed by flow cytometry for surface expression of (A) CD11b and (B) CD62L, n=6-7 over 
2 experiments. Peripheral blood neutrophils from normoxic and hypoxic mice, 24 hours post-
LPS, were analysed for CXCR2 expression by flow cytometry (C), n=6-7 over 2 experiments. 












































































Defining the proteome of inflammatory lung neutrophils 
Understanding the identity of an inflammatory neutrophil is essential in 
devising novel therapeutic strategies to target neutrophilic inflammation. In 
order to characterise inflammatory lung neutrophils more fully and to determine 
how it is influenced by hypoxia, I undertook proteomic analysis of inflammatory 
lung neutrophils. 
Highly pure BAL neutrophils were isolated from mice 24 hours after LPS 
induced acute lung injury. High resolution mass spectrometry was used to 
define the proteome of these cells. Three biological replicates were analysed 
with strong correlation between replicates (Fig 3.4A). The mass spectrometry 
proteomics data have been deposited to the ProteomeXchange Consortium 
via the PRIDE partner repository with the dataset identifier PXD013672. 
I identified over 5000 proteins from 57 000 peptides. The absolute copy 
number of proteins was calculated using the ‘proteomic ruler’ approach[148]. 
Of the ~5000 proteins, a small number account for a large proportion of the 
protein mass with only 17 proteins accounting for 25% of the protein mass and 
73 proteins making up 50% of the protein mass (Fig 3.4B). All proteins were 
divided into quartiles and the top 2 quartiles were analysed for KEGG pathway 
enrichment (as compared to the whole neutrophil proteome). This analysis of 
the most abundant proteins provides insights into the key processes 
undertaken by inflammatory neutrophils with metabolic, migratory and 
inflammatory pathways being highlighted (Fig 3.4C). The 25 most abundant 
proteins are expanded in figure 3.4C and, again, shows the high abundance 
of inflammatory and metabolic proteins. I also investigated the cellular identity 
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of the inflammatory neutrophil by comparing the genes corresponding to the 
whole neutrophil proteome with the whole mouse genome. In this analysis 
neutrophils demonstrate enrichment in inflammatory but also metabolic 
pathways (Table 1 and 2). The abundant glycolytic capacity of these cells is 
illustrated by the very high copy number of all of the glycolytic enzymes (Fig 
3.4D) with the majority of enzymes being present at >100,000 copies per cell. 
Despite being harvested at a time point where significant degranulation has 
occurred, the copy number of granule proteins from all three granule subtypes 
remains high (Fig 3.4E), over 1x106 copies of many granule proteins were 
found. Both glycolytic enzymes and granule proteins are represented in the 
top 25 proteins (highlighted in Fig 3.4C in orange and purple respectively), 





Figure 3.4: The proteome of the inflammatory neutrophil 
 (A) Correlation of protein copy number for three biological replicates (N1-N3) with R2 value 
shown for each comparison. (B) The contribution of each protein to the total protein mass was 
calculated using the copy number and molecular mass for each of the  5398 identified proteins, 
the number of proteins accounting for percentage of total protein mass is shown in blue. (C) 
Proteins were divided into quartiles based on the copy number abundance and KEGG pathway 
analysis of enriched pathways in the top two quartiles of the proteome was carried out. 
Pathways enriched in the top quartile are in dark blue and those enriched in the 2nd quartile 
are in turquoise. The top 25 proteins (by copy number) are expanded, highlighting glycolytic 
enzymes (orange) and inflammatory pathways (purple). (D) Glycolytic enzymes are expressed 
in high copy numbers; the dotted line illustrates that most are present at more than 105 copies 
per cell. (E) Copy number of granule proteins from all granule types. For all data n=3. (B) and 
(C) copy number analysis based on mean of three biological replicates. (D)&(E) Data 
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Rank Protein Gene symbol
Est Copy 
number
1 Histone H4 Hist2h4 1.06E+08
2 Protein S100-A9 S100a9 6.10E+07
3 Actin, cytoplasmic 1 Actb 5.88E+07
4 Histone H3 Hist2h3b 4.99E+07
5 Histone H2A Hist1h2ah 3.52E+07
6 Annexin A1 Anxa1 3.31E+07
7 Histone H2B Hist1h2bm 2.41E+07
8 Protein S100-A8 S100a8 1.69E+07
9 Histone H1.4 Hist1h1e 1.59E+07
10 Cofilin-1 Cfl1 1.55E+07
11 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 1.17E+07
12 Rho GDP-dissociation inhibitor 2 Arhgdib 1.09E+07
13 Chitinase-like protein 3 Chil3 1.09E+07
14 Histone H1.3 Hist1h1d 1.05E+07
15 Profilin-1 Pfn1 9.92E+06
16 Pyruvate kinase PKM Pkm 8.76E+06
17 Peroxiredoxin-5, mitochondrial Prdx5 8.43E+06
18 Alpha-enolase Eno1 8.32E+06
19 Transketolase Tkt 7.55E+06
20 Leukocyte elastase inhibitor A Serpinb1a 7.22E+06
21 Neutrophilic granule protein Ngp 7.20E+06
22 Cathelin-related antimicrobial peptide Camp 7.14E+06
23 Lactotransferrin Ltf 6.03E+06
24 Histone H1.5 Hist1h1b 5.98E+06







KEGG Pathway Term Count P Value Fold Enrichment 
Fc gamma R-mediated phagocytosis 65 1.1E-13 2.118 
Bacterial invasion of epithelial cells 56 9.4E-10 1.965 
Lysosome 87 1.7E-14 1.952 
NOD-like receptor signalling pathway 39 1.8E-06 1.906 
VEGF signalling pathway 41 1.9E-06 1.870 
Endocytosis 185 1.2E-24 1.821 
Phagosome 105 2.6E-10 1.651 
TNF signalling pathway 63 1.1E-05 1.582 
Toll-like receptor signalling pathway 56 1.7E-04 1.517 
HIF-1 signalling pathway 57 2.2E-04 1.500 
NF-kappa B signalling pathway 49 5.8E-03 1.382 
Antigen processing and presentation 41 1.5E-02 1.368 
MAPK signalling pathway 124 4.2E-05 1.341 
Chemokine signalling pathway 89 9.0E-03 1.243 











KEGG Pathway Term Count P Value 
Fold 
Enrichment 
Pentose phosphate pathway 27 1.9E-08 2.463 
Amino sugar and nucleotide sugar metabolism 44 1.3E-13 2.457 
Fructose and mannose metabolism 29 5.3E-08 2.334 
Citrate cycle (TCA cycle) 27 2.7E-07 2.309 
Galactose metabolism 25 1.0E-05 2.138 
Pentose and glucuronate interconversions 28 2.8E-06 2.128 
Propanoate metabolism 21 7.9E-05 2.128 
Carbon metabolism 90 5.7E-19 2.123 
mTOR signalling pathway 45 2.7E-09 2.087 
Biosynthesis of amino acids 56 9.4E-10 1.965 
Pyruvate metabolism 28 3.3E-05 1.965 
Fatty acid metabolism 35 1.1E-05 1.878 
Insulin signalling pathway 90 5.2E-11 1.759 
Glutathione metabolism 35 1.2E-04 1.741 
Biosynthesis of unsaturated fatty acids 17 1.3E-02 1.723 
Glucagon signalling pathway 62 4.9E-07 1.697 
Cysteine and methionine metabolism 24 5.4E-03 1.642 
Starch and sucrose metabolism 19 1.8E-02 1.625 
AMPK signalling pathway 75 4.2E-07 1.616 








Tables 1 and 2: Neutrophils show enrichment for inflammatory and metabolic pathways 
The genes encoding the 5398 proteins identified in the neutrophil proteome were compared 
with the whole mouse genome using DAVID software to identify pathway enrichment. Enriched 
KEGG pathway terms with their corresponding gene counts, significance and fold enrichment 
are shown. Table one shows selected inflammatory pathways and table 2 shows selected 




Hypoxia results in a distinct neutrophil proteomic signature 
The increased neutrophilic inflammation and lung damage which is associated 
with hypoxia was not explained by enhanced neutrophil recruitment in hypoxic 
mice (Fig 3.1). I therefore hypothesised that exposure to hypoxia results in a 
phenotypic shift to a hyperinflammatory neutrophil causing excess tissue 
damage. In order to characterise this phenotype, I carried out proteomic 
analysis of BAL neutrophils from C57Bl6 mice which had been housed in 
hypoxia for 24 hours following administration of nebulised LPS. Comparison 
of neutrophils from hypoxic mice with those from normoxic controls confirms a 
distinct hypoxic proteomic signature with principle component analysis 
demonstrating differential clustering of the 2 groups (Fig 3.5A). The data was 
analysed using Perseus software[115] and this demonstrated significant 
upregulation of 272 proteins in hypoxic samples and down regulation of 230 
proteins (P<0.05, FDR 0.05, S0=0.1)(Fig 3.5B). KEGG pathway enrichment 
analysis was carried out on the significantly upregulated proteins, this 
highlighted four pathways which were enriched in the protein set (Fig 3.5C) 
including the lysosome whose relevance will be discussed in detail in the next 
chapter. The complement and coagulation cascade was also an interesting hit 
with the potential to influence inflammatory responses. More detailed analysis 
however identified that of the 10 pathway members which were significantly 
upregulated in hypoxia, four corresponded to subunits of SerpinA1 (alpha 1-
antitrypsin) and three corresponded to other Serpin family members (C1, G1 
and F2) which would be predicted to dampen rather than exacerbate 
inflammation. The complement receptor C4b was also significantly 
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upregulated although other complement cascade members were not regulated 
by hypoxia. 
Overall though the pathway analysis did not identify factors which would be 
expected to mediate inflammation. 
Taken together, these data confirmed our hypothesis that hypoxia profoundly 
alters the identity of a neutrophil, but the pathway enrichment analysis did not 
prove particularly illuminating in unpicking the mechanisms which drive the 
hyperinflammatory phenotype seen in hypoxia. I therefore proceeded to 
examine the proteome for individual proteins which were significantly 






Figure 3.5: In vivo hypoxia results in a distinct neutrophil proteomic signature 
Proteomic analysis of BAL neutrophils from normoxic and hypoxic mice, 24 hours post LPS 
(n=3) were analysed using Perseus software and (A) principle component analysis was 
performed without category enrichment in components. (B) Volcano plot illustrating significant 
up (green) and downregulation (red) of over 200 proteins in hypoxic samples (P<0.05, FDR 
0.05, S0=0.1). (C) Enrichment analysis identifies KEGG pathways which are enriched in the 

























Pathways enriched in upregulated proteins
KEGG Pathway Term Fold Enrichment P Value
Glycosaminoglycan degradation 3.374 0.021209
Vasopressin-regulated water reabsorption 2.062 0.056719




Hypoxia results in a hyperinflammatory phenotype with increased expression 
of inflammatory receptors 
Analysis of those proteins which were most upregulated by hypoxia provided 
important insights into the behaviour of hypoxic neutrophils. In keeping with 
the in vivo phenotype of increased sickness and lung damage, I identified 
upregulation of a number of key inflammatory pathways in the neutrophils of 
hypoxic mice.  
TNF-a has been shown to regulate neutrophil functions including 
adhesion[149], priming[47] and apoptosis[150].  I found a significant increase 
in TNF receptor 1B (TNFRSF1B) protein in hypoxic neutrophils(Fig 3.6A) and 
higher levels of TNF-a in the BAL supernatant of hypoxic mice (Fig 3.6B). I 
confirmed surface expression of this receptor using flow cytometry and 
furthermore demonstrated temporal regulation of TNF receptors: BAL 
neutrophils isolated 6 hours post-LPS demonstrate low levels of TNFRSF1B 
surface expression, however, by 24 hours the surface expression has 
increased, and significantly higher levels are seen in hypoxic compared with 
normoxic samples (Fig 3.6C). This pattern of expression was specific to 
TNFRSF1B as demonstrated by the distinct expression pattern of TNFRSF1A 
(Fig 3.6D) which showed significantly higher expression of in hypoxia at 6 
hours but no difference in expression between normoxic and hypoxic mice at 
24 hours. The TNFRSF1A protein was not identified in the proteomic dataset. 
Furthermore, the regulation of TNF receptor expression was specific to BAL 
neutrophils. Flow cytometric analysis of peripheral blood neutrophils at 6 and 
24 hours post-LPS showed no evidence of hypoxic regulation of either 
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TNFRSF1B or TNFRSF1A expression at either time point (Fig 3.7A&B). I 
noted variation in the raw fluorescence values between experiments and so, 
in order to avoid missing a signal, I replotted the data for blood TNFRSF1B 
expression at 24 hours as a fold change and reanalysed (Fig 3.7C), this 
showed a trend towards increased expression in hypoxia but did not meet 
statistical significance.   
The effects of TNF-a on neutrophil functions are complex, varying over the 
time course of an inflammatory response. Additionally, the two different 
receptors are thought to have different downstream effects. The data 
described here suggests that temporal regulation of receptor expression may 
play a role in determining TNF-a responsiveness in inflammatory neutrophils 
and that hypoxia may further regulate the expression of these receptors. 
Formylated peptide receptors are G-protein-coupled receptors (GPCRs) 
whose ligands include bacterial and mitochondrial formylated peptides. Upon 
activation, FPRs induce intracellular signalling cascades which result in 
neutrophil chemotaxis, degranulation, ROS production and transcriptional 
regulation[12]. Both FPR1 and FPR2 were significantly upregulated in the 




















Figure 3.6: BAL neutrophil TNF receptor expression is modulated by in vivo hypoxia 
(A) Label free quantification of TNFRSF  1B protein expression in BAL neutrophils from 
normoxic and hypoxic mice, 24 hours post-nebulised LPS, n=3. (B) BAL supernatant TNF-a 
concentration measured by multiplex cytokine assay, n=5. Flow cytometry was used to 
analyse surface expression of (C) TNFRSF1B and (D) TNFRSF1A on BAL neutrophils, from 
normoxic and hypoxic mice, 6 and 24 hours post-LPS, n=8 over 2 experiments. (A) analysed 
by unpaired two tailed t-test (B)-(D) Mann-Whitney test of significance. Data represents 
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Figure 3.7: Hypoxia does not significantly alter blood neutrophil TNF receptor 
expression 
Peripheral blood neutrophils from normoxic and hypoxic mice, 24 house post-nebulised LPS 
were analysed by flow cytometry for surface expression of (A) TNFRSF1A and (B) 
TNFRSF1B. (C) 24-hour TNFRSF1B blood neutrophil expression expressed as fold change. 
(A)-(C) n≥8 over 2 experiments, Mann-Whitney test of significance. Data represents individual 
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Figure 3.8: Formylated peptide receptors are upregulated in hypoxia 
(A) Label free quantification of FPR1 and FPR2 protein expression in BAL neutrophils from 
normoxic and hypoxic mice, n=3, unpaired two tailed t-test. Data represents individual values 


























Hypoxia increases GM-CSF receptor expression in neutrophils 
Like TNF-a, GM-CSF is an important regulator of multiple neutrophil functions 
including activation, degranulation and survival. The functional GM-CSF 
receptor is composed of a heterodimer consisting of an alpha and a beta 
subunit. The beta subunit of the GM-CSF receptor (CSF2RB) was one of the 
most upregulated proteins in hypoxia with a 7-fold increase in label free 
quantification (Fig 3.9A). Surface expression of the GM-CSF receptor on 
neutrophils in the lungs would be predicted to contribute to increased release 
of granule proteins and therefore increased tissue injury. In order to investigate 
the surface expression of this receptor I carried out flow cytometry analysis of 
freshly isolated BAL neutrophils. This identified significantly higher surface 
expression of CSF2RB in hypoxic neutrophils 6 hours post-LPS (Fig 3.9B), as 
well as significantly higher levels of the co-receptor CSF2RA at this time point 
(Fig 3.9C). The trends towards increased hypoxic neutrophil CSF2RB 
expression persists until 24 hours but is not statistically significant. The protein 
quantification noted in Fig 3.9A will represent both surface receptor and 
internalized protein. I hypothesised that the high protein level seen at 24 hours 
is therefore the result of high levels of receptor activation and internalisation 
between 6 and 24 hours. I then investigated the expression of GM-CSF in the 
BAL fluid over the course of the inflammatory response. This was consistent 
with GM-CSF being an early signal in acute lung injury, showing that GM-CSF 
concentrations at 2 hours were approximately 100-fold higher than at 24 hours. 
It was interesting to find that at each time point GM-CSF levels appeared lower 
in hypoxic BAL supernatant although whether, at such high concentrations, 
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this difference is rate limiting is difficult to say.  Upregulation of GM-CSF 
receptor expression early in the inflammatory response is important in the 
context of work by Hoenderdos et al[142] which demonstrated that hypoxia 
results in enhanced neutrophil degranulation. Consistent with this hypothesis, 
our proteomic data identifies significant upregulation of the downstream 
regulator of GM-CSF mediated degranulation, Rab27a[151] in hypoxic 





Figure 3.9: The GM-CSF pathway is upregulated in hypoxic neutrophils 
(A) Label free quantification of CSF2RB protein expression in BAL neutrophils from normoxic 
and hypoxic mice, n=3. Surface expression of (B) CSF2RB and (C) CSF2RA on BAL 
neutrophils, from normoxic and hypoxic mice, 6 and 24 hours post-nebulised LPS, n≥7 over 
2-3 experiments. (D) Normoxic and hypoxic mouse BAL supernatant GM-CSF concentration, 
measured by ELISA at 2, 6 and 24 hours post-nebulised LPS n≥4. (E) Label free quantification 
of Rab27A protein expression in BAL neutrophils from normoxic and hypoxic mice, n=3, 
unpaired two tailed t-test. (A)&(E) unpaired two tailed t-test, (B)&(C) Mann-Whitney test of 
significance (D) significance analysed by multiple t-tests (corrected for multiple comparisons 
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Hypoxia results in enhanced neutrophil degranulation in vivo 
I went on to investigate whether increased GM-CSF receptor expression at the 
earlier, 6-hour, time point was associated with in vivo evidence of altered 
degranulation in hypoxia. I found that 6 hours post-LPS there is significantly 
greater neutrophil elastase activity (Fig 3.10A) and MMP9 (Fig 3.10B) in the 
BAL supernatant and a trend towards increased myeloperoxidase (MPO) 
activity (Fig 3.10C). This early increase in degranulation is associated with 
significantly increased lung injury at this time point in hypoxia with increased 
albumin leak at 6 hours (Fig 3.10D). There are fewer neutrophils in the BAL 
fluid of hypoxic mice at 6 hours compared with normoxic mice (as described in 
Fig 3.1B), suggesting an even greater propensity to degranulate than the BAL 
supernatant data alone demonstrates. These findings suggest that early 
enhanced degranulation may be a contributing factor to the increased lung 













Figure 3.10: In vivo hypoxia leads to increased neutrophil degranulation at 6 hours 
BAL supernatant was collected from mice 6 hours post-LPS and analysed for (A) elastase 
activity, (B) MMP9  concentration, (C)MPO activity and (D) albumin concentration. Elastase 
and MPO activity were measured by EnzCheck activity kits and MMP9 and albumin 
concentration analysed by ELISA. (A)-(C) n≥6 over 2-3 experiments, (D) n=4. All data 




















































































Hypoxic neutrophils show preserved intracellular granule protein expression 
Despite strong evidence of enhanced degranulation in hypoxia, at a protein 
level there was no corresponding decrease in these intracellular granule 
proteins at 24 hours when comparing hypoxic to normoxic samples (Fig 3.11A-
C). Analysis by western blot supported this finding (Fig 3.11D-F). This is 
consistent with the data in Fig 3.4E showing high copy numbers of many 
granule proteins at the 24-hour time point, despite significant degranulation 
occurring by this time point. 
Taken together these data show that, in the context of lung inflammation, 
hypoxia represents a damaging ‘second hit’ associated with significant 
hypothermia and lung damage. I have also shown evidence of increased 
neutrophilic activation in hypoxic animals.  Inflammatory neutrophils 
dynamically regulate expression of inflammatory receptors and this too is 
modulated by exposure to hypoxia. Persistence of granule proteins in hypoxic 
neutrophils, despite increased degranulation, raised the interesting possibility 
that neutrophils may continue to synthesise inflammatory mediators upon 
recruitment to the hypoxic inflammatory niche. TaqMan analysis of gene 
expression confirmed that BAL neutrophils possess mRNA for granule 
proteins in inflammatory airway neutrophils (Figure 3.12 A-C) although levels 















Figure 3.11: Enhanced hypoxic degranulation does not result in a reciprocal drop in 
intracellular granule proteins 
Label free quantification of (A) elastase, (B) MMP9 and (C) MPO protein expression in BAL 
neutrophils from normoxic and hypoxic mice, n=3. Protein expression by western blot of (D) 
elastase, (E) MMP9 and (F) MPO in BAL neutrophils from normoxic and hypoxic mice 24 hours 
post-LPS. n≥4 over 2 experiments, representative blot shown for each protein with p38 loading 
control. (A)-(C) unpaired two tailed t-test, (D)-(E) Mann-Whitney test of significance. Data 






















































































































Figure 3.12: BAL neutrophils continue to express transcript for granule proteins 
(A)-(C) Expression of granule content genes was analysed by TaqMan analysis of highly pure 
BAL neutrophils from mice 24 hours post-LPS which had been housed in either normoxia or 
hypoxia. Data is expression relative to beta-actin gene expression. n≥5, Mann-Whitney test of 














































































Inflammatory lung neutrophils synthesise granule proteins and inflammatory 
mediators 
In order to investigate the synthetic capacity of inflammatory BAL neutrophils 
I utilised an alternative proteomic approach. By incubating ex vivo BAL 
neutrophils with the heavy labelled amino acids 13C6 and 15N4 L-arginine (R10) 
and 13C6 L-Lysine (K6) I was able to identify newly synthesised proteins by 
mass spectrometry: only proteins which were newly synthesised would contain 
a mass shift associated with incorporation of a labelled amino acid. I used BAL 
neutrophils from animals which had been housed in hypoxia following LPS 
stimulation because I hypothesised that these would have the greatest 
capacity for generating inflammatory mediators, based on the evidence 
presented in this chapter. Following purification, neutrophils were cultured in 
hypoxia with labelled amino acids (or control media with unlabelled amino 
acids) for 18 hours prior to lysis and analysis by mass spectrometry. I identified 
62 proteins which were labelled in at least 2 of the 4 labelled samples and 
demonstrated either no label or significantly less label in the control samples. 
These newly synthesised proteins included those involved in cytoskeletal 
regulation and metabolism (Fig 3.13A). However, I also identified inflammatory 
proteins such as complement C3 and integrins (Fig 3.13B) and, importantly, 
some known granule proteins including the protease cathepsin D and 
lysozyme C2 (Figure 3.13C).  
These data provide evidence of ongoing synthesis of inflammatory mediators, 
including components of neutrophil granules, by tissue neutrophils. These 
data, coupled with the evidence of preserved intracellular granule proteins 
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despite enhanced degranulation, suggests that de novo synthesis of 
inflammatory mediators is a mechanism by which hypoxic neutrophils drive a 












Figure 3.13: Inflammatory neutrophils synthesise granule proteins and inflammatory 
proteins 
Labelled proteins (total number =62) were assigned to a functional group as detailed in (A). 
Those involved in inflammation (B) and neutrophils granules (C) are detailed below. The raw 











Neutrophil cytosol factor 1 Leukotriene A-4 hydrolase
Cis-aconitate decarboxylase Complement C3
Chitinase-3-like protein 1 Integrin beta-2
Macrophage migration inhibitory factor Protein S100-A8



















The data in this chapter confirm that exposure to hypoxia can dramatically alter 
the course of an inflammatory response, mirroring our group’s previous 
findings in infection models [143]. Importantly, in the context of infection, the 
sickness associated with hypoxia was not related to bacterial burden but due 
to the host response. Neutrophil depletion resulted in partial recovery of the 
hypothermia observed in hypoxia, implicating these cells in the pathogenesis 
of this phenotype.  However, the underlying mechanisms have not been fully 
resolved.  In order to address this question of how hypoxia regulates neutrophil 
mediated inflammatory responses, I utilised a sterile injury model. I confirmed 
that in this model, in vivo hypoxia results in significant hypothermia and lung 
damage. Increased neutrophil elastase activity in the BAL fluid supernatant of 
hypoxic mice again implicates neutrophilic inflammation in the damage 
however, the phenotype is independent of neutrophil numbers. As discussed 
in the introduction, neutrophils are increasingly understood to have varying 
subtypes or polarisation states both in the context of tumour biology and 
inflammation[144,145].  Studies of circulating blood neutrophils in patients with 
sepsis[152], COPD[153] and ARDS[25] have also identified different 
neutrophil phenotypes thought to contribute to disease. The finding that the 
excessive neutrophilic inflammation observed in hypoxic animals with ALI is 
independent of neutrophil number is suggestive of an altered and 
proinflammatory neutrophil phenotype in this context. Consistent with this, 
hypoxia was associated with enhanced CD11b expression and shedding of 
CD62L, often described as an activated neutrophil phenotype. These data are 
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consistent with data from Juss et al[25] showing that in patients with acute lung 
injury, both blood and alveolar neutrophils show enhanced CD11b expression 
and CD62L expression.  
Microenvironmental cues have been identified as important regulators of 
immune cell polarisation in both the macrophage and T cell populations and 
hypoxia and hypoxic signalling pathways have been identified as one such 
cue. Considerable interest exists in therapeutic targeting of hypoxic signalling 
pathways in the context of pathological inflammation. In some tissues, for 
example in the intestine, hypoxia, and specifically HIF-1a activity, are viewed 
as protective, anti-inflammatory signals[154,155]. Prolyl hydroxylase inhibitors 
which potentiate HIFa activity have shown promise in treating intestinal 
inflammation in mouse models of colitis[156-158]. There is also some evidence 
that HIF-1a activity in the alveolar epithelium may be protective in stretch 
induced acute lung injury[80].  However, in a different model, alveolar epithelial 
cell HIF-1a activity was implicated in dysfunctional airway remodelling after 
influenza infection[81]. These contrasting findings highlight the complexity and 
context specificity of hypoxic responses in inflammation. Hypoxia frequently 
complicates both acute and chronic respiratory disease. This hypoxia may be 
local or systemic and as such will have wide ranging effects on immune cells 
but also potentially on the endothelium and epithelium. The overall effect of a 
hypoxic challenge will therefore  represent the sum of effects on multiple 
tissues and the impact of hypoxia on infiltrating immune cells will be an 
important determinant of the overall outcome of a hypoxic inflammatory 
response. 
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Ex vivo studies of neutrophils in hypoxia have proved invaluable in unravelling 
how these cells respond to hypoxia. However, there is an increasing 
awareness that multiple factors in the inflammatory microenvironment, not just 
hypoxia, influence neutrophil function in vivo. Furthermore, the process of 
transmigration fundamentally alters neutrophil identity. Replicating these 
events in vitro is virtually impossible and so experimental models which allow 
analysis of neutrophils exposed to hypoxia in vivo in the inflammatory 
environment are important in understanding how these tissue cells behave.  
Proteomic analysis of immune cells provides a quantitative and unbiased 
assessment of the identity of these cells. 
Proteomic analysis of inflammatory neutrophils has provided insights into the 
important pathways and processes which are active in these cells. Comparison 
of genes encoding the neutrophil proteome with the whole mouse genome 
highlights enrichment of metabolic processes and inflammatory pathways. The 
presence of metabolic enzymes in the ‘top 25’ list and their predominance in 
the top quartiles for protein abundance further highlights their importance. It 
has long been established that neutrophils are primarily glycolytic cells[159] 
and derive little or no energy from aerobic respiration which occurs within the 
mitochondria. Neutrophils do possess a network of mitochondria and express 
at least some of the machinery of the TCA cycle essential for aerobic 
respiration. Our group has previously investigated the role of this machinery in 
neutrophils through examining the neutrophils of patients with a mutation in 
the TCA cycle enzyme succinate dehydrogenase B (SDHb) [160] and found 
that loss of this enzyme altered neutrophil metabolism, ROS production and 
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survival. Fossati et al[161] have investigated the role of mitochondria in 
neutrophils through the use of chemical inhibitors and found that intact 
neutrophil mitochondria were required for chemotaxis and may be required for 
maximal respiratory burst capacity. Given this, it was interesting to find that not 
only were neutrophils enriched for glycolysis and the related KEGG pathways 
of fructose and pyruvate metabolism, but they were also enriched for TCA 
cycle proteins. Additionally, neutrophils were enriched for pathways involved 
in fatty acid metabolism. Fatty acid metabolism in neutrophils has recently 
been linked with differentiation of bone marrow neutrophils[162] but its role in 
inflammatory neutrophils has not been investigated. Our proteomic data shows 
a nearly 2-fold enrichment in this KEGG pathway suggesting it may have 
important roles in inflammatory neutrophils as well as in differentiating bone 
marrow neutrophils.  
Of particular interest in the enrichment analysis are those pathways which link 
inflammation, hypoxia and metabolism such as the HIF, mTORC and AMPK 
signalling pathways. Relatively little is known about mTOR and AMPK 
signalling in neutrophils. These  pathways and the role of metabolic 
adaptations to hypoxia will be discussed in more detail in the next chapter. 
Comparison of the proteome of normoxic and hypoxic neutrophils confirms that 
hypoxia significantly alters neutrophil phenotype. Hypoxia resulted in 
significant up- and down-regulation of hundreds of proteins. Pathway 
enrichment analysis did not at first identify clear links between the altered 
neutrophil proteome and the hyperinflammatory in vivo phenotype. The 
identification of the lysosome as a pathway enriched in the upregulated 
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proteins is of interest and will be discussed in detail in the following chapter. 
Analysis of those proteins most significantly upregulated by hypoxia 
highlighted that hypoxic neutrophils upregulate a range of inflammatory 
receptors including TNF receptor 1b, formylated peptide receptors and the 
GM-CSF receptor.  The repertoire of receptors expressed on the neutrophil 
cell surface has important implications for pathogen recognition, effector 
functions such as chemotaxis and phagocytosis and neutrophil survival. 
Surface expression of a given receptor may be regulated at multiple levels: 
transcription and translation of receptor protein, post-translational 
modifications and trafficking of the receptor to the cell surface. Additionally, 
many receptors require cofactors or coreceptors to function at the cell surface 
and so availability of these will further regulate receptor activity. In neutrophils, 
degranulation may also alter surface receptor expression. TNF receptors and 
formylated peptide receptors are both expressed in the inner membrane of 
specific granules in neutrophils and so, upon fusion of the granule membrane 
with the plasma membrane, these receptors may be presented on the cell 
surface.  Analysis of TNF receptor expression by flow cytometry provided 
further insights into how this pathway is regulated. I found that surface 
expression of TNF receptors changes over the time course of an inflammatory 
response in the lung. This was particularly true for TNFRSF1B which is lower 
in hypoxic samples at 6 hours but dramatically higher in hypoxic samples by 
24 hours. Comparison of the 6-hour BAL neutrophil TNF receptor data with the 
data from 24 hours suggests that surface expression of the TNF receptor 1B 
increases between 6 and 24 hours. Technical factors and experimental design 
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mean that it is difficult to draw absolute conclusions from this flow cytometry 
data from different time points but the experimental protocol, antibody 
concentration and flow cytometer settings were unchanged between 
experiments, so it is likely that TNFRSF1B surface expression increases over 
time. This finding would be consistent with increased degranulation over the 
time course of the inflammatory response although TNFRSF1A does not 
demonstrate the same changes in surface expression over time, suggesting 
that it is either not present in granules or is also regulated by other factors.  
Flow cytometry was also important in delineating the time course of GM-CSF 
receptor expression in BAL neutrophils. These data showed early hypoxic 
upregulation of the GM-CSF receptor at a surface level. While the proteomic 
data shows a persistent increase in the beta subunit in hypoxic samples this is 
not reflected in the flow cytometry data. Ligation and activation of the GM-CSF 
receptor on neutrophils leads to its internalisation by endocytosis. 
Interestingly, stimulation of neutrophils with both TNF-a and fMLF also led to 
downregulation of the GM-CSF receptor at the cell surface[163] which may 
explain the high protein but low surface expression seen in hypoxic neutrophils 
by 24 hours.  Although levels of formylated peptides were not measured in the 
BAL supernatants in this experimental model, levels of mitochondrial 
formylated peptides have been shown to be increased in both the serum and 
BAL fluid of patients with ARDS, highlighting their role in this disease[164]. 
Hypoxia has been found to regulate neutrophil degranulation in vitro in 
response to a range of stimuli, including GM-CSF[142].  The data in this 
chapter confirm that in vivo hypoxia regulates neutrophil degranulation and 
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that this occurs early in the course of the inflammatory response. Furthermore, 
early degranulation leads to early lung damage in hypoxic mice. The lack of a 
reciprocal reduction in hypoxic neutrophil intracellular granule proteins led to 
the hypothesis that hypoxic neutrophils may continue to synthesise these 
inflammatory mediators in situ. This would clearly go against the paradigm that 
granule proteins are only synthesised during neutrophil maturation in the bone 
marrow. TaqMan analysis of BAL neutrophil gene expression confirms the 
presence of elastase, MMP9 and MPO transcripts.  Hypoxia did not upregulate 
the abundance of these transcripts in BAL neutrophils from the 24-hour time 
point. This suggests that expression of these proteins may be regulated at a 
translational or post-translation level.  
By culturing neutrophils in the presence of labelled amino acids, I was able to 
delineate a subset of proteins which are synthesised de novo by tissue 
neutrophils. The identification of newly synthesised inflammatory mediators 
and granule proteins is an important finding as it identifies a novel mechanism 
by which neutrophils, given the right stimuli, continue to cause tissue damage 
following transmigration. The data in this chapter suggest that hypoxic 
neutrophils display a greater capacity for the synthesis of granule proteins, 
based on their increased degranulation without reduced intracellular granule 
protein content. One mechanism by which hypoxic neutrophils might 
upregulate expression of these inflammatory mediators is through increased 
substrate availability and this hypothesis will be addressed in the next chapter. 
The data in this chapter also suggest that, in hypoxia, there may be failure of 
inflammation resolution. While there are fewer neutrophils in the BAL fluid of 
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hypoxic mice up to 24 hours following LPS, by 48 hours there is a trend 
towards more neutrophils in hypoxic mice. This is in keeping with persistence 
of neutrophils in hypoxic lungs. Multiple factors are likely to contribute to this 
persistent inflammation. Hypoxia itself is a profound survival stimulus for 
neutrophils. I have shown that hypoxia upregulates TNF receptor 1B 
expression and TNF signalling through the TNFRSF1B receptor may also 
contribute to increased neutrophil survival. The effects of TNF-a on neutrophil 
survival are complex and while TNF-a may be pro-apoptotic at early time 
points[165], but in primed neutrophils and at later time points it is pro-survival. 
Furthermore, TNFRSF1A, rather than TNFRSF1B, is the dominant receptor in 
relaying pro-apoptotic effects[150] so overall the upregulation of TNFRSF1B 
at the later, 24-hour time point is likely to enhance survival of neutrophils. It is 
also probable that hypoxic neutrophils have a degree of metabolic advantage 
over their normoxic counterparts. As discussed above, neutrophils express the 
machinery for carbohydrate, fat and protein metabolism and the role of these 
in hypoxic neutrophils will be addressed in the next chapter. 
In summary, hypoxia drives neutrophilic inflammation in the lung through 
upregulation of inflammatory receptors, enhanced neutrophil degranulation 
and persistence of neutrophilic infiltrates. I went on to interrogate the hypoxic 




Chapter 4: Protein Scavenged from the Extracellular 
Environment Fuels Neutrophilic Inflammation in Hypoxia 
Introduction 
The data discussed in the previous chapter supports the hypothesis that 
hypoxia results in a hyperinflammatory neutrophil phenotype. An early feature 
of this phenotype is the increased GM-CSF receptor expression and 
degranulation which occurs. This results in significant lung damage. The 
enhanced degranulation without a reduction in levels of intracellular granule 
proteins is suggestive of continued synthesis of inflammatory mediators by 
hypoxic neutrophils. These data, coupled with the persistence of neutrophilic 
infiltrates in hypoxia would suggest a requirement for substrate, both in the 
form of energy and amino acids for de novo protein synthesis. As noted in 
figure 3.12, this program of protein synthesis is not regulated at a 
transcriptional level. This observation led me to consider whether hypoxic 
neutrophils may have an advantage in terms of substrate availability.  
As discussed previously, neutrophils are highly glycolytic at baseline and 
generate little to no ATP through aerobic respiration, irrespective of oxygen 
availability meaning that they are “pre-adapted” to function in low oxygen 
environments. This is logical in cells which, as the first responders to infection 
and inflammation, are often required to function in environments where oxygen 
is limited. In these situations, nutrient availability may also be limited, and it is 
interesting to consider how the highly glycolytic neutrophil may respond and 
adapt to this additional metabolic stress.  There are multiple parallels between 
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the hostile inflammatory environment in which neutrophils function and the 
tumour microenvironment. Solid tumours often proliferate to the extent that 
they out-strip their blood supply and as a consequence develop regions 
deficient in both oxygen and nutrients.  Adaptations to these environmental 
stresses are often noted in tumour cells and are under investigation as 
potential therapeutic targets[166-168], reviewed in[169]. Another interesting 
link between tumour cell and neutrophil metabolism is the Warburg effect[170] 
which describes a switch from aerobic metabolism to glycolysis in tumour cells, 
even in the presence of adequate oxygen, mirroring the baseline glycolytic 
metabolism of neutrophils described above. 
The airway has been shown to represent a relatively low glucose environment 
in comparison to the circulation[171]. This is in stark contrast to standard cell 
culture media which is rich in both glucose and amino acids such as glutamine. 
Thus, immune cells which have transmigrated to the airways will travel down 
a glucose gradient, arriving in a glucose deplete environment. It is therefore 
important to consider alternative sources of nutrients in this context and tumour 
biology may provide some clues in this regard.  
Macropinocytosis is a process by which cells take up extracellular fluid and its 
constitutive molecules, including proteins. This non-specific uptake is a highly 
conserved process and has consequences for cellular motility, metabolism, 
and immunity[172]. Macropinocytosis has been identified as a route by which 
tumour cells may adapt to low nutrient availability: it is found to be upregulated 
in Ras -transformed pancreatic tumour cell lines and has been shown to be a 
key mechanism of nutrient acquisition in these cells[173-175]. 
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Macropinocytosed proteins are trafficked to the lysosome where they are 
broken down to their constitutive amino acids. Glutamine from 
macropinocytosed proteins can be utilised for ATP generation via central 
carbon metabolism[173]and is required for in vitro tumour cell proliferation and 
in vivo tumour growth. Neutrophils have been shown to carry out 
macropinocytosis[176], although this process and the factors which regulate it 
are not well studied in these cells. In contrast, the capacity of other immune 
cells, particularly antigen presenting cells such as monocytes[177] and 
dendritic cells[178] to carry out macropinocytosis is well established and, in 
contrast to most tumour cells, may be constitutive as well as in response to 
stimulus[179,180] . Carpentier et al utilised electron microscopy to investigate 
the internalisation and subsequent localisation of the complement receptor 
CR1 in neutrophils and found that this occurs via macropinocytosis and was 
augmented by fMLF and PMA stimulation. This process did require anti-CR1 
antibody so the capacity of neutrophils to carry out non-specific 
macropinocytosis and the factors regulating this remain uncertain. Nutrient 
acquisition by macropinocytosis has not previously been studied in 
neutrophils. 
 The uptake and breakdown of proteins by tumour cells is a highly regulated 
process. The mammalian target of rapamycin (mTOR) and its associated 
complexes, mTORC1 and mTORC2, are essential in integrating signals 
regarding nutrient availability and determining the cellular response to these 
signals in terms of transcription and translation of new proteins and in directing 
proliferation. Multiple environmental factors upstream of mTORC signalling 
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feed into this pathway, including growth factors, amino acid availability, oxygen 
tension and glucose availability. The downstream consequences of mTORC1 
and mTORC2 activation are varied. mTORC1 primarily directs the synthesis 
of proteins, lipids and nucleotides, required for cell growth while mTORC2 
regulates cell survival and proliferation[91]. Consistent with this, Palm et 
al[174] have demonstrated that, in Ras transformed pancreatic cancer cells, 
mTORC1 plays an essential role in regulating protein catabolism in response 
to amino acid starvation. The authors show that when free amino acids are in 
abundance, mTORC activity promotes cells growth, however, in low amino 
acid conditions, when the cells are reliant upon extracellular protein as their 
source of amino acids, mTORC activation prevents protein catabolism and 
thus inhibits cell growth. Furthermore, mTORC inhibition leads to enhanced 
protein catabolism, linking substrate availability to downstream protein 
synthesis. 
While neutrophils in areas of inflammation may be subject to similar metabolic 
stresses as tumour cells, there are fundamental differences between tumour 
cells and neutrophils which must be considered. While a key fate decision for 
tumour cells is whether or not to proliferate, neutrophils are terminally 
differentiated, non-proliferating cells and so a more important outcome 
decision is likely to be survival versus apoptosis/necrosis. Both the rate of 
neutrophil cell death and the mechanism (i.e. apoptosis or necrosis) will have 
important effects on resolution of inflammation.  
The pathways which regulate protein uptake and breakdown are potentially 
pertinent to neutrophil function in the inflamed lung, particularly given the 
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abundant protein leak described in the previous chapter. The role of hypoxia 
in regulating these processes is also of interest due to the close links between 
hypoxic signalling pathways and metabolic processes, including the mTOR 
pathway. mTORC1 dependent HIF activity is required to maintain glycolysis in 
effector T cells[181] and this axis also plays a role in trained immunity in 
myeloid cells[182]. In neutrophils, mTOR activity has been linked to formation 
of neutrophil extracellular traps (NETs) in a HIF-a dependent fashion[108]. 
mTOR has also been implicated in the regulation of neutrophil migration[183] 
and cytokine production[184]. Thus, mTOR signalling is clearly active in 
neutrophils but its role in regulating hypoxic responses and metabolism 
remains unclear.  
The data described in chapter 3 demonstrates that active regulation of receptor 
expression and synthesis of inflammatory mediators are likely to underlie the 
hyperinflammatory phenotype seen in hypoxic neutrophils. The aim of this 
section is to  determine the mechanisms which underlie this with particular 




Inflammatory neutrophils are maximally glycolytic 
I first sought to ascertain whether hypoxic neutrophils have an enhanced 
capacity for glycolysis compared to their normoxic counterparts. Despite a 
number of glycolytic enzymes being well described HIF target genes, I did not 
see any significant upregulation of glycolytic enzymes in the hypoxic neutrophil 
proteome (Fig 4.1A). I next investigated whether substrate availability was a 
factor in the glycolytic capacity of normoxic and hypoxic neutrophils. The 
glucose transporters Glut1 and Glut3 (SLC2A1 and SLC2A3) are also known 
to be HIF target genes. The proteomic data reveals that Glut3 is the dominant 
receptor in inflammatory neutrophils with expression levels very much higher 
than that of Glut1. Furthermore, Glut3 expression is significantly higher in 
hypoxic samples (Fig 4.1B). So, while hypoxia in the context of an 
inflammatory response does not elicit an increase in the abundance of 
glycolytic enzymes, it does increase glucose transporter protein expression, 















Figure 4.1: Hyperinflammatory hypoxic neutrophils have a distinct metabolic 
phenotype  
(A) Label free quantification of (A) glycolytic enzymes and (B) glucose transporters in BAL 
neutrophils from normoxic (grey bars) and hypoxic (white bars) mice, 24 hours post-nebulised 
LPS. n=3, unpaired two tailed t-tests of significance. (A) Data represents mean ± SEM (B) 
Data represents individual values and mean ± SEM. 
  













































Glutamine, but not glucose is increased in hypoxic neutrophils 
In order to investigate the metabolic status of normoxic and hypoxic 
neutrophils, I performed analysis of metabolite abundance by HPLC-MS in 
BAL neutrophils from normoxic and hypoxic mice 24 hours post-LPS. Despite 
the increase in glucose transporter expression described above, HPLC-MS did 
not demonstrate an increase in intracellular glucose in hypoxic neutrophils (Fig 
4.2A). The airway is known to be a relatively glucose deplete 
environment[171]. I hypothesised that the unchanged intracellular glucose 
levels in hypoxic neutrophils, despite increased expression of glucose 
transporters, was due to low substrate availability. To investigate this, I 
measured glucose levels within the BAL fluid and found them to be extremely 
low with levels of less than 0.1mM (Fig 4.2B) compared to a blood glucose 
concentration in our model of approximately 12mM (data not shown). Our 
group has previously shown that regulation of glycogen stores occurs in 
response to knockout of the prolyl hydroxylase PHD2. Loss of PHD2 (and 
consequent enhanced HIFa accumulation, akin to hypoxic exposure) resulted 
in increased neutrophil glycogen stores. I therefore measured intracellular 
glycogen stores in freshly isolated BAL neutrophils (Fig 4.2C) and found no 
significant difference between normoxic and hypoxic BAL neutrophils. 
I went on to investigate whether hypoxic neutrophils utilise an alternative 
energy source. In  contrast to glucose and glycogen levels, intracellular levels 
of both glutamine and glutamate, measured by HPLC-MS are significantly 
higher in hypoxic neutrophils (Fig 4.2D). However, free glutamine was 
undetectable in BAL fluid (data not shown, lower limit of detection of assay 
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2nM). Given the data from tumour cell lines that scavenged proteins may 
provide a source of amino acids, including glutamine, and the increased 
extracellular albumin availability in hypoxic BAL fluid (Fig 3.2A) it was 
interesting to find significantly increased intracellular albumin levels in hypoxic 
neutrophils in the proteomic analysis (Fig 4.2E). This was an unexpected 
finding and was strongly suggestive of an active protein uptake pathway in 
these cells, not previously identified in neutrophils. This has proven to be 
essential in the hyperinflammatory phenotype observed in hypoxia and will be 
discussed in detail later in this chapter. I also examined the energy status of 
normoxic and hypoxic neutrophils using the HPLC-MS data. I found lower 
levels of ADP and ATP in hypoxic compared to normoxic neutrophils (Fig 
4.2F). However, when the energy charge was calculated ( a measure of the 
overall energetic status of cells) there was no difference between treatment 
groups (Fig 4.2G). These findings are challenging to interpret, while the lower 
ATP level may suggest depleted energy stores, the preserved energy charge 
(which is due to the lower ADP and AMP levels as well) may suggest that 
hypoxic neutrophils maintain lower levels of all three nucleotides, without 
compromising cellular energetics. Furthermore, these data represent only a 
snapshot of the energetic status at the 24-hour time point. Further experiments 
are required to understand the energetic status of neutrophils over the whole 
time-course of the inflammatory response. 
In tumour cells, lack of available extracellular amino acids may be 
compensated for by uptake and breakdown of extracellular albumin. The high 
intracellular albumin and glutamine levels in hypoxic neutrophils suggested 
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that uptake (and breakdown) of proteins such as albumin from the extracellular 
environment may be a potential source of amino acids in neutrophils and I 
hypothesised that this amino acid source may provide substrate for central 





Figure 4.2: Hyperinflammatory hypoxic neutrophils have a distinct metabolic 
phenotype 
Highly pure BAL neutrophils from normoxic and hypoxic mice, 24 hours post-nebulised LPS 
were analysed for (A) Intracellular glucose abundance, (D) glutamine and glutamate 
abundance, (F) AMP, ADP and ATP abundance and (G) energy charge by HPLC-MS and 
expressed as fold change from normoxic mean, n=8 over 2 experiments. The equation for 
calculation of energy charge is shown. (B) BAL supernatant glucose concentration measured 
by colourimetric assay, n=5, Mann-Whitney test of significance. (E) Label free quantification 
of albumin in BAL neutrophils from normoxic and hypoxic mice, 24 hours post-LPS, n=3. (A)-
(D) and (F)-(G) Mann-Whitney test of significance. (E) unpaired two tailed t test of significance. 
The equation used to calculate energy charge is shown. Data represents individual values and 
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Hypoxia upregulates expression of proteins required for glutaminolysis 
Supporting the hypothesis that in hypoxia, metabolism of glutamine is an 
important source of energy, a number of key enzymes and transporters 
involved in glutaminolysis are upregulated at the protein level in hypoxia (Fig 
4.3A). These data also identified an important role for enzymes traditionally 
thought of as TCA cycle enzymes in the neutrophil. While the TCA cycle and 
downstream electron transfer chain are not used for ATP generation in the 
neutrophil, the proteomic data shows that they express the individual 
enzymatic components of this cycle (Fig 4.4A) but at lower levels than was 
seen for the glycolytic enzymes (Fig 3.4D). The HPLC-MS also shows that 
neutrophils express TCA cycle intermediates and, interestingly, show a trend 
towards higher levels of succinate which has been identified as a metabolite 
which also has immunomodulatory functions[89,160]. Lysosomal breakdown 
of proteins would be crucial to supply free amino acids from scavenged 
proteins. As noted in Fig 3.5C, the lysosomal pathway was enriched in those 
proteins which were up-regulated in hypoxia. I therefore hypothesised that 
increased lysosome activity may in part determine the metabolic and 















Figure 4.3: Hypoxic neutrophils show enhanced capacity for glutaminolysis 
(A) Label free quantification of proteins involved in glutaminolysis in BAL neutrophils from 
normoxic and hypoxic mice, 24 hours post-LPS, n=3, unpaired two tailed t test of significance. 
Data represents mean ± SEM. Diagram represents the glutaminolysis pathway with enzymes 
in yellow and metabolic intermediaries in green. GLS; Glutaminase, GLUD1; glutamate 




































































































































Figure 4.4: Neutrophils express TCA cycle enzymes and Intermediaries 
(A) Estimated copy number of TCA cycle enzymes in BAL neutrophils from normoxic mice 24 
hours post-nebulised LPS, n=3. The dotted line illustrates that most are present at fewer than 
105 copies per cell. (B) Metabolite abundance measured by HPLC-MS in highly pure BAL 
neutrophils from normoxic and hypoxic mice 24 hours post-nebulised LPS, n=4, Mann-
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Neutrophils scavenge and breakdown extracellular albumin 
To investigate the uptake of extracellular proteins by neutrophils I utilised 
Texas Red fluorescently labelled bovine serum albumin (BSA) and double-
quenched (DQ)-Green labelled BSA. The Texas Red albumin has constitutive 
fluorescence, but the DQ-Green BSA requires proteolytic cleavage of the 
quencher (usually in the lysosome) before it emits green fluorescence. 
Incubation of healthy human peripheral blood neutrophils with both Texas Red 
BSA and DQ Green BSA shows that uptake occurs quickly with a significant 
increase in Texas Red signal after just 30 minutes incubation, but the DQ-
Green signal requires 90 minutes to significantly increase (Fig 4.5A). This 
supports the hypothesis that neutrophils can rapidly take up albumin from the 
extracellular environment and, over a longer time course, can break it down. 
As discussed previously, a key feature of the neutrophil anti-microbial 
response involves release of proteases into the extracellular environment. In 
order to confirm that the observed DQ-Green signal is a result of intracellular 
proteolysis (rather than extracellular proteolysis following degranulation, 
followed by uptake of unquenched, fluorescent BSA), the DQ-Green BSA time 
course was repeated but after 30 minutes of incubation with DQ-Green BSA 
the cells were washed to remove any residual extracellular albumin. Following 
a further 2-hour incubation in fresh media, there was a significant increase in 
intracellular fluorescence (Fig 4.5B), consistent with intracellular breakdown of 
DQ-Green BSA which had already been taken up.  
In order to delineate the mechanism by which neutrophils take up albumin, I 
used confocal microscopy and measured co-localisation of fluorescently 
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labelled 70kDa dextran with FITC-BSA (Fig 4.5C). This large molecular weight 
dextran has previously been found to be taken up exclusively via 
macropinocytosis, i.e. fluid phase uptake[179]. The co-localisation of the FITC-
BSA with the dextran is therefore suggestive of albumin uptake via 








Figure 4.5: Neutrophils take up and breakdown extracellular proteins 
(A) Time course of human neutrophils incubated with either Texas-red labelled BSA or DQ-
Green BSA, data expressed as % maximum signal. (B) Geometric mean fluorescence of 
human neutrophils incubated with DQ-Green BSA for 30 minutes then washed and analysed 
for fluorescence over a further 120 minutes. (C) Confocal microscopy of neutrophils incubated 
with FITC-BSA (green) and 70kDa dextran (red) with DAPI nuclear staining in blue and 
red/green colocalization highlighted in yellow. (A)&(B) n=3, analysed for significance by one-
way ANOVA with multiple comparisons. Data represents mean ± SEM. 











































Lysosomal proteins are upregulated by hypoxia 
The lysosome would be predicted to be essential for breakdown of 
macropinocytosed proteins by neutrophils. In order to further interrogate the 
enrichment of the lysosomal pathway noted in figure 3.5C, I curated a list of 
known lysosomal proteins[185] and analysed their expression in the 
proteomes of normoxic and hypoxic neutrophils (Fig 4.6A and B). This 
highlights that the majority (although not all) of the known lysosomal proteins 
which were significantly different between groups were upregulated in hypoxia. 
These data suggest that in hypoxia (where substrate availability in the form of 
extracellular protein is high), neutrophils upregulate the whole pathway 
required for utilising these proteins, both the lysosomal components involved 
in proteolysis and, as shown in Fig 4.3, those enzymes required to metabolise 
the resultant free amino acids such as glutamine.  
I went on to investigate the intracellular localisation of DQ-Green BSA using 
confocal microscopy. This demonstrated lysosomal trafficking of DQ-Green 
BSA as evidenced by staining for the lysosomal marker LAMP1 following 
incubation with DQ-Green BSA and identifying areas of  colocalization (Fig 
4.7A). 
The central role of the lysosome is further established by the finding that 
manipulation of lysosomal activity alters the capacity of neutrophils to 
breakdown DQ-Green BSA: pre-treatment of healthy human peripheral blood 
neutrophils with the lysosomal protease inhibitor E64 (Fig 4.7B) or the inhibitor 
of lysosomal acidification chloroquine (Fig 4.7C) results in a small but 
significant reduction in DQ-Green signal 
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These data therefore confirm that neutrophils take up and breakdown 







Figure 4.6: Upregulation of the lysosome in hypoxic neutrophils 
(A) Volcano plot of normoxic Vs hypoxic neutrophil proteomes with lysosomal proteins 
highlighted, significantly upregulated proteins are in green and down regulated in red, n=3, 
significance defined as p<0.05, S0=0.1. Corrected for multiple hypothesis testing using 
permutation-based FDR=0.05. (B) Table showing details of significantly up- and down-








Phosphatidylinositol-glycan-specific phospholipase D Gpld1 7.8093 0.0004
V-type proton ATPase 116 kDa subunit a isoform 2 Atp6v0a2 1.9209 0.0085
Epididymal secretory protein E1 Npc2 1.9188 0.0171
Solute carrier family 15 member 3 Slc15a3 1.8297 0.0019
CSC1-like protein 1 Tmem63a 1.6388 0.0100
Arylsulfatase B Arsb 1.6018 0.0021
Sortilin Sort1 1.5990 0.0133
N-acetylgalactosamine-6-sulfatase Galns 1.5236 0.0093
Di-N-acetylchitobiase Ctbs 1.4789 0.0076
Beta-hexosaminidase subunit beta Hexb 1.4192 0.0001
Sphingosine kinase 2 Sphk2 1.4077 0.0093
Beta-hexosaminidase subunit alpha Hexa 1.3850 0.0028
Beta-mannosidase Manba 1.3549 0.0052
Adenosine deaminase Ada 1.3432 0.0010
Annexin A6 Anxa6 0.6900 0.0011
Serum paraoxonase/arylesterase 2 Pon2 0.6839 0.0064
V-type proton ATPase subunit d 1 Atp6v0d1 0.6362 0.0119
Enhancer of mRNA-decapping protein 3 Edc3 0.6235 0.0185
N-acylethanolamine-hydrolyzing acid amidase Naaa 0.6145 0.0190




Figure 4.7: The lysosome is essential for neutrophil protein catabolism 
(A) Confocal microscopy of neutrophils incubated with DQ-Green BSA (green)and stained for 
lysosomal marker LAMP1 (red) with DAPI nuclear staining in blue and red/green colocalization 
highlighted in yellow. Geometric mean fluorescence of LPS treated human neutrophils 
incubated with DQ-Green BSA and pre-treated with (B) the protease inhibitor E64 or (C) the 
inhibitor of lysosomal acidification chloroquine. n=7 over 3 experiments, Wilcoxon test of 
statistical significance for paired, non-parametric, data. Data represents individual values and 



















































Uptake and breakdown of extracellular proteins is regulated by glucose and 
oxygen availability 
I next sought to determine the factors which regulate the processes of protein 
uptake and breakdown in neutrophils. I hypothesised that nutrient availability, 
particularly glucose, may play a role in regulation of protein uptake and so 
incubated LPS treated human peripheral blood neutrophils in the presence or 
absence of glucose and compared normoxic (21% O2) with hypoxic (1% O2) 
culture. I utilised Texas-red labelled BSA to assess uptake and DQ-Green BSA 
to assess breakdown. The ratio of DQ-Green breakdown to Texas red uptake 
was used as an indicator of the breakdown activity of the cells. I found that 
hypoxic neutrophils in the presence of glucose, take up significantly more BSA 
than all other conditions (Fig 4.8A). In both normoxia and hypoxia, glucose free 
culture resulted in a significant reduction in Texas red albumin uptake. 
However, analysis of the DQ-Green signal in the same conditions showed that 
hypoxia significantly increased the signal, both in the presence and absence 
of glucose (Fig 4.8B). The ratio of breakdown to uptake showed that 
neutrophils incubated in hypoxia without glucose (conditions most closely 
resembling the hypoxic lung) had the highest breakdown activity (Fig 4.8C), 
consistent with the hypothesis that in conditions of nutrient scarcity, neutrophils 
exploit their environment to scavenge alternative energy supplies in the form 








Figure 4.8: Oxygen and glucose availability regulate protein uptake and catabolism 
Geometric mean fluorescence of LPS treated human neutrophils incubated with (A) Texas-
Red labelled BSA (n=6) or (B) DQ-Green BSA (n=7) in normoxia or hypoxia (1% O2) in RPMI 
± glucose (11mM), data expressed as fold change from normoxia + glucose condition, data 
merged from 3 experiments. (C) Ratio of DQ-Green to Texas Red signal to illustrate 
breakdown efficiency in the conditions described in (A) and (B), n=6. Data represents 
individual values and mean ± SEM. 




























































































In vivo and ex vivo hypoxia regulate protein catabolism in inflammatory 
neutrophils 
I then investigated whether the hypoxic upregulation of the lysosome pathway 
identified in our proteomic dataset corresponded to a change in protein uptake 
and breakdown by hypoxic inflammatory murine neutrophils.  BAL neutrophils 
from normoxic and hypoxic mice were cultured ex vivo with fluorescent 
albumin compounds to measure uptake and breakdown. Neutrophils were 
isolated from the BAL 24 hours post-LPS induced lung injury and cultured ex 
vivo in glucose free media (to recapitulate the low glucose environment of the 
airway) in either hypoxia or normoxia. There were no significant differences in 
uptake of Texas red BSA between treatment groups (Fig 4.9A). Neutrophils 
from hypoxic mice, cultured in hypoxia ex vivo showed significantly higher DQ-
Green signal (Fig 4.9B) than any other treatment group. Neutrophils from 
normoxic mice cultured ex vivo in hypoxia also showed a trend towards higher 
DQ-Green signal than when cultured in normoxia ex vivo, suggesting that while 
neutrophils from hypoxic mice have a pre-existing advantage in terms of 
capacity to take up and breakdown proteins, these pathways show a degree 
of plasticity and new hypoxic challenge ex vivo can further augment protein 
catabolism. Consistent with these findings, hypoxic neutrophils exposed to 
ongoing hypoxia show the highest breakdown to uptake ratio (Fig 4.9C). These 
data show that inflammatory neutrophils in glucose deplete, hypoxic conditions 
are most efficient at breaking down proteins which have been scavenged from 







Figure 4.9: In vivo and ex vivo hypoxia regulate BAL neutrophil catabolic activity 
Geometric mean fluorescence of murine BAL neutrophils isolated from normoxic and hypoxic 
mice 24 hours following LPS nebulisation and incubated with (A) Texas Red BSA or (B) DQ-
Green BSA in glucose free media in normoxia or hypoxia (1% O2). (C) Ratio of DQ-Green to 
Texas Red signal to illustrate breakdown efficiency in the conditions described in (A) and (B). 
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mTORC activity links oxygen and glucose availability to protein catabolism in 
neutrophils 
The current literature suggests a critical role for the kinase complex mTORC 
in regulating lysosomal breakdown of proteins. I therefore investigated the role 
of mTORC activity in neutrophils. Our proteomic data confirms that neutrophils 
express the key components of mTORC1 but interestingly, the mTORC2 
component RICTOR was suppressed completely in the hypoxic 
neutrophils(Fig 4.10A). Neutrophils also express the Ragulator complex 
proteins LAMTOR1-3 (Fig 4.10B) which are required for translocation of 
mTORC to the lysosomal membrane[186]. Neutrophil mTORC activity was 
measured by the phosphorylation status of the downstream target S6 kinase 
(S6K). The basal activity of mTOR in human peripheral blood neutrophils was 
analysed following culture with or without LPS stimulation. These data showed 
that, in unstimulated neutrophils, mTORC activity is low and LPS treatment 
results in a significant increase in the ratio of phosphorylated S6K (p=0.0061 
by 2-way ANOVA, Fig 4.11A). Oxygen and glucose availability dramatically 
alter the activity of mTORC in human peripheral blood neutrophils treated with 
LPS (Fig 4.11B). Hypoxia and glucose deprivation independently significantly 
regulate mTORC activity in the LPS treated groups (p=0.0015 and p<0.0001 
respectively by 2-way ANOVA). Glucose deprivation and hypoxia have an 
additive effect to almost completely suppress mTORC activity in hypoxic 
glucose free culture.  When compared with the data presented in Fig 4.8, these 
data show that low mTORC activity correlates with efficient breakdown of 
extracellular proteins in our model. Furthermore, when mTORC activity was 
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assessed in BAL neutrophils from hypoxic and normoxic mice, mTORC activity 
was again suppressed in the hypoxic group (Fig 4.12A) although not to the 
same extent as was seen in the glucose deprived hypoxic human neutrophils. 
To investigate whether this was simply a correlation or whether mTORC 
activity was causative in regulating catabolism of extracellular proteins, human 
peripheral blood neutrophils were incubated with the mTORC activator 
MHY1485 or with the mTORC inhibitor Rapamycin prior to the addition of LPS 
and DQ-Green BSA. With mTORC activation there is a significant decrease in 
DQ-Green signal and with mTORC inhibition, there is a significant increase 
(Fig 4.12B). These data are consistent with the findings of Palm et al[174] that 
mTORC activity suppresses lysosomal breakdown of proteins. 
Taken altogether, the data so far suggests that the hypoxic lung represents an 
optimal niche for excessive neutrophilic inflammation. Early degranulation 
results in significant early lung damage and as a consequence the extracellular 
environment is rich in protein. Hypoxic neutrophils show enhanced uptake of 
extracellular albumin and, in low glucose environments, enhanced lysosomal 
breakdown. This is likely to be due, at least in part, to suppression of mTORC 
activity and thus unfettered breakdown of protein in the lysosome. Additionally, 
there is upregulation of lysosomal proteins, further promoting breakdown of 









Figure 4.10: Neutrophils express mTORC machinery 
Label free quantification of (A) mTORC components and (B) LAMTOR proteins involved in 
localising mTORC to the lysosome in highly pure BAL neutrophils from normoxic and hypoxic 
mice 24 hours post-nebulised LPS. (A)&(B) n=3, unpaired two tailed t test of significance Data 
represents mean ± SEM 
  

















































Figure 4.11: Neutrophil mTORC activity is regulated by LPS, glucose availability and 
hypoxia 
Ratio of phosphorylated to total S6K measured by western blot in unstimulated and LPS 
treated human peripheral blood neutrophils cultured in normoxia or hypoxia (A). n=4 over 2 
experiments, analysed by 2-way ANOVA with multiple comparisons, representative blot shown 
including rapamycin (mTOR inhibitor) control. (B) LPS treated human peripheral blood 
neutrophils were cultured in normoxia or hypoxia with or without glucose (11mM) and mTORC 
activity assessed by the ratio of phosphorylated to total S6K. n=7 over 4 experiments, data 
expressed as fold change from normoxia+glucose culture, representative blot shown. 
Analysed by 2-way ANOVA with multiple comparisons. Data represents individual values and 








































































Figure 4.12: In vivo hypoxia results in reduced neutrophil mTOR activity 
(A) Ratio of phosphorylated to total S6K measured by western blot in highly pure murine BAL 
neutrophils isolated from normoxic and hypoxic mice 24 hours following LPS nebulisation, n=8 
over 2 experiments, Mann-Whitney test of significance, representative blot shown. (B) 
Geometric mean fluorescence of LPS treated human peripheral blood neutrophils cultured 
with DQ-Green BSA and MHY1485 (an mTORC activator) or rapamycin (an mTORC inhibitor), 
n=4 over 2 experiments, analysed by ordinary one-way ANOVA with multiple comparisons, 
data expressed as fold change from untreated control. Data represents individual values and 





























































Glutamine from scavenged proteins can be metabolised by neutrophils 
In order to test the hypothesis that extracellular proteins can be utilised by the 
neutrophil to fuel inflammation, I utilised labelled protein lysates from a cell line 
to investigate the fate of scavenged proteins. First, HEK cells which had been 
grown in media supplemented with 13C5 labelled glutamine were lysed and the 
protein precipitated with acetone to remove any residual free labelled 
glutamine or metabolites. Ex vivo BAL neutrophils from hypoxic mice were 
cultured in media supplemented with the labelled protein lysates or with control 
(unlabelled) HEK cell lysates. Following 18 hours of culture in hypoxia, the 
neutrophils were harvested, lysed and HPLC-MS carried out to measure 
metabolite abundance and to identify the presence of metabolic intermediaries 
with heavy label incorporated. As illustrated in Fig 4.13A, label could be traced 
into TCA cycle metabolites, consistent with metabolism of glutamine into 
central carbon metabolism. With specific regard to 2-oxaloglutarate, this 
metabolite was only present in low levels in some samples, rendering the data 
unreliable. The graph shows those samples where there was sufficient 
metabolite to quantify label incorporation accurately (n=1 for control and n=2 
for label) and is consistent with the data from other metabolites which were 
present at sufficient levels to include all samples.  
It was also interesting to note that significant label incorporation occurred in 
UDP-GlcNAc (Figure 4.13B). This metabolite is the substrate for glycosyl 
transferases which regulate protein O-GlcNAcylation, an important post-
translation modification with consequences for protein stability, activity and 
localisation[187]. Glutamine, as well as glucose, can be metabolised to UDP-
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GlcNAc in T cells with important consequences for T cell functions[188]. 
Neutrophils have been found to have increased protein O-GlcNAcylation when 
stimulated with fMLF and the data presented here suggests that glutamine 









Figure 4.13: Glutamine from proteins can be traced into metabolic intermediaries 
Highly pure BAL neutrophils harvested 6 hours post-nebulised LPS from hypoxic mice were 
cultured ex vivo for 18 hours in hypoxia (1%O2) in glucose free media supplemented HEK cell 
lysates from unlabelled HEK cells (white) or HEK cells which had been cultured with 13C5 
glutamine for 72 hours prior to lysis. Metabolite abundance and labelling was measured by 
HPLC-MS. n=4 (excluding 2-Oxaloglutarate, see text), Mann-Whitney test of significance. 




































































































































In vivo chloroquine treatment attenuates neutrophilic lung inflammation 
The data presented in this chapter demonstrate that neutrophils can take up 
and breakdown extracellular protein to use as fuel. In vitro, chloroquine inhibits 
this breakdown. Furthermore, chloroquine has been shown to improve 
outcomes in other acute lung injury models[189,190]. I therefore went on to 
carry out a pilot study to investigate whether chloroquine may have therapeutic 
value in an LPS induced lung injury and whether this was associated with a 
reduction in protein breakdown by lung neutrophils. In the published literature, 
chloroquine has been shown to affect recruitment of neutrophils to the lung, 
depending on the time frame of administration relative to the injurious stimulus. 
In order to isolate the effect of chloroquine on the behaviour of lung 
neutrophils, rather than on the recruitment of lung neutrophils, I trialled two 
different dosing schedules. Mice were injected IP with 50mg/kg of chloroquine 
diphosphate in 100µl of PBS or, for control mice, 100µl of sterile PBS alone. 
In the first dosing schedule this was done immediately following LPS 
nebulisation and in the second schedule the chloroquine was injected four 
hours post-LPS nebulisation. As in previous experiments, following 
nebulisation of LPS, mice were housed in either normoxia or hypoxia. 
Administration of IP chloroquine immediately following LPS nebulisation 
appeared to reduce neutrophil numbers in the BAL fluid 24 hours following 
LPS administration in both normoxic and hypoxic groups (Fig 4.14A). 
However, administration of chloroquine four hours after LPS stimulus does not 
alter neutrophil recruitment to the airways at 24 hours (Fig 4.14B). I therefore 
proceeded with this model. Analysis of peripheral blood cell numbers showed 
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no significant effect of chloroquine on circulating leucocyte populations when 
administered at the four-hour time point (Fig 4.14C). When BAL neutrophils 
were cultured ex vivo with DQ-Green albumin for two hours, there was a trend 
towards lower DQ-Green fluorescence in the chloroquine treated mice in both 
normoxia and hypoxia (although the effect was subtle in hypoxia) suggesting 
that IP chloroquine may be sufficient to reduce the lysosomal breakdown 
capacity of neutrophils recruited to the airways (Figure 4.14D). Whereas in 
previous experiments, BAL neutrophils from hypoxic mice had a higher DQ-
Green signal than normoxic mice (Fig 4.9B), this was not the case in this 
experiment. It is therefore possible that the hypoxia/PBS treatment group have 
a sub-maximal DQ-green signal in this experiment for unknown reasons and 
the experiment will need to be repeated to resolve this discrepancy. 
Importantly, analysis of the BAL supernatant also revealed a reduction in 
elastase activity in the chloroquine treated mice (Figure 4.14E). Again, the 
effect was subtle in the hypoxic mice and more marked in the normoxic mice. 
Finally, I measured the body temperatures of the mice immediately before they 
were culled (i.e. at the 24-hour time point). I found that, in normoxia, 
chloroquine treatment led to an increase in body temperature (Figure 4.14F). 
Due to a technical error, the temperature of the three out of the four 
hypoxia/PBS mice was not measured. I have therefore plotted this single 
measurement only however, it is consistent with the mean temperature of 
hypoxic mice at 24 hours in previous experiments (33.2°C, see Figure 3.1) and 
the temperature of the hypoxic, chloroquine treated mice was slightly higher 
than this (mean=34.6°C, Figure 4.14F). This preliminary data is consistent with 
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the literature which suggests that chloroquine can have a therapeutic benefit 
in models of acute lung injury. The less pronounced benefits in hypoxia may 
be due to the greater injury in these mice. Additionally, at the time of injection 
(four hours post-LPS) the hypoxic mice are more hypothermic than their 
normoxic counterparts and previous work from our group demonstrates that in 
an infection model, acute hypoxia results in lower blood pressure and lower 
cardiac output[143]. It is therefore possible that hypoxic mice do not achieve a 
therapeutic level of chloroquine as rapidly as the normoxic mice, resulting in a 
less marked effect of chloroquine treatment. While the reduced DQ-Green 
signal and supernatant elastase activity do not reach statistical significance 
here, this is likely to be due to the small number of mice in each group and 
increasing this number will be required to identify any significant differences 
between groups.  Optimisation of the dose and schedule will be required to 
fully elucidate the effect and therapeutic potential of chloroquine in this model, 







Figure 4.14: Chloroquine attenuates acute lung injury in vivo 
BAL neutrophil counts from mice 24 hours following LPS nebulisation, treated with IP 
chloroquine or IP PBS at T0 (A) or T4 hours (B) and housed in normoxia or hypoxia, n=3-4. (C) 
Circulating blood leucocyte populations 24 hours following LPS nebulisation from mice treated 
with IP chloroquine or IP PBS at T4 hours and housed in either normoxia or hypoxia. (D) BAL 
neutrophils incubated ex vivo with DQ-Green BSA and analysed by flow cytometry, (E) 
elastase activity in the BAL supernatant and (F) body temperatures at 24 hours. (D)-(F) in 
mice treated with IP chloroquine or IP PBS at T4 hours and housed in normoxia or hypoxia, n=3-
4. All data represents individual values and mean ± SEM except (C) where data represents 
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The lung represents a unique microenvironment: its role in gas transfer and its 
dual circulation result in highly variable oxygen availability, even in health. The 
lung is also immunologically interesting. It is constantly exposed to innocuous 
foreign material and failure of immune tolerance can result in significant 
pathology such as allergy, asthma or autoimmune disease. Conversely, the 
lung is susceptible to infections including bacterial, viral and fungal infections. 
This susceptibility to infections is often exacerbated by chronic inflammatory 
diseases such as cystic fibrosis, bronchiectasis and COPD which are all 
characterised by recurrent infectious exacerbations.  There is increasingly 
evidence that the microenvironment of the lung is essential in maintaining 
effective immunity. In particular, the alveolar epithelium plays an important role 
in maintaining this microenvironment and inflammation may lead to 
perturbation. The low glucose concentrations within the airway are thought to 
be an important factor in maintaining the sterility of the airways and 
dysregulation of airway glucose levels, for example in diabetes mellitus may 
result in increased bacterial colonisation of the airways[191-193]. The data 
presented here suggest that neutrophils are highly adapted to function in this 
low glucose environment, despite their predisposition to generate energy via 
glycolysis. Furthermore, in vitro and ex vivo experiments suggest that the low 
glucose environment may itself alter neutrophil function.  
Nonetheless, glycolysis is essential in fuelling neutrophils during the 
inflammatory response.  The rate of glycolysis is dependent on a number of 
factors including abundance of glycolytic enzymes, enzymatic activity and 
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substrate availability. Hypoxia would be predicted to upregulate glycolysis 
because both glucose transporters and glycolytic enzymes are known HIF 
target genes, however, inflammatory stimuli can also stimulate glycolysis in 
neutrophils. The proteomic data set shows that, in the inflammatory 
environment, an additional hypoxic stimulus cannot upregulate glycolytic 
enzyme abundance in neutrophils. LPS has been shown to stabilise HIFa in 
both neutrophils[143] and macrophages[194] and so it is possible that 
neutrophils from normoxic mice undergo a degree of HIF stabilisation and thus 
induction of glycolytic genes which cannot be further induced by concomitant 
hypoxia. Hypoxia is, however, able to induce other HIF target proteins above 
the levels seen in normoxic inflammatory neutrophils including the glucose 
transporter Glut3. The quantitative nature of the proteomic data set identified 
Glut3 as the dominant transporter in BAL neutrophils. Both normoxic and 
hypoxic neutrophils did also express Glut1 but at very much lower levels. The 
Glut3 LFQ intensity translated to over 100,000 of copies of this protein per cell 
in hypoxia. Coupled with the very high expression levels of glycolytic proteins 
(as detailed in Figure 3.4D) in both treatment groups these data highlight the 
enormous glycolytic capacity of these cells. It is well established that 
neutrophils do not utilise oxidative phosphorylation for ATP generation[159]. It 
was therefore interesting to find that neutrophils express all of the essential 
enzymes for the TCA cycle, albeit at lower levels than glycolytic enzymes. The 
HPLC-MS metabolite data also showed the presence of TCA cycle 
intermediates in both normoxic and hypoxic neutrophils. These data raise the 
question of what the function of these proteins and metabolites is in 
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neutrophils. Studies of the neutrophils of patients with mutations in the SDHb 
gene demonstrated succinate accumulation and enhanced neutrophil survival 
as well as reduced oxidative stress, confirming a role for components of TCA 
cycle out-with energy generation in this cell type[160]. It is important to note 
that the TCA cycle is really a series of bidirectional enzymatic reactions whose 
directionality will be altered by multiple factors including enzyme activity and 
availability but also metabolite abundance. There is increasing interest in the 
role of metabolites in regulating immune cell function. Tannahill et al[89] 
identified succinate production by macrophages as a pro-inflammatory signal 
required for production of IL-1b. The metabolite S-2HG also has 
immunomodulatory functions in T cells[90] and HIF-1a regulates S-2HG 
accumulation[195]. Glutamine metabolism is required to generate both 
succinate and S-2HG. The data presented in this chapter demonstrate that 
glutamine is an important source of TCA intermediaries in inflammatory 
neutrophils and that the proteins involved in glutaminolysis are upregulated by 
in vivo hypoxia. Thus, while neutrophils may not utilise the TCA cycle for 
energy generation in the traditional sense, some of its components may be 
important in energy generation from glutamine and others may have important 
immunomodulatory roles. This is likely to be of particular relevance in the 
context of hypoxia. The prolyl hydroxylase enzymes PHD1-3 which 
hydroxylate HIFa in the presence of oxygen also require the TCA cycle 
intermediate 2-oxoglutatrate as a substrate. Furthermore, both succinate and 
fumarate can inhibit PHD function[196] and so hypoxic signalling is sensitive 
to levels of TCA cycle intermediaries (Figure 1.2). Hence, while the TCA cycle 
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may not be required for energy generation in neutrophils, its components are 
likely to play an important role in glutamine metabolism, immune function and 
the hypoxic response. 
The parallels between the tumour microenvironment and the inflamed lung 
have proved useful for understanding some of the biological processes 
identified in hypoxic neutrophils. The identification of high intracellular levels 
of albumin in neutrophils was initially surprising but, in the context of the 
literature regarding albumin utilisation by tumour cells it led to the identification 
of important neutrophil behaviours which were modulated by hypoxia.  
The finding that amino acids from scavenged proteins can be utilised for 
central carbon metabolism mirrors findings in tumour cells[173]. In tumour cell 
lines, Palm et al[174] found that mTOR was an important regulator of this 
process. Interestingly, the source of amino acids appeared to be important in 
directing mTOR signalling in this context: free amino acids resulted in mTOR 
activation and protein synthesis while amino acids from scavenged proteins 
inhibited mTOR activation . The data presented here show that, in vitro, 
glucose and oxygen availability regulate mTOR activity in neutrophils.  
Unstimulated blood neutrophils from healthy donors have very low levels of 
mTOR activity, as measured by the phosphorylation state of the S6 kinase. 
LPS stimulation induces mTOR activity in peripheral blood neutrophils but the 
degree of activation is clearly modulated by glucose availability and by 
hypoxia. In contrast, BAL neutrophils from LPS stimulated mice show basal 
mTOR activity which is moderately supressed in the BAL neutrophils of 
hypoxic mice (although not to the same degree as seen in glucose deprived 
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hypoxic human blood neutrophils).  These data are consistent with the concept 
that, when nutrients are limited, switching off mTOR signalling allows 
unfettered catabolism of proteins in the lysosome. In the neutrophil population, 
low mTOR activity coincides with increased protein breakdown as measured 
by DQ-Green albumin fluorescence. Furthermore, experiments with chemical 
activation or inhibition of mTOR lead to reduced or increased fluorescence 
respectively which is consistent with a causative link between mTOR activity 
and protein catabolism in neutrophils.  Another factor in the capacity of hypoxic 
neutrophils to catabolise scavenged proteins efficiently is likely to be their 
upregulation of lysosomal proteins. Hypoxia has been found to upregulate 
lysosomal proteins in colon carcinoma cells[197]. Additionally, hypoxia has 
been shown to be a positive regulator of the related process of autophagy in 
multiple cell types[198-200]. Investigation of in vivo hypoxia as an 
inflammatory stimulus in neutrophils has led to the identification of this process 
in neutrophils, however, while the data in this chapter are consistent with these 
processes being upregulated in hypoxic neutrophils, they are likely to occur to 
some extent in all inflammatory neutrophils. The hypoxic inflamed lung 
represents an ideal niche to promote protein uptake and catabolism. 
Neutrophils have previously been considered a homogenous population of 
simple cells with limited capacity for protein synthesis. This paradigm meant 
that designing therapeutic interventions which could limit inflammation without 
obliterating immunity was extremely challenging and revolved around 
‘switching off’ neutrophils. As we begin to understand the degree of 
heterogeneity in the neutrophil population, the capacity of neutrophils to adapt 
 168 
to their environment and, critically, to continue to synthesise inflammatory 
mediators, this opens up a much wider range of therapeutic targets which 
could modulate neutrophil function in a more specific fashion. It also raises the 
interesting possibility of enhancing neutrophil function as well as limiting it. This 
may be useful in the context of tumour associated neutrophils or in chronic 
diseases such as COPD where persistent neutrophil infiltration is 
accompanied by recurrent infections, suggesting a degree of exhaustion in the 
neutrophil antimicrobial response. It is interesting to consider whether 
manipulation of the processes described here could be used to ‘re-arm’ the 
neutrophil population to enhance immunity. 
The data presented here suggest a number of novel therapeutic strategies 
which require further investigation. Firstly, the data suggests that manipulation 
of the lysosome may have potential therapeutic benefits in neutrophilic lung 
inflammation. The lysosome appears to be essential in generating the amino 
acid pool required for de novo synthesis of inflammatory mediators. There is 
some evidence that chloroquine may have therapeutic benefit in acute lung 
injury. Intraperitoneal injection of chloroquine prior to paraquat induced ALI 
resulted in reduced lung damage and lower numbers of infiltrating immune 
cells at 3 days as well as lower rates of lung fibrosis at 28 days[189], although 
the mechanism by which chloroquine was acting was not investigated.  Pre-
treatment with chloroquine was also protective in ALI associated with a rat 
model of pancreatitis[190]. Furthermore, both pre-treatment and delayed 
treatment with chloroquine proved protective in a mouse model of LPS induced 
sepsis.  Chloroquine is most commonly used as an anti-malarial drug, 
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inhibiting parasitic haemoglobin digestion within erythrocytes[201]. However, 
it has also been utilised as an immunomodulatory agent in autoimmune 
diseases such as systemic lupus erythematosus (SLE) and rheumatoid 
arthritis and although the exact mechanism of action in this context is 
uncertain, it is postulated to be due to alterations in antigen processing. 
Chloroquine has also been found to reduce TNF-a production in 
macrophages[202]. Therefore this drug will have pleiotropic effects in acute 
lung injury which may include (but are highly unlikely to be limited to) 
suppression of neutrophilic protein catabolism. Systemic administration of 
chloroquine is likely to further muddy the waters. The data presented here 
suggest that IP chloroquine can attenuate LPS induced lung injury with 
evidence of a reduction in the capacity of lung neutrophils to catabolise protein 
in this context.  It is possible that the benefit is not sufficient to overcome the 
major increase in lung injury caused by concurrent hypoxic exposure but also 
that absorption of the drug is limited in hypoxia due to the increased sickness 
of these mice and this requires further investigation. The timing of drug 
administration is also vital to consider. In patients, the onset and progression 
of ALI and ARDS are difficult to predict and so pre-treatment is rarely an option. 
A recent paper from Proudfoot et al investigating the potential of targeting TNF 
signalling in acute lung injury utilised a nebulised drug treatment with some 
benefit[203]. Thus, this form of ‘topical’ lung therapy may be useful in delivering 
a drug with multiple potential off-target effects to specifically target neutrophilic 
inflammation. Additionally, as chloroquine would be hypothesised to block the 
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persistent neutrophilic inflammation seen in hypoxia, rather than the onset of 
lung injury, delayed administration could still be therapeutic.  
Secondly, these data highlight the potential of targeting metabolism to 
influence inflammation. The data raises interesting questions regarding 
regulation of neutrophil energetics by signalling pathways such as mTOR and 
AMPK, both of which have both been implicated in tumorigenesis. The 
inhibition of mTOR is consistent with increased catabolism of proteins but less 
consistent with ongoing protein synthesis. The time-course of the mTOR 
response in inflammatory lung neutrophils will be important to shed light on 
this apparent contradiction. It will also be important to investigate the 
intracellular localisation of mTOR as this is known to be important in sensing 
lysosomal signals. 
In order to design therapeutic agents which specifically target neutrophilic lung 
inflammation, it is essential to understand how these cells behave in situ, and 
which factors regulate this. Examination of the neutrophil proteome has 
provided insights into the processes which are important in inflammatory 
neutrophils. The proteomic data confirmed that hypoxic exposure dramatically 
alters the neutrophil phenotype in vivo. Investigating the factors which 
contribute to hyperinflammatory phenotypes in hypoxia has identified novel 
neutrophil behaviours with important consequences for inflammation and 
resolution. The capacity of neutrophils to continue to synthesise inflammatory 
mediators following transmigration goes against existing dogma which states 
that granule proteins are synthesised and packaged in bone marrow 
neutrophils and can simply be released upon activation. These data also 
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highlight the degree of plasticity which exists and the adaptations which 
neutrophils are able to make in response to environmental stresses.   
  
 172 
Chapter 5: PHD1 Regulates Neutrophil Metabolism and 
Survival with Consequences for Lung Inflammation 
Introduction 
Hypoxia profoundly alters the outcome of neutrophilic inflammation. The HIF 
transcription factors and their regulatory proteins the prolyl hydroxylases 
(PHDs) and factor inhibiting HIF (FIH) are of vital importance in regulating 
cellular responses to hypoxia. As such, these proteins are of interest as 
therapeutic targets in neutrophilic inflammation. In a seminal paper, Cramer et 
al investigated the consequences of HIF-1a loss on myeloid cell function[75]. 
This study found that HIF-1a was essential for myeloid cells and that it 
regulated cellular energetics, bactericidal capacity, motility and migration. 
Additionally, HIF-1a is essential for neutrophil hypoxic survival[69], an 
important factor in the capacity of neutrophils to respond to infections in hostile 
inflammatory environments. HIF-1a is therefore not an optimal therapeutic 
target as its blockade is likely to result in failure of innate immunity. HIF-2a 
function has also been investigated in neutrophils and has been found to have 
a more specific role in neutrophil function. HIF-2a over-expression results in 
prolonged neutrophil survival as might be predicted and, consistent with this, 
loss of HIF-2a led to enhanced inflammation resolution due to increased 
neutrophil apoptosis at the site of inflammation[143]. This isoform selective 
function has also been identified within the PHD enzymes and, as such, it is 
hoped that manipulation of these proteins may allow more specific 
augmentation of hypoxic responses. 
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The isoform specific functions of PHDs in neutrophils are clearly illustrated by 
the very different phenotypes which are observed when PHD2 or PHD3 is 
knocked down. Loss of PHD2 led to enhanced neutrophil inflammation and 
failure of inflammation resolution, whereas loss of PHD3 resulted in loss of 
hypoxic survival in neutrophils, despite preserved HIF activity and this, in turn 
led to improved inflammation resolution.  
The role of PHD1 in neutrophil function has not previously been investigated 
but PHD1 knockout has been found to be of benefit in a number of animal 
models, particularly in the setting of an ischaemic challenge. This therapeutic 
effect of PHD1 knockdown was first reported in a model of skeletal muscle 
ischaemia[204]. Using whole animal PHD1 knockout mice, the authors 
identified that PHD1 deficient skeletal muscle exhibited reduced oxygen 
consumption compared to WT mice. This reduction in oxygen consumption 
was due to an altered metabolic profile in PHD1 deficient myofibers with a 
switch from oxidative phosphorylation to glycolysis. This switch was mediated 
in part by upregulation of pyruvate dehydrogenase kinase (PDK) 1 and 4 which 
prevented entry of pyruvate into the TCA cycle. This adaptation allowed PHD1 
deficient mice to tolerate an ischaemic injury to their hind-limb: increased 
glycolysis resulted in continued ATP generation and reduced oxidative stress 
in knockout muscle and therefore protection from the ischaemic necrosis which 
occurred in WT mice. PHD2 deficiency has also been shown to protect mice 
from an ischaemic limb injury but through a distinct mechanism, illustrating the 
isoform selective functions of these enzymes. PHD2+/- mice had a degree of 
“preconditioning” with increased collateral vessels at baseline (an adaptation 
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which was not present in PHD1 deficient mice) and a pre-adapted M2 
macrophage population which triggered arteriogenesis[205]. Furthermore, 
genetic profiling of the macrophage population in PHD2 haplodeficient mice 
identified a shift to an M2 phenotype (M2 skewing) in PHD2+/- peritoneal 
macrophages with increased transcription of M2 markers including arginase1 
and TGF-b.  
PHD1 deficient mice were also found to be protected from a liver 
ischaemia/reperfusion injury, again due to reduced oxidative stress following 
reperfusion[206]. In keeping with the data from skeletal muscle, PHD1 
deficient livers showed reduced oxygen consumption and increased PDK1 
expression consistent with enhanced glycolysis. In both the ischaemic limb 
and liver injury models, PHD1-/- mediated protection was dependent on HIF-
2a activity. More recently, PHD1-/- mice were shown to be protected from 
cerebral ischaemic injury. Neurons, like myofibers and hepatocytes, are 
ordinarily dependent on oxidative glucose metabolism. However, the 
protection conferred by PHD1 knockdown in this model does not rely on 
increased glycolysis, or on altered angiogenesis but instead on alteration in 
the redox status of hypoxic neurons and therefore enhanced ROS buffering 
capacity[207]. Interestingly, this phenotype is independent of HIF activity, 
unlike those described in the muscle and liver.  
PHD1 has also been implicated in inflammatory processes. PHD1-/- mice were 
protected from dextran sulphate sodium (DSS)-induced colitis[208]. This 
protection was associated with improved intestinal epithelial barrier function 
due to enhanced survival of PHD1 deficient enterocytes. This in turn led to 
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reduced inflammation and reduced neutrophil infiltration. Furthermore, 
analysis of biopsies from patients with colitis found that PHD1 was upregulated 
in colitis and levels of PHD1 were correlated with inflammatory cytokine 
expression in patient biopsies[209]. In more recent studies from the Hindryckx 
group, haematopoietic cell PHD1 knockout was found to be required for 
protection against colitis[210]. The authors used a combination of Tie2Cre 
driven PHD1 deletion (which results in both endothelial and haematopoietic 
cell PHD1 loss) and bone marrow chimeras to identify that haematopoietic cell 
PHD1 deletion was necessary and sufficient to protect against colitis. In data 
which has interesting parallels with the studies of PHD2 haplodeficiency by 
Takeda et al[205], PHD1 deficiency resulted in skewing of the macrophage 
population to a more M2, anti-inflammatory phenotype. Taken together these 
data illustrate that specific functions may be attributed to each PHD isoform 
and that there is a lack of redundancy within the system. However, it is 
important to note that in some specific scenarios, loss of one isoform may be 
compensated for by another. In the paper by Takeda et al, when using a 
myeloid specific PHD2 deletion model, haplodeficient macrophages exerted 
the protective effect but PHD2 null macrophages did not. This was found to be 
due to a significant, compensatory uplift in PHD3 transcript in the PHD2 null 
macrophages. Additionally, in a study of PHD mediated regulation of T cell 
development, Clever and colleagues[211] found that knock down of all three 
PHD isoforms in CD4+ T cells regulated lung inflammation. Specifically, PHD 
proteins were required to restrain proinflammatory Th1 cell function and to 
promote regulatory T cell (Treg) development in response to innocuous immune 
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stimuli.  This effect was not mediated by a specific PHD isoform, rather deletion 
of all three was required, consistent with context specific redundancy in the 
system. 
The evidence above that PHD1 may regulate inflammatory responses in 
addition to hypoxic responses led us to consider whether PHD1 may play a 
role in neutrophilic inflammation. Given the previous work from our group 
demonstrating a specific role for PHD2 and PHD3 in regulation of neutrophil 
function which was distinct from their role in modulating macrophage 
behaviour, we elected to use a neutrophil specific PHD1 knockout model. In 
order to investigate the specific role of PHD1 in the neutrophil population, I 
have generated a mouse line with neutrophil-specific PHD1 knockdown. This 
utilised Cre-Lox technology as described in the methods section. Mice with 
LoxP sites flanking the PHD1 gene (PHD1fl/fl) have been previously 
described[210] and these mice were crossed with a mouse line expressing the 
Cre recombinase under the transcriptional control of MRP8 (also known as 
S100-A8) with IRES mediated co-expression of green fluorescent protein 
(GFP). This line has been shown in the literature to selectively knock down the 
floxed protein in neutrophils[76,111,212]. This specificity is driven by the very 
high levels of expression of S100-A8 in neutrophils, however, it is important to 
acknowledge that although this protein is predominantly expressed in 
neutrophils, it is also expressed (albeit at lower levels) in myeloid and epithelial 
cells and so, like most Cre-Lox driven deletions, cannot be said to be 
completely specific.  All mice were on a C57/Bl6 background. 
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The aims of this chapter were to characterise neutrophil specific PHD1 
deficient mice and to investigate the consequences of neutrophil specific 
PHD1 loss for inflammatory responses in both normoxia and hypoxia. I 
hypothesised that loss of PHD1 would result in metabolic adaptations in the 
neutrophil population and that this would have knock-on consequences for 




MRP8 driven Cre recombinase allows neutrophil specific deletion of PHD1 
I first investigated whether MRP8 driven Cre expression in PHD1fl/fl mice did 
result in neutrophil specific loss of PHD1. Highly pure bone marrow neutrophils 
were isolated from PHD1f/f MRP8Cre-/- (wild-type, WT) and PHD1f/f 
MRP8Cre+/- (knockout, KO) mice. I carried out TaqMan analysis of gene 
expression using commercial primer/probe sets. This confirmed knockout of 
PHD1 mRNA in Cre+/- mice with no alteration in expression levels of PHD2 or 
PHD3 (Fig 5.1A). Bone marrow mononuclear cells were isolated and cultured 
until matured into BMDMs, as assessed by surface expression of F4/80 (Fig 
5.1B). These BMDMs were then analysed for gene expression of PHD1, 2 and 
3. This confirmed no reduction in PHD1 expression in the BMDMs from KO 
mice and no changes in expression of PHD2 or 3 (Fig 5.1C). 
In order to assess knockdown of PHD1 in blood and lung neutrophils, I took 
advantage of the co-expression of GFP in the MRP8Cre positive cells. Using 
flow cytometry to measure GFP positivity, I found that 93% of peripheral blood 
neutrophils were GFP positive in KO mice while <1% of WT neutrophils were 
GFP positive (Fig 5.2A). This pattern held true for BAL neutrophils with 92.5% 
of BAL neutrophils being GFP positive in KO mice compared to <3% of WT 
BAL neutrophils (Fig 5.2B). Additionally, only 6% of peripheral blood 
monocytes were GFP positive in KO animals, and <2% of BAL macrophages 
were GFP positive in KO animals indicating neutrophil specific Cre expression 








Figure 5.1: PHD1fl/flMRP8Cre+/- mice display neutrophil specific loss of PHD1 mRNA in 
the bone marrow 
TaqMan analysis of gene expression for PHD1 (egln2), PHD2 (egln1) and PHD3 (egln3) in (A) 
highly pure murine bone marrow neutrophils n=3-4. (B) Bone marrow derived monocytes 
(BMDMs were differentiated from bone marrow mononuclear cells and analysed by flow 
cytometry for expression of the monocyte marker F4/80, n=6. Bone marrow derived 
monocytes from wild-type (PHD1fl/flMRP8Cre-/-) and KO (PHD1fl/flMRP8Cre+/-) mice were 
subsequently analysed for gene expression for PHD1 (egln2), PHD2 (egln1) and PHD3 







































































































Figure 5.2: PHD1fl/flMRP8Cre+/- mice display neutrophil specific knock out of PHD1 in 
blood and BAL neutrophils 
Flow cytometry analysis of GFP positive and negative myeloid cells in the blood (A) and BAL 
(B) of WT and KO mice. Blood leucocytes were identified by CD45 positivity and blood 
monocytes by CD115 positivity. In both blood and BAL neutrophils were identified by Ly6G 
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Neutrophil specific PHD1 deficient mice have normal circulating leucocyte 
populations 
I went on to characterise the impact of PHD1 deletion on the behaviour and 
function of neutrophils. In order to establish that they had normal immune cell 
maturation and recruitment, I analysed leucocyte numbers and differentials in 
mice with or without an inflammatory stimulus. Whole blood was collected from 
WT and KO mice and analysed by flow cytometry for leucocyte differential 
counts. There was no difference between genotypes in the percentages or 
absolute numbers of circulating leucocytes in naïve mice (Fig 5.3A&B) or in 
mice 24 hours post-nebulised LPS challenge (Fig 5.3C&D). In both genotypes, 
LPS challenge results in a significant increase in the number of circulating 






Figure 5.3: PHD1 deficiency does not alter circulating leucocyte populations 
Whole blood from WT and KO mice was analysed by flow cytometry to establish the make-up 
of the leucocyte population and counted using a haemocytometer to establish absolute 
leucocyte counts. The % of each leucocyte population and absolute leucocyte count are shown 
for naïve mice (A)&(B) and for mice 24 hours after nebulised LPS (B)&(C). The absolute 
neutrophils numbers were calculated for WT and KO mice in both unstimulated and LPS 
treated animals (E), analysed by 2-way ANOVA. (A)-(C) and (E) n=3, (D) n=6 over 2 
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PHD1 deficient neutrophils are functionally competent 
Having established that neutrophil PHD1 deficiency does not alter circulating 
leucocyte numbers, I went on to investigate what, if any, the functional 
consequences are of PHD1 loss for the neutrophil. Inflammatory BAL 
neutrophils were isolated from WT and KO mice, 24 hours following nebulised 
LPS. Chemotaxis towards the mouse chemokine KC (CXCL1) was measured 
using ChemoTx plates (Neuro Probe). As Figure 5.4A shows, there was a dose 
dependent increase in chemotaxis in response to KC but no difference 
between the genotypes. 
Phagocytosis was measured using fluorescently labelled heat-killed E Coli. 
This experiment was carried out using whole animal PHD1-/- mice (KOPHD1) 
with C57/Bl6 wild-type controls rather than the PHD1fl/fl MRP8Cre mouse line. 
There was no difference between genotypes in their capacity to phagocytose 
heat killed bacteria (Fig 5.4B). 
Thus, loss of PHD1 does not specifically alter neutrophil homeostasis or 
recruitment from the bone marrow following stimulation and PHD1 deficient 
















Figure 5.4: PHD1 deficient neutrophils are functionally competent 
BAL neutrophils were isolated 24 hours after nebulised LPS from WT and KO mice and 
analysed for chemotaxis towards the chemokine KC (A, data expressed as the % of the 
positive control), analysed by 2-way ANOVA, and for phagocytosis of AF488 labelled heat 
killed E Coli when incubated at an MOI of 1 (B). Phagocytosis was measured in cells cultured 
in an iced water bath (“ice control”) and at 37°C to control for adhesion of bacteria to the 
extracellular surface of the neutrophils. (A) n=6 over 2 experiments, (B) n=8 over 2 
experiments. Data represent individual data points and the mean ± SEM. 









































PHD1 deficient neutrophils show enhanced respiratory burst capacity and 
increased oxidative stress 
I went on to investigate whether inflammatory PHD1 deficient neutrophils had 
an altered capacity for reactive oxygen species (ROS) generation. This 
experiment was also carried out using whole animal PHD1-/- mice (KOPHD1) 
with C57/Bl6 wild-type controls rather than the PHD1fl/fl MRP8Cre mouse line. 
This was due to the spectral overlap between the GFP tag on the MRP8Cre 
mouse line and the fluorescent signal associated with DCF generation. 
I found no difference in baseline ROS generating capacity between genotypes 
(Fig 5.5A) and, although it did not reach statistical significance, there was a 
trend towards an increased ROS generating capacity in response to f-Met-
Leu-Phe (fMLF) stimulation in the KOPHD1 neutrophils (Fig 5.5A). In order to 
define the neutrophil response to fMLF, I calculated the increase in ROS 
following fMLF stimulation. This showed a significantly greater response in KO 
than WT neutrophils (Fig 5.5B). 
In order to further characterise this phenotype, I undertook HPLC-MS analysis 
of BAL neutrophil metabolites from WT and KO mice, 24 hours post-nebulised 
LPS. I found that the increased ROS generating capacity of PHD1 deficient 
neutrophils was associated with increased levels of metabolic oxidative stress, 
as measured by the ratio of NADP:NADPH, which was significantly higher in 
KO than WT neutrophils (Fig 5.5C). Additionally, there was a trend towards a 
higher proportion of oxidised glutathione (GSSG) to reduced glutathione 
(GSH) (Fig 5.5D). 
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There is no associated increase in the abundance of OxPPP intermediaries in 
KO neutrophils (Fig 5.5E) but as this is a snapshot of the neutrophil metabolic 
profile, rather than a tracing assay capable of measuring flux, these data do 






Figure 5.5: PHD1 deficient neutrophils generate more ROS and display increased 
oxidative stress 
Measurement of WT and KOPHD1 BAL neutrophil ROS generation at baseline and in response 
to stimulation with fMLF (A). Respiratory burst activity as calculated by the uplift in DCF gMFI 
following fMLF stimulation (B), Mann-Whitney test of significance. HPLC-MS analysis of the 
ratio of NADP:NADPH (C) and the fraction of oxidised glutathione (D) in WT and KO BAL 
neutrophils isolated 24 hours post-LPS nebulisation, (C) & (D)Mann-Whitney test of 
significance. (E) Abundance of OxPPP metabolic intermediaries in WT and KO BAL 
neutrophils, expressed as fold change from normoxia. (A)&(B) n=8 over 2 experiments. (C)-
(E) n=4. Data represent individual data points and the mean ± SEM. 
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PHD1 deficiency alters hypoxic neutrophil dynamics in vivo 
In order to investigate how this phenotype of enhanced oxidative stress would 
affect neutrophil function in vivo, I utilised the LPS induced acute lung injury 
model in both normoxic and hypoxic conditions. There was no significant 
difference in the body temperatures of WT and KO mice over the 24-hour time 
course (Fig 5.6A & 5.6B). In normoxic conditions, there was no significant 
difference between genotypes in the number of neutrophils in the BAL fluid at 
24 or 48 hours (Fig 5.6C) however, in hypoxia the neutrophil dynamics were 
altered. At 24 hours, KO mice had a significantly higher number of BAL 
neutrophils than their WT counterparts (Figure 5.6D). In wild-type mice housed 
in hypoxia, neutrophil numbers in the BAL continue to rise up to 48 hours post-
LPS (Figure 5.5D). This trajectory is reversed in KO mice where neutrophil 
numbers fall between 24 and 48 hours and this results in a significant 
difference between genotypes in terms of resolution of neutrophil numbers (Fig 
5.6E). These data suggest that PHD1 deficiency may result in enhanced 








Figure 5.6: PHD1 deficiency alters neutrophil recruitment and resolution in vivo 
Body temperatures of WT and KO mice housed in normoxia or hypoxia for 24 hours following 
nebulised LPS (A) n=6 over 2 experiments, 2-way ANOVA with multiple comparisons. (B) 
Body temperatures of WT and KO mice 8 hours after nebulised LPS housed in either normoxia 
or hypoxia, ordinary one-way ANOVA with multiple comparisons n≥12 over 3 experiments. 
BAL neutrophil counts of WT and KO mice 24 and 48 hours after nebulised LPS housed in 
normoxia (C) or hypoxia (D) n=8-9 over 2 experiments, Mann-Whitney test of significance. 
Resolution of neutrophilic inflammation in hypoxia as calculated by the fold change in 
neutrophil numbers at 48 hours compared to mean 24-hour counts (E) n=9 over 2 
experiments, Mann-Whitney test of significance.  
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PHD1 deficiency does not significantly alter neutrophil driven lung damage  
I went on to analyse the effect of neutrophil PHD1 deficiency on lung injury in 
this model. As previously described, hypoxia results in an increased level of 
neutrophil elastase activity in the BAL supernatant of WT mice and this pattern 
persisted in KO mice (Figs 5.7A&B) with no significant differences between the 
genotypes in either normoxia or hypoxia at 24 hours. The pro-resolution 
phenotype of hypoxic KO mice described in Fig 5.6 does not correlate with 
significantly lower BAL elastase activity in KO mice at 48 hours. I also 
measured BAL supernatant albumin concentration. Once again, hypoxia was 
associated with a sharp increase in BAL albumin levels and this was true for 
KO as well as WT mice at 24 hours (Figs 5.7C&D). In normoxia, there was no 
difference between genotypes at 48 hours. In hypoxia there was a trend 
towards lower albumin levels in KO mice (mean albumin concentration 
















Figure 5.7: BAL elastase activity and albumin concentrations are unchanged between 
genotypes 
Elastase activity as measured by the Elastase EnzCheck kit in BAL supernatant from WT and 
KO mice 24 or 48 hours after nebulised LPS housed in normoxia (A) or hypoxia (B). Albumin 
concentration in BAL supernatant from WT and KO mice 24 or 48 hours after nebulised LPS 
housed in normoxia (C) or hypoxia (D). n≥6 over 2 experiments, data represent individual data 
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PHD1 deficiency alters neutrophil apoptosis in a context specific fashion 
In order to interrogate the apparent resolution phenotype I had observed in 
vivo, I went on to investigate how PHD1 loss altered neutrophil apoptosis. I 
analysed blood and BAL neutrophils from WT and KO mice which had been 
treated with nebulised LPS and housed in normoxia for all apoptosis 
experiments. Ex vivo culture of peripheral blood neutrophils showed that, in 
normoxic culture, PHD1 deficiency results in significantly reduced rates of 
neutrophil apoptosis (Fig 5.8A). Both genotypes demonstrated reduced 
apoptosis in hypoxia although this did not reach statistical significance in the 
KO mice (p=0.08). Furthermore, in hypoxic culture, PHD1 deficiency was 
associated with a trend towards reduced neutrophil apoptosis in comparison 
to WT hypoxic neutrophils but, again, this did not reach statistical significance. 
Thus, in blood neutrophils, PHD1 deficiency is pro-survival but this effect is 
superseded by the pro-survival effect of hypoxic culture. Nevertheless, hypoxic 
PHD1 deficient neutrophils showed the lowest overall rates of apoptosis. This 
pro-survival phenotype is clearly inconsistent with the resolution of neutrophil 
numbers seen in vivo in hypoxia, so I went on to investigate whether the 
phenotype holds true for inflammatory lung neutrophils. BAL neutrophils were 
isolated 24 hours post-LPS and cultured ex vivo in normoxia or hypoxia. After 
10 hours of culture there was no difference in the rates of apoptosis between 
genotypes and no evidence of enhanced survival in hypoxic culture (Fig 5.8B). 
After 20 hours, in normoxic culture the mean rate of apoptosis was lower in 
KO neutrophils but not significantly so (4.4% Vs 7.1%, p-value 0.07 by 
unpaired t-test). In hypoxic culture though, this effect was completely lost (Fig 
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5.8C) and, as was seen at 10 hours, hypoxic culture was not associated with 
increased neutrophil survival.  
These data demonstrate that culture conditions, and the tissue compartment 









Figure 5.8: PHD1 regulates neutrophil apoptosis 
Apoptosis rates of WT and KO blood (A) and BAL (B) neutrophils after 10 hours of ex vivo 
culture in either normoxia or hypoxia as analysed by nuclear morphology. Apoptosis rates of 
BAL neutrophils after 20 hours of ex vivo culture in either normoxia or hypoxia (C). n≥6 over 2 
experiments, analysed by ordinary one-way ANOVA with multiple comparisons. Data 

















































Glucose availability regulates neutrophil survival 
Given the differences in apoptosis behaviour between blood and BAL 
neutrophils and the evidence that the lung is a glucose deplete environment, I 
went on to investigate the effect of glucose deprivation of neutrophil survival. 
Peripheral blood neutrophils from LPS-treated KO and WT mice were cultured 
ex vivo in normoxia and hypoxia in either standard RPMI or glucose free RPMI. 
In normoxic culture, glucose deprivation led to increased WT neutrophil 
survival (Fig 5.9A) on a par with the pro-survival effect of hypoxic culture. The 
effect was much less pronounced in KO neutrophils. Interestingly, culture of 
blood neutrophils in hypoxia without glucose led to such marked cell necrosis 
that it was not possible to analyse apoptosis rates by morphology. This 
suggested that, in blood neutrophils, hypoxic survival is dependent on glucose 
availability. Analysis of BAL neutrophils cultured ex vivo in the same conditions 
showed that glucose deficiency in normoxia appears to promote neutrophil 
survival (although not statistically significant in this experiment). However, 
unlike the peripheral blood neutrophils, BAL neutrophils can survive in hypoxic 
culture without glucose with similar rates of apoptosis as those seen in glucose 
replete hypoxic culture (Fig 5.9B). Thus, a number of physiological stresses 
can modulate neutrophil apoptosis, including oxygen tension (which has long 
been established in the literature[21,69]) and glucose availability. Furthermore, 













Figure 5.9: Glucose availability regulates neutrophil survival 
Apoptosis rates of WT and KO neutrophils after 10 hours of ex vivo culture in normoxia or 
hypoxia ± glucose, analysed by nuclear morphology of blood neutrophils (A), n=4-5 and BAL 
neutrophils (B), n=4. Ordinary one-way ANOVA with multiple comparisons. Data represent 







































Hypoxia abrogates metabolic differences between PHD1 deficient and wild-
type neutrophils 
Analysis of the metabolic profiles of BAL neutrophils from hypoxic KO and WT 
mice provides some insights into the apoptosis data discussed previously. 
When BAL neutrophils were cultured in hypoxia and without glucose, rates of 
apoptosis were equivalent between genotypes, this is mirrored by unchanged 
abundance of glycolytic intermediaries in WT and KO BAL neutrophils isolated 
from hypoxic mice 24 hours after nebulised LPS (Fig 5.10A) and equivalent 
energy charge between genotypes (Fig 5.10B). 
The data from normoxic BAL neutrophils presented in Figure 5.5C&D showed 
that there was increased oxidative stress in KO neutrophils. Interestingly, when 
these data are compared with that acquired from hypoxic neutrophils, the 
difference between genotypes is lost with no significant differences seen 
between genotypes in NADP/NADPH or GSSG/GSH in the samples from 
hypoxic animals (Fig 5.10C&D). Furthermore, the values found in hypoxia for 
both genotypes are more similar to those seen in normoxic KO samples. This 
raises the possibility that, at baseline, PHD1 deficient neutrophils have a 
pseudo-hypoxic metabolic phenotype. To further investigate this possibility, I 
measured HIF-1a levels using a fluorescently labelled antibody and flow 
cytometry to measure staining. In this pilot experiment, there was a small 
increase in the mean fluorescence of KO compared to WT BAL neutrophils 
from normoxic mice (Fig 5.10E). This observation would be consistent with the 
enhanced survival seen in normoxic PHD1 deficient neutrophils but there are 
some important caveats. As shown in Figures 5.6 and 5.7, the in vivo 
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phenotype of PHD1 deficiency in normoxia does not represent a phenocopy 
of hypoxic challenge as described in chapter 3 of this thesis, suggesting that 
there are fundamental differences between a hypoxic neutrophil and a PHD1 
deficient neutrophil. Additionally, PHD1 deficient BAL neutrophils respond to 
glucose deprivation in the same way as WT neutrophils in terms of apoptosis 
whereas hypoxic blood neutrophils appear to respond very differently. Thus, 
while some elements of the PHD1 KO phenotype are consistent with a ‘HIF-
stabilised’ neutrophil signature, the context is key in determining outcome. 
Importantly, in vivo hypoxic challenge seems to overcome the metabolic PHD1 
KO signature but also alter neutrophil dynamics in vivo. These data did raise 
interesting questions regarding the role of glucose in regulating neutrophil 




Figure 5.10: Hypoxia mitigates differences in PHD1 deficient neutrophil metabolism 
(A) HPLC-MS analysis of metabolic intermediaries of glycolysis in WT and KO neutrophils 
from hypoxic mice expressed as fold change from the mean normoxic value. Analysed by 
multiple t-tests corrected for multiple comparisons by the Bonferroni method. (B) Energy 
charge of BAL neutrophils isolated from hypoxic WT and KO mice 24 hours post LPS. HPLC-
MS analysis of the ratio of NADP:NADPH (C) and the fraction of oxidised glutathione (D) in 
WT and KO BAL neutrophils isolated 24 hours post-LPS nebulisation from both normoxic and 
hypoxic mice. (E) HIF-1a quantity measured by intracellular staining and flow cytometry of 
BAL neutrophils from normoxic WT and KO mice 24 hours post-LPS, Mann-Whitney test of 
significance. (A)-(D) n=4, (E) n=3-4. Data represent individual data points and the mean ± 
SEM. 
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Albumin availability modulates the impact of glucose deprivation on neutrophil 
survival 
To try to understand the mechanisms underlying the role of glucose in 
regulating neutrophil apoptosis, I used peripheral blood neutrophils from 
healthy human volunteers. I found that, as was observed in murine blood 
neutrophils, glucose deprivation in normoxic culture has a pro-survival effect 
(Fig 5.11A) in neutrophils cultured for 20 hours but in hypoxic culture, glucose 
deprivation has a pro-apoptotic effect (Fig 5.11B). This subtle effect on 
apoptosis in hypoxic glucose free culture was not consistent with the markedly 
necrotic morphology I observed in murine blood neutrophils and so I also 
analysed cell numbers following 20 hours of culture. This showed a profound 
cell loss in hypoxic glucose free culture with approximately an 80% reduction 
in cells numbers over 20 hours (from 5x106/ml to 0.7x106/ml) (Fig 5.11C).  
The data in Figure 5.9B does suggest that BAL neutrophils are protected from 
the detrimental effect of glucose deprivation in hypoxia. There are a number 
of potential reasons for this: the process of transmigration is likely to alter the 
identity of the neutrophil, BAL neutrophils will have been exposed to an 
inflammatory milieu with a number of pro-survival elements, including GM-
CSF, TNF-a and other cytokines. Finally, the availability of other sources of 
energy, including extracellular proteins, may also be protective during glucose 
depletion. It is likely that these factors act in combination to promote neutrophil 
survival. I was interested to see if supplementing glucose free media with 
albumin (in the form of BSA) could provide any protection in hypoxic glucose 
free culture.  Supplementing the glucose deplete media with 2% BSA did not 
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result in different rates of apoptosis in hypoxia (Fig 5.11D) but did result in a 
significant increase in the remaining cell numbers at 20 hours (Fig 5.11E). 
Although this improvement was small and did not return the cell number back 
to levels seen in glucose replete media, these data do suggest that protein 
can, at least to some extent, replace glucose as a substrate for neutrophils, 












Figure 5.11: Albumin availability partially compensates for glucose deprivation in in 
vitro culture 
Rates of apoptosis as measured by flow cytometry in human peripheral blood neutrophils after 
20 hours of culture in media ±  glucose in normoxia (A) or hypoxia (B) n=9 over 4 experiments, 
(A)&(B) analysed by a single one-way ANOVA with multiple comparisons. Neutrophil counts 
measured using CountBright beads and flow cytometry following 20 hours of culture in 
normoxia or hypoxia ±  glucose (C), n=5 over 3 experiments, analysed by row-matched one-
way ANOVA with multiple comparisons. The initial concentration of neutrophils at T0 was 
5x106/ml. Rates of apoptosis (D) and residual neutrophils counts (E) of human peripheral 
blood neutrophils cultured for 20 hours in hypoxia without glucose ±  2% BSA supplementation, 
(D) n=9 over 4 experiments, (E) n=5 over 3 experiments, Mann-Whitney test of significance. 
Data represent individual data points and the mean ± SEM. 
 





















































































































Our group have previously identified specific roles for PHD2[76] and PHD3[77] 
in regulating neutrophil inflammatory responses. The data in this chapter 
demonstrate that neutrophil specific PHD1 deficiency can alter neutrophil 
dynamics during an inflammatory response but that this is highly context 
dependent. I have characterised a new mouse line, generated using Cre-Lox 
technology. PHD1 floxed mice were developed by our collaborators in Leuven, 
Belgium and Oxford, UK. We have crossed them with the MRP8 driven Cre 
line to generate neutrophil specific PHD1 knock-down which is evident in bone 
marrow, blood and lung neutrophils. Loss of PHD1 does not alter the 
expression of the other PHD isoforms at a transcriptional level. This is 
consistent with other models of cell specific, isoform specific, PHD knockdown. 
The failure of PHD isoforms to compensate for loss of one another in mammals 
is strongly suggestive of specific roles for each isoform without major 
redundancy within the system. 
Neutrophil specific PHD1 deficiency does not alter the make-up of the 
circulating leucocyte populations at baseline or in response to an LPS 
challenge. PHD1 deficient neutrophils carry out normal chemotaxis and 
phagocytosis. Importantly, these ex vivo studies of neutrophil function were 
only carried out on neutrophils from normoxic mice and in the future, it will be 
important to investigate how both in vivo and ex vivo hypoxia may augment 
the effect of PHD1 deficiency.  
Data from other cell types has consistently shown that PHD1 deficiency can 
result in altered metabolic phenotypes, particularly in the setting of ischaemic 
 204 
injury. In skeletal muscle, the primary metabolic adaptation was a reduction in 
oxidative stress due to a shift from oxidative phosphorylation to the anaerobic 
process of glycolysis and therefore preserved ATP generation, despite oxygen 
deprivation[204]. In cerebral ischaemia PHD1 deficiency is also protective but 
the metabolic mechanism is distinct. PHD1 deficient neurons displayed 
reduced glycolysis and glucose consumption but increased glutamine 
oxidation and, critically, increased redox buffering capacity. This was due to 
enhanced flux through the oxidative pentose phosphate pathway (OxPPP), 
increased NADPH generation and therefore replenishment of reduced 
glutathione[207]. We were interested to investigate how PHD1 deficiency 
might regulate these metabolic pathways in neutrophils because, as has been 
discussed previously, they are predominantly glycolytic at baseline so a 
‘switch’ from oxidative phosphorylation cannot occur. Additionally, while 
neurons may use OxPPP to generate redox buffering capacity, neutrophils use 
NADPH to drive ROS generation via the action of the NADPH oxidase and so 
increased flux through this pathway might be predicted to alter neutrophil 
inflammatory function rather than redox potential. 
PHD1 deficient neutrophils demonstrate enhanced ROS generation in 
response to fMLF and this was associated with an increase in the ratio of 
NADP:NADPH and a higher fraction of oxidised glutathione as shown in Figure 
5.5. This increased oxidative stress is therefore in contrast to the response 
described in neurons. The mechanism which underlies this increased ROS 
production in PHD1 deficient neutrophils requires further investigation. In 
neurons this is regulated in part by the enzyme TIGAR which has fructose-2,6-
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bisphosphatase activity and thus directs glucose away from glycolysis and into 
OxPPP. In skeletal muscle the metabolic switch is regulated by pyruvate 
dehydrogenase kinase upregulation which blocks the entry of pyruvate into the 
TCA cycle. Analysing expression or activity of these regulatory metabolic 
enzymes will therefore be of interest in clarifying the metabolic consequences 
of PHD1 loss in neutrophils.  
The in vivo data presented in this chapter suggest that in normoxia, neutrophil 
specific PHD1 deficiency does not alter the outcome of an inflammatory insult. 
However, concurrent hypoxic challenge does lead to differences in neutrophil 
recruitment and resolution between genotypes. Whereas in wild-type mice, 
neutrophilic inflammation persists at 48 hours, PHD1 deficiency results in 
enhanced resolution of neutrophil numbers in hypoxia at 48 hours. This is 
suggestive of a highly context specific role for PHD1 in hypoxic neutrophils and 
is in contrast to findings in PHD2 deficient neutrophils which resulted in 
enhanced neutrophil survival and prolonged neutrophilic inflammation in a 
normoxic acute lung injury model[76]. Both PHD1 and PHD2 deficiency result 
in enhanced survival of cultured blood neutrophils in normoxia. In PHD2 
deficient neutrophils this difference persists in hypoxic culture whereas the 
data in this chapter show that PHD1 deficiency does not significantly enhance 
neutrophil survival above and beyond the increase caused by hypoxia. This 
observation led us to investigate the apoptosis phenotype of PHD1 deficient 
neutrophils in more detail and, although these experiments did not fully explain 
the in vivo findings, they did identify the availability of glucose as a novel 
regulator of neutrophil survival. Firstly, we found that BAL and blood 
 206 
neutrophils are differentially regulated by both hypoxia and glucose availability. 
Peripheral blood neutrophils display enhanced survival in hypoxia, as has 
been established in the literature for many years[21,69]. However, this is not 
true for inflammatory BAL neutrophils whose survival ex vivo is unchanged in 
hypoxia. In contrast, hypoxic BAL neutrophils are tolerant of glucose depletion 
while hypoxic blood neutrophils display increased apoptosis and profound cell 
loss in these conditions. These data are consistent with the findings in chapter 
4 which suggest that hypoxia and glucose availability have the capacity to alter 
neutrophil signalling pathways such as the mTOR pathway and are important 
in regulating catabolism of extracellular proteins in neutrophils.  
The disastrous consequences for blood neutrophils of glucose deprivation in 
hypoxia are partially rescued by the addition of albumin to the culture media. 
Albumin is equally abundant in the BAL fluid of PHD1 deficient mice and WT 
mice in hypoxia (as shown in Figure 3.7D) and so substrate availability is not 
limiting the persistence of these cells. However, it is possible that PHD1 
deficient neutrophils are not able to utilise extracellular proteins to same extent 
as their wild-type counterparts and consequently cannot persist in the low 
glucose environment of the hypoxic airway. Ordinarily, hypoxia would inhibit 
mTORC1 activity through increased AMPK activity and increased REDD1 
activity. If this hypoxic down-regulation of mTORC activity did not occur, then 
the subsequent upregulation of lysosomal protein catabolism would be 
prevented. When considering the consequence of genetic ablation (rather than 
acute knock-down) of one of the oxygen-sensing PHD enzymes, the duration, 
as well as the amplitude, of hypoxic responses are important to consider. 
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Hypoxic preconditioning is an established phenomenon in multiple systems 
including in neutrophilic inflammation. Our group has previously demonstrated 
that prolonged exposure to hypoxia prior to an infectious insult abrogates the 
deleterious effect of acute hypoxia[143]. It is interesting to consider whether 
PHD1 deficiency leads to increased HIF activity at baseline and as a 
consequence ‘resets’ the HIF threshold. The pro-survival phenotype observed 
in peripheral blood neutrophils is consistent with this, as is the increased 
oxidative stress which is on a par with that seen in hypoxic WT neutrophils. If 
this chronic baseline increase in HIF activity were to act as a preconditioning 
stimulus, one would hypothesis that PHD1 deficient neutrophils may fail to 
respond maximally to a second hypoxic challenge. One potential consequence 
of this in the lung is a failure of the hypoxic upregulation of catabolic pathways 
discussed in the previous data chapters. If PHD1 deficient neutrophils do not 
suppress mTORC and upregulate protein catabolism they may not be able to 
persist as WT neutrophils do in the inflamed lung, consistent with the more 
rapid resolution of cell numbers seen in hypoxic KO mice at 48 hours.  
Further work is needed to test this hypothesis. Measurement of HIF-1a and 
HIF-2a levels (and indeed transcription of HIF target genes) in blood and lung 
neutrophils will be key in determining if PHD1 deficiency does result in 
enhanced HIF activity and pseudo-hypoxia. It will also be important to assess 
how PHD1 loss alters the dynamics of HIF stabilisation in response to a 
hypoxic challenge. In the literature PHD1 phenotypes are variably associated 
with HIF activity. The skeletal muscle phenotype describes by Aragones et al 
was dependent on HIF-2a activity[204]. HIF-2a was also required for 
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protection in a liver ischaemia-reperfusion model in PHD1 deficient mice[206]. 
Conversely, in the model of cerebral ischaemia described by Quaegebeur et 
al, the protection conferred by PHD1 loss was independent of HIF1-a, HIF-2a 
and HIF-1b[207] but was dependent on NF-kB activity. 
In order to test the theory that PHD1 deficient neutrophils cannot utilise 
extracellular protein to the same extent as hypoxic WT neutrophils, 
measurement of mTORC activity and lysosomal function should be carried out. 
Although this further work is required to establish the full consequences of 
PHD1 loss on neutrophil function, it is a potentially appealing phenotype in 
lung inflammation. PHD1 deficient neutrophils appear to be functionally 
competent but do not persist in the damaging way that hypoxic WT neutrophils 
do. It will be important to investigate the consequences of PHD1 loss in 
infection models, as well as the sterile inflammatory insult described here to 
ensure that PHD1 deficient neutrophils can adequately control infection. Their 
preserved chemotaxis, and phagocytosis, coupled with their enhanced 
respiratory burst is strongly suggestive that they will be effective bactericidal 
cells. This raises the possibility that inhibition of PHD1 activity may facilitate a 




Chapter 6: Discussion and Future Directions 
Summary of key findings 
Systemic hypoxia frequently complicates respiratory disease. Additionally, 
inflammatory insults in many organs may be associated with localised hypoxia. 
The regulation of inflammation by hypoxia is therefore of importance in 
understanding, and therefore preventing, dysfunctional inflammation. We have 
previously shown that, in both pulmonary and skin infections, concurrent 
exposure to hypoxia results in a significant increase in neutrophil mediated 
morbidity and mortality[143]. The overall aim of this project was to interrogate 
the mechanisms which underlie this phenotype. 
Hypoxic neutrophils are hyperinflammatory 
I have shown that hypoxia represents a damaging ‘second hit’ in sterile 
neutrophilic inflammation with evidence of systemic illness and localised 
neutrophilic injury in the lung. I used proteomic analysis of inflammatory lung 
neutrophils to investigate what drives this damage. This analysis confirmed 
our hypothesis that hypoxia dramatically alters the phenotype of a neutrophil. 
Proteomic analysis provides important insights into cellular identity: it is an 
unbiased approach, which therefore has inherent advantages in terms of 
identifying novel therapeutic targets. It also provides a snapshot of the 
pathways and processes which are active and important in the cells of interest 
because it provides quantitative information about which proteins are 
expressed and, crucially, how the abundance of these proteins is regulated by 
a given stimulus. Although in this dataset we did not analyse post-translational 
modifications in a proteomic dataset, this is an emerging technique which can 
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provide even more detailed information about the identity and function of 
proteins within a population of cells.  
Several of the experiments which are detailed in this thesis illustrate the 
importance of the microenvironment, including the tissue origin (i.e. blood 
versus BAL) in the regulation of neutrophil function. These differences are 
likely to be multifactorial: the process of transmigration from the circulation 
fundamentally alters the phenotype of a neutrophil, tissue neutrophils are 
exposed to different inflammatory stimuli including cytokines, DAMPs and 
pathogens, and, finally, the metabolic environment in the tissue is distinct from 
the circulation. I have shown that the lung represents a low glucose, high 
protein environment and that this has important consequences for infiltrating 
neutrophils. Recapitulating these stimuli in vitro is challenging and so we 
focussed on neutrophils isolated from the site of inflammation. To our 
knowledge, this is the first proteomic analysis of inflammatory tissue 
neutrophils and, for the reasons detailed above, it was important to use this 
population, rather than blood or bone marrow neutrophils, to understand the in 
vivo phenotype which we observed.  
In keeping with the sickness and lung damage we observed in hypoxic mice, 
hypoxic neutrophils were found to have a hyperinflammatory phenotype with 
wide-ranging adaptations. Hypoxic neutrophils alter their cell surface receptor 
expression resulting in an enhanced capacity to respond to inflammatory 
stimuli such as TNF-a, formylated peptides and GM-CSF. These factors are 
also established survival stimuli for neutrophils and so this cell surface 
repertoire is likely to contribute to persistent, as well as enhanced, 
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inflammation. While the majority of the work presented here has focussed on 
the regulation of neutrophil function specifically by hypoxia, this response does 
not occur in isolation. Hypoxia is likely to alter the behaviour of other immune 
cells and to influence other cell types, particularly the endothelium and 
epithelium within the lung tissue. All of these factors combined generate a 
profoundly inflammatory niche in which the hypoxic neutrophils operate, 
resulting in a vicious cycle of inflammation, neutrophil recruitment and further 
tissue damage leading to persistent neutrophilic inflammation. 
Hypoxia has previously been found to enhance neutrophil degranulation in 
vitro[142] and we provide evidence here of enhanced hypoxic degranulation in 
vivo. It was therefore surprising that this enhanced degranulation did not 
correspond to lower levels of intracellular granule proteins in the proteome of 
hypoxic neutrophils. These findings were strongly suggestive of continued 
synthesis of inflammatory granule proteases by lung neutrophils. This is in 
contrast to our current understanding of neutrophil biology which suggests that 
granule proteins are synthesised only during neutrophil maturation in the bone 
marrow and that the inflammatory capability of the neutrophil is limited to 
releasing these proteases from their preformed granules. Once this had 
occurred, the neutrophil was thought to be without capacity to regenerate 
inflammatory granule proteases. However, the persistent expression of mRNA 
coding for granule proteins is consistent with the ongoing synthesis of these 
proteins by tissue neutrophils, given the right conditions. Furthermore, ex vivo 
culture of BAL neutrophils with 13C and 15N labelled amino acids has allowed 
us to identify those proteins which are synthesised by these tissue neutrophils. 
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These data identified incorporation of labelled amino acids into the most 
abundant proteins, which is to be expected. However, we also identified newly 
synthesised, labelled granule proteins including lysozyme C2 and neutrophil 
granule protein (NGP), consistent with ongoing synthesis of granule proteins 
by inflammatory neutrophils. This ongoing synthetic capacity is a novel finding 
and enhances our understanding of how neutrophilic inflammation may 
become persistent and dysfunctional in the lung. Hypoxic neutrophils therefore 
have an enhanced capacity for inflammation and I next sought to understand 
how this is fuelled. 
Extracellular proteins fuel hypoxic neutrophils 
Protein-rich exudates are pathognomonic of acute lung injury. I have shown 
here that, not only is protein leak a marker of lung damage, but it has the 
capacity to drive further inflammation. I have shown for the first time that 
neutrophils take up and break down proteins from the environment and, using 
labelled protein lysates, I have shown that the glutamine from scavenged 
proteins can be metabolised by neutrophils to provide substrate for central 
carbon metabolism. Work from other members of our group has shown that 
neutrophils can utilise glutamine for central carbon metabolism (Sadiku et al 
2018, under review) and here we show that proteins are a source of this 
substrate. The identification of this pathway is also supportive of the 
hypothesis that amino acids from scavenged proteins may further contribute 
to inflammation by providing substrate for de novo synthesis of inflammatory 
mediators, including granule proteins. This is particularly relevant in the 
hypoxic lung where protein leak is high, but this process is likely to be relevant 
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in other inflammatory and infective contexts too. Neutrophils have been 
established to contribute to the initiation and propagation of joint inflammation 
in rheumatoid arthritis (RA) [213]. The rheumatoid joint is a relatively hypoxic 
environment, Ng et al[214] measured oxygenation in vivo and found a mean 
oxygen tension of approximately 3%. Furthermore, the degree of hypoxia was 
found to correlate with the magnitude of the inflammatory response, with 
higher concentrations of IL-1b, TNF-a and IFN-g[214]. In keeping with the 
changes found in lung inflammation, alterations in microvascular permeability 
are found within the inflamed joint, resulting in protein leak into this space. 
Indeed, when compared to osteoarthritis, rheumatic joints were found to have 
significantly higher flux of plasma proteins, including albumin[215]. In health, 
glucose levels in the joint are similar to those in the plasma but in rheumatoid 
arthritis glucose levels may be low[216]. Thus, the rheumatic joint represents 
a similar, low glucose, high protein niche to the inflamed lung and it is tempting 
to speculate that neutrophils at this site can also exploit their environment to 
fuel inflammation.  
Chloroquine attenuate LPS induced acute lung injury 
Further evidence of the importance of this pathway is provided by the 
chloroquine treatment of mice with acute lung injury. I first examined the 
capacity of chloroquine to inhibit neutrophil protein breakdown in vitro and then 
trialled in vivo administration of this lysosomal inhibitor. Although chloroquine 
may alter neutrophil recruitment when given early in the inflammatory process, 
delayed administration does not significantly change neutrophil numbers in the 
LPS-induced acute lung injury. However, intraperitoneal injection of 
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chloroquine does result in a reduction in the capacity of BAL neutrophils to 
breakdown proteins (as measured by DQ-Green albumin fluorescence) and, 
importantly, in reduced elastase activity in the BAL supernatant and 
improvement in hypothermia. In this proof of concept experiment, I did not see 
such a marked improvement in these parameters in hypoxic mice, although 
there was a subtle shift towards improvement. It is possible that the degree of 
injury in hypoxia is too great to overcome using this strategy but, as discussed 
previously, it is also possible that the cardiovascular compromise caused by 
acute hypoxia resulted in less efficient absorption of the drug. A number of 
factors make chloroquine an attractive therapy: it has been used for decades 
in other diseases and as such, extensive safety data exists for its use and it is 
affordable. Additionally, it appears to be beneficial after the onset of 
inflammation and so, because development of ARDS can be difficult to predict 
in patients, a therapy which is efficacious after delayed administration is 
essential. An important consideration in developing therapies for lung disease 
is the potential for topical treatment in the form of inhaled or nebulised drugs. 
This was illustrated by a recent paper utilising pre-treatment with a nebulised 
TNF receptor inhibitor in the treatment of acute lung injury[203]. To our 
knowledge, chloroquine has never been used topically, in the lung or 
elsewhere. However, the potential for improved local delivery and reduced 
overall systemic dosing mean that this route is worthy of further consideration.  
Microenvironmental regulation of neutrophil function 
A recurrent theme in the data presented here is the importance of the 
environment in determining neutrophil fate and function. Neutrophils have long 
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been considered a simple, homogeneous population of cells with limited 
plasticity. Increasingly the literature points to a much more complex and 
diverse population with the capacity to critically alter inflammatory, infective 
and malignant processes. The identification of this functional diversity opens 
up new possibilities for targeting harmful neutrophil behaviour without 
obliterating their essential innate immune functions. 
Experimental hypoxia has two roles in this work. The first is that it is a 
physiologically relevant stimulus due to the requirement for neutrophils to 
function in low oxygen environments. Secondly, it is an experimental tool, used 
to potentiate neutrophilic inflammation and, in this context has led to the 
identification of novel neutrophil behaviours which are likely to be relevant to 
both normoxic and hypoxic cells. 
It is also important to consider that both the HIF transcription factors, and their 
regulatory prolyl hydroxylases may be regulated by both hypoxic and non-
hypoxic stimuli, including inflammatory mediators. Once again, the context 
here is key. This is illustrated by the data regarding loss of PHD1 in neutrophils. 
Despite evidence that PHD2 is the dominant regulator of HIF under normoxic 
conditions[66], specific loss of PHD1 results in changes in neutrophil apoptosis 
in normoxic culture, an effect which is supplanted by hypoxic culture. This 
observation led us to consider whether PHD1 deficient neutrophils may exhibit 
a ‘pseudo-hypoxic’ phenotype. Further experimental work is required to 
investigate whether loss of PHD1 can alter basal levels of HIFa isoforms and 
how this may be regulated by hypoxic challenge. Importantly, this pro-survival 
effect of PHD1 deficiency is also lost when BAL neutrophils are examined, 
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irrespective of oxygen tension. It was therefore interesting to find that, in vivo, 
PHD1 loss results in more rapid resolution of hypoxic neutrophilic 
inflammation. This suggests that, despite the baseline pseudo-hypoxic, pro-
survival phenotype, PHD1 deficient neutrophils in vivo did not replicate WT 
hypoxic neutrophil behaviour. 
A number of checks and balances have been identified in the hypoxic 
signalling pathways discussed here, including negative feedback loops and 
temporal regulation of different pathway members. Chronic hypoxia represents 
a very different insult to acute hypoxia. Our group has found that hypoxic 
preconditioning prior to infection results in protection from the morbidity and 
mortality associated with subsequent acute hypoxia[143] and that this 
protection was associated with lower HIF stabilisation in preconditioned 
animals. Thus, chronic hypoxia appears to reset the HIF threshold, altering the 
responsiveness of the system to subsequent hypoxia. The PHD1 deficient 
neutrophils display some parallels with these data and this observation 
suggests that there is potential therapeutic utility in PHD1 inhibition. 
Hypoxia, inflammation and metabolism are inextricably linked 
The data in this thesis have also confirmed the importance of neutrophil 
metabolism and energetics in regulating function and therefore inflammatory 
outcomes. In keeping with this observation is the finding that mTOR plays a 
role in directing neutrophil metabolic processes. Fascinating links exist 
between hypoxic signalling pathways, metabolic sensing pathways (including 
regulation of mTOR and AMPK) and inflammation. This complex network of 
signals is crucial for cells to sense and respond to their metabolic environment. 
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A direct link between PHD activity and mTOR was recently identified in tumour 
cells and this paper also highlighted the role of post-translational modifications 
in altering activity of key enzymes including PHDs[217]. The authors identified 
phosphorylation of serine residue 125 (Ser125) in PHD2 as a regulatory post-
translational modification. This residue was phosphorylated by the mTOR 
target S6 kinase (S6K) and dephosphorylated (resulting in reduced PHD2 
activity) by the phosphatase PP2A, which also dephosphorylates S6K. In 
hypoxic tumour cells, the balance of mTOR and PP2A activity shifted in favour 
of PP2A resulting in reduced S6K activity and reduced PHD2 activity due to 
lower rates of Ser125 phosphorylation. This in turn led to enhanced survival of 
tumour cells due to activation of autophagy pathways.  
As discussed in results chapter 2, mTOR signalling is closely link to AMP 
activated protein kinase (AMPK) and the balance of activity of these pathways 
is important in regulation of cellular energetics. A recent study of AMPK in 
neutrophils provided insights into the role of this kinase, particularly in the 
regulation of neutrophil survival and responses to hypoxia. Interestingly the 
authors found that in AMPK deficient neutrophils, there was a blunted 
response to hypoxia, as analysed by proteomic analysis of hypoxic bone 
marrow neutrophils from AMPK wild-type and AMPK knockout mice. This was 
associated with altered expression of pro-and anti-apoptotic factors in AMPK 
knockout neutrophils and evidence of enhanced resolution of neutrophilic 
infiltration in a model of limb ischaemia. This paper clearly illustrates that 
AMPK has a role in neutrophil function. It will be important to assess this in 
alternative culture conditions (including low glucose media) and, as discussed 
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above, to analyse neutrophils from both the blood and inflammatory tissues to 






The work presented here highlights a number of areas which are worthy of 
further investigation.  
Direct evidence that amino acids from scavenged proteins can be incorporated 
into newly synthesised proteins will be important in confirming this hypothesis 
which is based on indirect evidence at present. I plan to use proteins isolated 
from HEK cells which have been cultured with labelled Lysine and Arginine as 
a source of amino acids. I will culture ex vivo neutrophils with the labelled 
proteins (purified to ensure no free labelled amino acids are present) and then 
perform proteomic analysis to identify which, if any, newly synthesised proteins 
have incorporated the amino acids which originated in exogenous proteins. 
I am interested in further delineating the role of mTOR in neutrophils, 
specifically with regard to how this kinase may direct neutrophil protein 
consumption and catabolism, energetics and ultimately survival. The data 
presented here demonstrate that mTOR is regulated by both hypoxia and 
glucose availability, but further work will focus on the relative importance of 
mTORC1 versus mTORC2 and on the downstream effects of activation and 
inhibition of these complexes. Additionally, the role of mTOR in directing 
protein translation has not been studied in neutrophils. While the data in this 
thesis support the hypothesis the mTOR blockade increases the availability of 
amino acids through enhanced protein breakdown, this would normally also 
be associated with reduced translation due to reduced activity of the eIF family 
of translational initiators. This question could be addressed by comparison of 
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the transcriptome and proteome in neutrophils where the mTOR pathway has 
been manipulated. 
The finding that glucose is required for hypoxic survival of neutrophils raises a 
number of interesting questions requiring further study, particularly because of 
the relatively subtle changes in apoptosis compared to the dramatic cell loss, 
suggesting significant necrosis of neutrophils. Apoptosis is an energy requiring 
process and, as such, the glucose free hypoxia phenotype is in keeping with 
a complete energetic failure in these cells. Analysis of activation of AMPK and 
of AMP and ATP levels in these conditions will provide some insights into this 
phenotype. I hypothesise that this regulation is augmented in inflammatory 
cells, such as those isolated from the BAL fluid and this augmentation will 
account for some of the differences in apoptosis seen between blood and BAL 
neutrophils. The finding that albumin can partially improve hypoxic glucose 
free neutrophil persistence is consistent with the metabolic data showing that 
proteins can replenish central carbon metabolism, as has been shown in 
tumour cells. Whether this can in turn restore a favourable energetic profile, 
potentially through regulation of AMPK activity in this context will also be 
interesting to investigate. 
Our understanding of the role of the prolyl hydroxylases in regulating metabolic 
signalling pathways in neutrophils remains incomplete. The data from Di 
Conza et al[217] demonstrate that these pathways are linked at multiple levels. 
Establishing the effect of PHD1 loss on levels of both HIF-1a and HIF-2a and 
investigating how HIF dynamics are altered in PHD1 deficient neutrophils 
during hypoxia will be important in unpicking the in vitro and in vivo data 
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presented here. It will also be interesting to establish whether PHD1 deficiency 
does alter lysosomal protein breakdown which is usually upregulated in 
hypoxia and whether this, in turn, is due to alterations in mTOR 
responsiveness. 
While the literature regarding mTOR and AMPK in other cell types is extensive, 
it is important to look specifically at neutrophils due their unusual metabolic 
phenotype, their lack of capacity to replicate and their specific response to 





The data presented in this thesis show that hypoxia, and hypoxic signalling 
pathways are critical regulators of neutrophilic inflammation. Within the 
hypoxic lung, a vicious cycle of degranulation, lung damage, protein leak and 
increased substrate availability represents a perfect storm for dysfunctional 
and persistent neutrophilic inflammation. These findings have led to the 
identification of novel therapeutic targets, such as inhibition of lysosomal 
function with chloroquine. Future studies will focus on the regulation of these 
processes by metabolic and energetic signalling pathways including those 
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Appendix 1: Percoll Preparations 
 




For 10ml (3 gradients) 
90% Percoll 1X PBS 
73% 8.1ml 1.9ml 
61% 6.8ml 3.2ml 
49% 5.5ml 4.5ml 
 




For 10ml (3 gradients) 
90% Percoll 1X PBS 
78% 8.7ml 1.3ml 
69% 7.7ml 2.3ml 
52% 5.8ml 4.2ml 
 
Mouse Bone Marrow leucocyte preparation 
 
1xHBSS+0.2% BSA:  
5ml 10xHBSS (Gibco) + 45ml sterile H2O + 1332µl sterile 7.5% BSA (Sigma 
Aldrich) + 1-3 drops of sterile 7.5% sodium bicarbonate solution (Gibco) until 
solution turns pink – filter sterilise with 25µ syringe filter and 50ml syringe 
  
10xHBSS with NaHCO3: 
175mg NaHCO3 + 50ml 10x HBSS without NaHCO3 – use to make up 90% 






For 10 ml (3 gradients) 
90% Percoll 1x HBSS  
81% 9ml 1ml 
62% 6.9ml 3.1ml 





Appendix 2: EasySepÔ murine blood neutrophil isolation 
protocol 
 
1. Pellet whole leucocytes after red blood cell lysis 
2. Resuspend in 150µl of RoboSepÔ buffer (Stemcell technologies) and 
transfer to a 96 well plate 
3. Add Rat Serum 7.5µl per 150µl sample  
4. Add Enrichment cocktail 7.5µl per 150µl sample 
5. Incubate at 4°C for 15 minutes 
6. Wash cells by adding 100µl of buffer 
7. Spin plate at 300g for 7 minutes 
8. Aspirate off as much supernatant as possible (around 200-250µl) 
9. Resuspend in initial volume (i.e. 150µl) 
10. Add Biotin selection cocktail 7.5µl per 150µl sample 
11. Incubate at 4°C for 15 minutes 
12. Add magnetic particles (vortex beforehand) 20µl per 150µl sample 
13. Incubate at 4°C for 10 minutes 
14. Top up with buffer to a total of 250µl in the well (add 80µl buffer) 
15. Incubate on a plate magnet for 10 minutes 
16. Aspirate enriched cells carefully without disturbing pellet (around 200-
250µl) 
17. Pool (if appropriate) and top up to 500µl 
18. Count (neat) 
19. Top up with 10ml buffer to wash 
20. Spin at 300g for 10 minutes at 4°C 




Appendix 3: Lysis Buffers 
 
Proteomic sample processing buffers: 
 
stock lysis buffer digest buffer 
20% SDS 1000 μL [4% final] 10 μL [0.1% final] 
0.5M TCEP 100 μL [10 mM final] - 
1M TEAB 250 μL [50 mM final] 100 μL [50 mM final] 
1M CaCl2 - 2 μL [1 mM final] 
H2O 3650 μL 1888 μL 
 
Neutrophil Protein Lysate Buffers 
 
Laemmli Buffer   
0.5M Tris HCl pH 6.8 250ul 1.25ml 
100% Glycerol 200ul 1ml 
10% SDS 400ul 2ml 
Complete inhibitors (Roche 04693159001) 1 tablet in 2ml 400ul 2ml 
Phosphatase inhibitors (Roche 04906845001) 1 tablet in 
500ul 100ul 500ul 
H2O 650ul 3.25ml 
Final volume 2ml 10ml 
 
Additional protease inhibitors were added to complete Laemmli buffer as 
follows: 









Concentration To Add 
  Molarity %  
DTT 1M 0.2    308.5mg 
SDS 20%   4% 2ml 
Glycerol 100% 100%   20% 2ml 
Tris-HCl pH 6.8 0.5M 0.1   2ml 
Bromophenol Blue 2%   0.04% 0.1ml 
Protease inhibitor 
cocktail       0.2ml 
H2O        3.7ml 




Appendix 4: Immunoblot for protein expression 
 
SDS-PAGE gels: For 1.5mm gel plates 
 
Stacking Gel 1 gel 2 gels 
Water 3ml 6ml 
40% Acrylamide 620µl 1240µl 
0.5M Tris pH 6.8 1260µl 2520µl 
20% SDS 25µl 50µl 
20% APS 50µl 100µl 
TEMED 5µl 10µl 
 
Resolving Gel 8% 10% 12% 
Water 8ml 7.2ml 6.6ml 
40% Acrylamide 3ml 3.8ml 4.4ml 
1.5M Tris pH 8 3.8ml 3.8ml 3.8ml 
20% SDS 75µl 75µl 75µl 
20% APS 150µl 150µl 150µl 
TEMED 6µl 6µl 6µl 
 
Buffers for Immunoblot 
 
10X Running Buffer  
Glycine 190g 
Tris Base 30.3g 
20% SDS 50ml 
dH2O to 1 litre 
 
1x Running buffer made with 100ml of 10x running buffer and 900ml of dH2O 
 
10X Transfer Buffer  
Glycine 145g 
Tris Base 29g 
dH2O to 800ml 
 
1 X Transfer Buffer made with 100ml of 10X transfer buffer, 200ml methanol 
and 700ml dH2O 
 
 10X TBS-Tween  
 Tris-HCl 1M pH 8.0 M  100ml 
 NaCl 97.3g 
 Water to 1000ml 
 Tween-20 5ml 
 










Target Protein Host species 
Source and 
Reference Concentration 
p38 Rabbit Cell signaling technology #9212 1:2000 
Elastase Rat Abcam Ab205670 1:1000 
MMP9 Mouse Abcam Ab58803 2.5:1000 
MPO Rabbit Abcam Ab188211 1:1000 
P70 S6 Kinase Rabbit Cell signaling technology #2708 1:500 
Phospho-p70 S6 
Kinase (Thr389) Rabbit 
Cell signaling 

















Appendix 5: RNA extraction using Acid-Phenol:Chloroform 
 
1. Resuspend the cell pellet in 600µl of RNA lysis buffer 
2. Pre-heat nuclease-free H2O to 95C; allow wash solutions and filters to 
reach room temp  
3. Add 1/10th volume of miRNA homogenate additive to the lysate to 
stabilise RNA and inactivate RNases (i.e. if lysate is 600µl, then add 
60µl) 
4. Vortex to mix  
5. Incubate on ice for 10 minutes 
6. Add a volume of Acid-Phenol:Chloroform equivalent to that of the initial 
lysate (i.e. 600µl).  Withdraw the Acid-Phenol:Chloroform from the 
bottom phase of the tube (the top phase is a buffer solution) 
7. Gently mix x3 then vortex for 60 seconds – ensure mixes well 
8. Spin: 5 minutes, room temp, 13400rpm 
9. Carefully remove the upper aqueous layer and transfer to a clean 
RNase-free Eppendorf 
10. Note the volume removed   
11. Add 1.25 volumes of 70% ethanol to the aqueous layer 
12. Vortex 
13. Pipette a maximum of 700µl of this aqueous layer/ethanol mixture onto 
a filter cartridge within a labelled collection tube 
14. Spin: 15 seconds, room temp, 10000rpm 
15. Discard the flow through 
16. Repeat steps 12-14 if extra aqueous/ethanol mixture left 
17. Pipette 700µl miRNA wash-solution 1 to the filter cartridge 
18. Spin: 15 seconds, room temp, 10000rpm 
19. Discard the flow through 
20. Pipette 500µl miRNA wash-solution 2/3 to the filter cartridge 
21. Spin: 15 seconds, room temp, 10000rpm 
22. Discard the flow through 
23. Pipette another 500µl miRNA wash-solution 2/3 to the filter cartridge 
24. Spin: 15 seconds, room temp, 10000rpm 
25. Discard the flow through then spin for further 60 seconds 
26. Place filter cartridge into a clean fully-labelled collection tube 
27. Pipette 30-50µl pre-heated H2O onto the filter 
28. Spin: 20-30 seconds, room temp, 13400rpm 
29. Use nanodrop device to quantify RNA and assess purity 
 
DNAse Treatment: 
1. If sample contains>200ng/µl nucleic acid, dilute to <200ng/µl in RNase-
free water 
2. Add 1ul Turbo DNase per 40ul sample and 1ul 10x DNase buffer per 
10ul sample  
3. Incubate at 37°C for 20-30 minutes 
4. Add DNase inactivation reagent 1ul per 10ul sample, mix then spin at 
10,000G for 90 seconds at 4°C to pellet inactivation beads. 
 242 






Appendix 6: cDNA generation and TaqMan analysis 
 
Reverse transcription PCR mastermix (Promega UK) 
 
Reagent Volume per sample 
5x AMV buffer 8µl 
10mM dNTPs 16µl 
RNasin 1.2µl 
Random primers 1.2µl 
AMV-RT 1.2µl 






Target Source and product reference Exon location 
Elane Integrated DNA technologies 
Mm.PT.58.6682392.gs 
4-5 
MMP9 Integrated DNA technologies 
Mm.PT.58.10100097 
8-9 





Thermo Fisher Scientific Mm00459770_m1 3-4 
Egln2 
(PHD1) 
Thermo Fisher Scientific Mm00519067_m1 2-3 
Egln3 
(PHD3) 
Thermo Fisher Scientific Mm00472200_m1 1-2 







Appendix 7: Flow cytometry antibodies and panels 
 







CD11b BV 421 1:400 Biolegend 101235 
Ly6C FITC 1:200 Biolegend 128005 
Ly6G PE 1:200 Biolegend 127607 
SiglecF PE CF594 1:800 BD 562757 
CD64 APC 1:200 Biolegend 139305 
CD45 AF 700 1:200 Biolegend 103128 
 
Mouse Whole Blood Flow Cytometry Antibody Panel  
 
Antigen Fluorophore Concentration in mastermix Source 
Product 
code 
Ly6G V450 1:200 Biolegend 127612 
CD3 PE 1:200 Biolegend 100205 
CD19 PE 1:200 Biolegend 152407 
SiglecF PE CF594 1:800 BD 562757 
CD115 APC 1:200 Biolegend 135510 
CD45 AF 700 1:200 Biolegend 103128 
CD11B APC Cy7 1:200 Biolegend 101225 
CD62L PE Cy7 1:200 Biolegend 104417 
  
Additional Flow Cytometry Antibodies 
 
Antigen Fluorophore Concentration in mastermix Source 
Product 
code 
CSF2Ra APC 7.5µl per test Bio-techne FAB6130A 
CSF2Rb PE 5µl per test Bio-techne FAB5492P 
TNFRSF1 APC 1:100 Biolegend 113005 
TNFRSF2 PE 1:100 Biolegend 113405 





































25ul cells 25ul cells 25ul cells 25ul cells 
 




Appendix 9: Kegg pathway enrichment 
 
Term Count % P Value Pop Hits Fold Enrichment 
mmu03040:Spliceosome 125 2.10544 5.32E-44 133 2.57201 
mmu00920:Sulfur metabolism 10 0.16844 0.00286 11 2.48783 
mmu00030:Pentose phosphate pathway 27 0.45478 1.94E-08 30 2.46296 
mmu00520:Amino sugar and nucleotide sugar 
metabolism 44 0.74112 1.30E-13 49 2.45737 
mmu03050:Proteasome 40 0.67374 4.43E-12 45 2.43255 
mmu00051:Fructose and mannose metabolism 29 0.48846 5.28E-08 34 2.33417 
mmu04130:SNARE interactions in vesicular 
transport 28 0.47162 1.20E-07 33 2.32198 
mmu00020:Citrate cycle (TCA cycle) 27 0.45478 2.72E-07 32 2.30902 
mmu03030:DNA replication 29 0.48846 1.72E-07 35 2.26748 
mmu00062:Fatty acid elongation 21 0.35371 3.11E-05 26 2.21035 
mmu03018:RNA degradation 65 1.09483 1.43E-14 82 2.16927 
mmu05134:Legionellosis 45 0.75796 3.90E-10 57 2.16049 
mmu03015:mRNA surveillance pathway 75 1.26326 4.54E-16 96 2.13798 
mmu00052:Galactose metabolism 25 0.42109 1.03E-05 32 2.13798 
mmu00040:Pentose and glucuronate 
interconversions 28 0.47162 2.83E-06 36 2.12848 
mmu00640:Propanoate metabolism 21 0.35371 7.86E-05 27 2.12848 
mmu00511:Other glycan degradation 14 0.23581 0.00223 18 2.12848 
mmu01200:Carbon metabolism 90 1.51592 5.70E-19 116 2.12324 
mmu04666:Fc gamma R-mediated phagocytosis 65 1.09483 1.10E-13 84 2.11762 
mmu04150:mTOR signaling pathway 45 0.75796 2.66E-09 59 2.08725 
mmu05212:Pancreatic cancer 49 0.82533 8.82E-10 65 2.06299 
mmu04662:B cell receptor signaling pathway 52 0.87586 5.87E-10 70 2.03292 
mmu00010:Glycolysis / Gluconeogenesis 49 0.82533 2.09E-09 66 2.03173 
mmu03013:RNA transport 126 2.12228 2.94E-23 170 2.02832 
mmu05223:Non-small cell lung cancer 41 0.69058 1.07E-07 56 2.0036 
mmu03430:Mismatch repair 16 0.2695 0.00252 22 1.99027 
mmu05220:Chronic myeloid leukemia 52 0.87586 2.99E-09 72 1.97645 
mmu01230:Biosynthesis of amino acids 56 0.94324 9.37E-10 78 1.96475 
mmu05100:Bacterial invasion of epithelial cells 56 0.94324 9.37E-10 78 1.96475 
mmu00620:Pyruvate metabolism 28 0.47162 3.26E-05 39 1.96475 
mmu01130:Biosynthesis of antibiotics 153 2.57706 2.11E-25 214 1.95655 
mmu04142:Lysosome 87 1.46539 1.68E-14 122 1.95152 
mmu00860:Porphyrin and chlorophyll 
metabolism 29 0.48846 3.45E-05 41 1.93566 
mmu04966:Collecting duct acid secretion 19 0.32003 0.00139 27 1.92577 
mmu00053:Ascorbate and aldarate metabolism 19 0.32003 0.00139 27 1.92577 
mmu04621:NOD-like receptor signaling pathway 39 0.6569 1.76E-06 56 1.90586 
mmu04664:Fc epsilon RI signaling pathway 47 0.79165 1.66E-07 68 1.89149 
mmu04141:Protein processing in endoplasmic 
reticulum 116 1.95385 1.56E-17 168 1.88957 
mmu01212:Fatty acid metabolism 35 0.58952 1.13E-05 51 1.87807 
mmu01210:2-Oxocarboxylic acid metabolism 13 0.21897 0.01645 19 1.87242 
mmu04370:VEGF signaling pathway 41 0.69058 1.90E-06 60 1.87002 
mmu05221:Acute myeloid leukemia 38 0.64005 6.37E-06 56 1.85699 
mmu00071:Fatty acid degradation 33 0.55584 3.84E-05 49 1.84303 
mmu00280:Valine, leucine and isoleucine 
degradation 37 0.62321 1.17E-05 55 1.841 
mmu05132:Salmonella infection 52 0.87586 1.90E-07 78 1.82441 
mmu04144:Endocytosis 185 3.11605 1.16E-24 278 1.82113 
mmu05214:Glioma 43 0.72427 3.63E-06 65 1.81038 
mmu05211:Renal cell carcinoma 44 0.74112 3.63E-06 67 1.79718 
mmu05230:Central carbon metabolism in cancer 42 0.70743 6.53E-06 64 1.79591 
mmu04722:Neurotrophin signaling pathway 80 1.34748 1.71E-10 122 1.7945 
mmu04210:Apoptosis 39 0.6569 2.09E-05 60 1.7788 
mmu04910:Insulin signaling pathway 90 1.51592 5.23E-11 140 1.75925 
mmu05169:Epstein-Barr virus infection 138 2.32441 2.60E-16 215 1.75653 
mmu05142:Chagas disease (American 
trypanosomiasis) 66 1.11167 3.23E-08 103 1.75356 
mmu05210:Colorectal cancer 41 0.69058 2.02E-05 64 1.75315 
mmu04919:Thyroid hormone signaling pathway 72 1.21273 9.81E-09 113 1.74369 
mmu04720:Long-term potentiation 42 0.70743 1.97E-05 66 1.74148 
mmu00480:Glutathione metabolism 35 0.58952 1.15E-04 55 1.74148 
mmu04380:Osteoclast differentiation 80 1.34748 1.67E-09 126 1.73754 
mmu01040:Biosynthesis of unsaturated fatty 
acids 17 0.28634 0.01339 27 1.72306 
mmu04070:Phosphatidylinositol signaling system 61 1.02745 3.06E-07 97 1.72097 
mmu00562:Inositol phosphate metabolism 44 0.74112 1.86E-05 70 1.72016 
mmu04962:Vasopressin-regulated water 
reabsorption 27 0.45478 0.00117 43 1.71834 
mmu05020:Prion diseases 20 0.33687 0.00702 32 1.71039 
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mmu05133:Pertussis 46 0.7748 1.73E-05 74 1.70114 
mmu04071:Sphingolipid signaling pathway 77 1.29695 1.46E-08 124 1.69935 
mmu04012:ErbB signaling pathway 54 0.90955 2.91E-06 87 1.69859 
mmu00630:Glyoxylate and dicarboxylate 
metabolism 18 0.30318 0.01256 29 1.69859 
mmu03060:Protein export 18 0.30318 0.01256 29 1.69859 
mmu04922:Glucagon signaling pathway 62 1.0443 4.93E-07 100 1.6967 
mmu04660:T cell receptor signaling pathway 64 1.07799 4.57E-07 104 1.68407 
mmu05213:Endometrial cancer 32 0.53899 5.72E-04 52 1.68407 
mmu00980:Metabolism of xenobiotics by 
cytochrome P450 39 0.6569 1.59E-04 64 1.66763 
mmu05140:Leishmaniasis 39 0.6569 1.59E-04 64 1.66763 
mmu00900:Terpenoid backbone biosynthesis 14 0.23581 0.03996 23 1.66577 
mmu05152:Tuberculosis 107 1.80226 9.20E-11 176 1.66374 
mmu04145:Phagosome 105 1.76857 2.60E-10 174 1.65141 
mmu00270:Cysteine and methionine metabolism 24 0.40424 0.00544 40 1.64197 
mmu04920:Adipocytokine signaling pathway 43 0.72427 1.28E-04 72 1.63437 
mmu05231:Choline metabolism in cancer 60 1.01061 5.56E-06 101 1.62571 
mmu00500:Starch and sucrose metabolism 19 0.32003 0.01782 32 1.62487 
mmu04152:AMPK signaling pathway 75 1.26326 4.23E-07 127 1.61611 
mmu04146:Peroxisome 49 0.82533 5.85E-05 83 1.61559 
mmu00983:Drug metabolism - other enzymes 30 0.50531 0.00238 51 1.60978 
mmu03010:Ribosome 85 1.4317 1.01E-07 145 1.60422 
mmu04915:Estrogen signaling pathway 57 0.96008 2.35E-05 98 1.59171 
mmu04721:Synaptic vesicle cycle 36 0.60637 0.00105 62 1.589 
mmu04912:GnRH signaling pathway 51 0.85902 7.77E-05 88 1.58599 
mmu04668:TNF signaling pathway 63 1.06114 1.07E-05 109 1.58172 
mmu04120:Ubiquitin mediated proteolysis 82 1.38117 4.20E-07 142 1.5803 
mmu05161:Hepatitis B 84 1.41486 3.69E-07 146 1.57449 
mmu04960:Aldosterone-regulated sodium 
reabsorption 23 0.3874 0.01291 40 1.57356 
mmu05164:Influenza A 98 1.65067 4.47E-08 171 1.56835 
mmu04931:Insulin resistance 63 1.06114 1.58E-05 110 1.56734 
mmu05145:Toxoplasmosis 64 1.07799 2.16E-05 113 1.54994 
mmu04611:Platelet activation 74 1.24642 5.04E-06 131 1.54588 
mmu04914:Progesterone-mediated oocyte 
maturation 49 0.82533 2.81E-04 87 1.54131 
mmu05203:Viral carcinogenesis 130 2.18966 1.05E-09 231 1.54009 
mmu04917:Prolactin signaling pathway 41 0.69058 0.00106 73 1.537 
mmu04622:RIG-I-like receptor signaling pathway 38 0.64005 0.0019 68 1.52929 
mmu04540:Gap junction 48 0.80849 4.34E-04 86 1.52741 
mmu04730:Long-term depression 34 0.57268 0.0037 61 1.52533 
mmu04810:Regulation of actin cytoskeleton 119 2.00438 1.48E-08 214 1.52176 
mmu04520:Adherens junction 40 0.67374 0.00162 72 1.52034 
mmu04114:Oocyte meiosis 61 1.02745 7.98E-05 110 1.51758 
mmu04620:Toll-like receptor signaling pathway 56 0.94324 1.66E-04 101 1.51733 
mmu00510:N-Glycan biosynthesis 27 0.45478 0.01302 49 1.50793 
mmu05012:Parkinson's disease 82 1.38117 5.71E-06 149 1.50606 
mmu05014:Amyotrophic lateral sclerosis (ALS) 28 0.47162 0.01194 51 1.50246 
mmu04066:HIF-1 signaling pathway 57 0.96008 2.15E-04 104 1.49988 
mmu05222:Small cell lung cancer 46 0.7748 0.001 84 1.49862 
mmu00190:Oxidative phosphorylation 76 1.28011 1.79E-05 139 1.49628 
mmu04932:Non-alcoholic fatty liver disease 
(NAFLD) 85 1.4317 8.83E-06 157 1.48161 
mmu04670:Leukocyte transendothelial migration 65 1.09483 1.57E-04 121 1.47008 
mmu05215:Prostate cancer 47 0.79165 0.00174 88 1.4616 
mmu04650:Natural killer cell mediated 
cytotoxicity 56 0.94324 6.09E-04 105 1.45953 
mmu05010:Alzheimer's disease 94 1.58329 8.04E-06 177 1.45335 
mmu00982:Drug metabolism - cytochrome P450 35 0.58952 0.00883 66 1.45124 
mmu05160:Hepatitis C 72 1.21273 1.20E-04 136 1.4488 
mmu05168:Herpes simplex infection 110 1.85279 1.61E-06 208 1.44725 
mmu03420:Nucleotide excision repair 23 0.3874 0.04602 44 1.4305 
mmu04068:FoxO signaling pathway 70 1.17905 2.55E-04 134 1.42958 
mmu05162:Measles 71 1.19589 2.34E-04 136 1.42868 
mmu05146:Amoebiasis 61 1.02745 7.20E-04 117 1.42678 
mmu00310:Lysine degradation 27 0.45478 0.03171 52 1.42094 
mmu05016:Huntington's disease 102 1.71804 1.76E-05 198 1.40977 
mmu04921:Oxytocin signaling pathway 81 1.36433 1.76E-04 158 1.40295 
mmu05205:Proteoglycans in cancer 104 1.75173 1.95E-05 203 1.40201 
mmu04330:Notch signaling pathway 25 0.42109 0.04952 49 1.39623 
mmu04064:NF-kappa B signaling pathway 49 0.82533 0.00582 97 1.38242 
mmu04612:Antigen processing and presentation 41 0.69058 0.01493 82 1.36831 
mmu00561:Glycerolipid metabolism 29 0.48846 0.04364 58 1.36831 
mmu01100:Metabolic pathways 637 10.7293 9.76E-27 1278 1.36403 
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mmu00240:Pyrimidine metabolism 51 0.85902 0.00792 103 1.35502 
mmu04728:Dopaminergic synapse 66 1.11167 0.00277 134 1.34789 
mmu04010:MAPK signaling pathway 124 2.0886 4.22E-05 253 1.34127 
mmu04110:Cell cycle 58 0.97692 0.01857 124 1.28003 
mmu00230:Purine metabolism 82 1.38117 0.00943 179 1.25365 
mmu04062:Chemokine signaling pathway 89 1.49907 0.00901 196 1.24265 
mmu04261:Adrenergic signaling in 
cardiomyocytes 67 1.12852 0.03446 150 1.22236 
mmu04510:Focal adhesion 90 1.51592 0.03061 207 1.18983 
mmu04015:Rap1 signaling pathway 93 1.56645 0.02839 214 1.18928 




Appendix 10: Labelled proteins 
Protein 
IDs Protein names Gene names Peptides Unique peptides H/L Ratio 1 H/L Ratio 2 H/L Ratio 3 H/L Ratio 4 
O09172 Glutamate-cysteine ligase regulatory subunit Gclm 3 3 1.579 2.133 1.493 NaN 
O54824 Interleukin-16 Il16 19 19 NaN 0.105 0.183 NaN 
O89053 Coronin-1A Coro1a 46 44 NaN 0.014 0.047 0.034 
P01027 Complement C3 C3 83 73 0.026 0.048 NaN NaN 
P01887 Beta-2-microglobulin B2m 6 6 0.328 0.463 0.501 NaN 
P05064 Fructose-bisphosphate aldolase A Aldoa 50 39 0.142 0.171 0.199 0.172 
P06151 L-lactate dehydrogenase A chain Ldha 28 26 0.099 0.070 0.082 0.062 
P07356 Annexin A2 Anxa2 47 47 0.031 0.060 0.054 NaN 
P08752 Guanine nucleotide-binding protein G Gnai2;Gnai1 26 18 0.095 0.043 0.090 0.058 
P08905 Lysozyme C-2 Lyz2 15 8 0.007 0.013 0.020 NaN 
P09411 Phosphoglycerate kinase 1 Pgk1 46 46 0.158 0.137 0.058 0.028 
P09528 Ferritin heavy chain Fth1 18 18 1.274 2.055 2.514 1.563 
P10126 Elongation factor 1-alpha 1 Eef1a1 33 22 0.025 NaN 0.066 NaN 
P10649 Glutathione S-transferase Mu 1 Gstm1 26 22 0.052 0.099 0.083 NaN 
P10810 Monocyte differentiation antigen CD14 Cd14 5 5 1.149 1.861 NaN 1.735 
P10852 4F2 cell-surface antigen heavy chain Slc3a2 2 2 1.837 2.489 2.045 NaN 
P11835 Integrin beta-2 Itgb2 69 68 0.045 0.103 0.113 0.048 
P13020 Gelsolin Gsn 60 36 0.043 0.081 0.094 NaN 
P15379 CD44 antigen Cd44 4 4 0.247 0.259 0.363 NaN 
P16110 Galectin-3 Lgals3 12 12 0.147 0.230 0.166 0.112 
P16858 Glyceraldehyde-3-phosphate dehydrogenase Gapdh 40 40 0.048 NaN 0.058 0.045 
P17182 Alpha-enolase Eno1 55 52 0.043 0.095 0.031 0.051 
P17742 Peptidyl-prolyl cis-trans isomerase A Ppia 23 23 0.228 0.096 0.127 NaN 
P17751 Triosephosphate isomerase Tpi1 18 18 0.104 0.266 0.127 0.147 
P18242 Cathepsin D Ctsd 7 7 0.265 0.511 0.455 0.337 
P20029 78 kDa glucose-regulated protein Hspa5 51 50 0.187 0.247 0.704 NaN 
P24527 Leukotriene A-4 hydrolase Lta4h 55 55 0.160 0.034 NaN NaN 
P26041 Moesin Msn 62 46 0.146 0.225 0.218 0.095 
P27005 Protein S100-A8 S100a8 11 11 0.017 NaN 0.034 NaN 
P29351 Tyrosine-protein phosphatase non-receptor type 6 Ptpn6 31 31 0.168 0.232 NaN NaN 
P29391 Ferritin light chain Ftl1;Ftl2 16 16 6.162 6.615 5.124 3.798 
P31725 Protein S100-A9 S100a9 23 23 0.024 0.004 0.029 0.015 
P34884 Macrophage migration inhibitory factor Mif 3 3 0.521 0.707 NaN NaN 
P35700 Peroxiredoxin-1 Prdx1 12 11 NaN 0.784 0.533 0.611 
P37040 NADPH-cytochrome P450 reductase Por 15 15 0.400 0.502 NaN NaN 
P51150 Ras-related protein Rab-7a Rab7a 13 13 0.416 0.215 0.196 0.115 
P54987 Cis-aconitate decarboxylase Irg1 8 8 1.607 1.781 1.370 1.214 
P58058 NAD kinase Nadk 5 5 0.771 0.648 0.811 NaN 
P60335 Poly(rC)-binding protein 1 Pcbp1 17 15 0.240 0.240 NaN NaN 
P62962 Profilin-1 Pfn1 20 9 0.019 0.015 NaN NaN 
P63017 Heat shock cognate 71 kDa protein Hspa8 55 49 NaN 0.018 0.023 NaN 
P63101 14-3-3 protein zeta/delta Ywhaz 29 20 0.062 0.082 NaN 0.040 
P70460 Vasodilator-stimulated phosphoprotein Vasp 29 29 0.231 0.259 0.267 0.127 
P84228 Histone H3 Hist1h3b; Hist1h3a 23 23 NaN NaN 0.062 0.014 
P99029 Peroxiredoxin-5, mitochondrial Prdx5 22 22 0.040 0.085 0.049 0.041 
Q05144 Ras-related C3 botulinum toxin substrate 2 Rac2 22 14 NaN 0.073 0.067 0.048 
Q09014 Neutrophil cytosol factor 1 Ncf1 31 31 0.064 0.205 0.224 NaN 
Q61207 Prosaposin Psap 9 9 NaN 0.613 0.599 1.319 
Q61233 Plastin-2 Lcp1 56 56 0.100 0.152 0.106 0.062 
Q61362 Chitinase-3-like protein 1 Chi3l1 15 15 NaN 0.286 0.778 0.590 
Q61792 LIM and SH3 domain protein 1 Lasp1 23 23 NaN 0.104 0.096 NaN 
Q62426 Cystatin-B Cstb 6 6 0.335 NaN 0.907 NaN 
Q8R460 Interleukin-36 gamma Il36g 4 4 0.420 0.613 NaN NaN 
Q8VDD5 Myosin-9 Myh9 301 253 0.047 0.064 0.055 0.024 
Q91VW3 SH3 domain-binding glutamic acid-rich-like protein 3 Sh3bgrl3 9 9 0.031 0.053 0.078 NaN 
Q93092 Transaldolase Taldo1 35 35 0.063 0.118 0.101 0.089 
Q99JI6 Ras-related protein Rap-1b Rap1b 11 3 NaN 0.206 0.169 NaN 
Q9DBJ1 Phosphoglycerate mutase 1 Pgam1 30 30 0.391 0.185 0.108 NaN 
Q9DCD0 6-phosphogluconate dehydrogenase, decarboxylating Pgd 36 36 0.055 0.056 0.046 NaN 
Q9JHK5 Pleckstrin Plek 16 16 0.170 0.688 NaN NaN 
Q9JKF Ras GTPase-activating-like protein IQGAP1 Iqgap1 81 80 0.197 0.141 0.193 0.109 
Q9R0P3 S-formylglutathione hydrolase Esd 11 11 0.385 0.626 NaN NaN 
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Appendix 11: Additional Materials 
 
Product Source Product 
number 
IgM ELISA Abcam Ab133047 
Albumin ELISA Abcam Ab108792 
GM-CSF ELISA Abcam Ab201276 
Glutamine detection assay Abcam Ab197011 
MMP9 ELISA Bio-Techne MMPT90 
EnzCheck Elastase Activity Assay kit Invitrogen E12056 
EnzCheck MPO Activity Assay kit Invitrogen E33856 
Shandon Kwik-Diff stains Thermo Scientific 9990700 
DPX mountant Sigma 06522-100ml 
LAMP1 Antibody Abcam Ab25630 
Goat anti-mouse IgG H&L AF647 Abcam Ab150115 
Fixation/Permeabilisation Solution kit BD Biosciences 54714 
Texas red 70kDa dextran Invitrogen D1864 
Texas red BSA Invitrogen A23017 
FITC-BSA Invitrogen A23015 
DQ-Green BSA Invitrogen D12050 
AF488 E coli Invitrogen E13231 
CountBright beads Invitrogen C36950 
Prolong gold w DAPI Invitrogen P36931 
Cellmask far red Invitrogen H32721 
H2DCFDA Invitrogen C6827 
Red blood cell lysis buffer Sigma R7757-100ml 
TCEP Sigma 68957 
EZQ Invitrogen R33200 
LysC Promega VA1170 
Trypsin Promega V5280 
CBQCA Invitrogen C6667 
LPS Sigma L7018 
Red blood cell lysis buffer Biolegend 420301 
EasySep kit Stemcell technologies 19762 
Glucose assay Biovision K606 
13C6 Lysine Cambridge Isotope Laboratories CLM-2247-H 
13C6 15N4 Arginine Cambridge Isotope Laboratories CLNM-539-H 
13C5 Glutamine Cambridge Isotope Laboratories CLM-1822-H 
Percoll GE Healthcare 17-0891-01 
ChemoTx plates Neuro Probe 101-5 
Glycogen assay Sigma MAK016  
Chloroquine Sigma-Aldrich C6628 
E64 Sigma-Aldrich E3132 
Robosep buffer Stemcell technologies 20104 
BCA assay kit Thermo Scientific 23225 
 
